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ABSTRACT:  
 
Expansion and activation of cytotoxic T lymphocytes (CTL) is one of the major goals of 
immunotherapy but the hurdles in generating a large number of antigen-specific CTL 
are manifold. One of the limiting factors is the scarce availability of antigen presenting 
cell (APC) for T cell priming; dendritic cells (DCs) are the best APCs but their 
generation from adult progenitors is difficult and expensive so there is currently an 
active research into suitable alternatives. 
In this project, three different APCs models, cellular and acellular, were prepared and 
characterized and their potential use for clinical immunotherapy was explored. One 
setup was acellular, liposome-based, prepared from material currently used in in vivo 
applications and was tested in vitro both in human and murine settings. The other two 
APC systems were cellular-based; in both cases the antigen-presenting potential of a 
specific cord blood (CB)-derived cell population was evaluated in vitro. In the first 
case, a DCs-autologous responder culture was set up using whole frozen CB samples as 
starting material and tested in a peptide-specific model. In the second case, the antigen-
presenting potential of γδ T cell in CB samples was evaluated and compared to the same 
population in adult, as γδ T cells have been recently shown to express antigen 
presentation-related markers and promote T cell proliferation in adult systems. All the 
three models were assessed for their practicality of preparation and use, antigen 
presenting capability and overall feasibility of employment in clinical settings.  
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MES 2-(N-Morpholino)ethanesulfonic acid  
MHC major histocompatibility complex 
MHSC mobilized hematopoietic stem cells 
MLR mixed lymphocyte reaction 
mRNA messenger RNA 
MWDa molecular weight (expressed in) Dalton 
NEAA non-essential amino acid 
       Abbreviations 
  
 
 
   21 
NK natural killer 
nm nanometre 
OD optical density 
ORF open reading frame 
PAMPs pathogen-associated molecular patterns 
PBMCs peripheral blood mononucleated cells 
PBS phosphate buffered saline 
PC     phosphatydilcholine 
PCR polymerase chain reaction 
pDC plasmacytoid DC 
PE phycoerythrin 
PEG polyethylenglycole 
PerCP peridinin chlorophyll protein complex 
PFA paraformaldehyde 
PHA phytohemoagglutinin 
PLGA poly(lactide-co-glycolide) 
poly I:C polyinosinic: polycytidylic acid 
PRR pattern recognition receptor 
pSMAC peripheral supramolecular activation clusters 
RHODA [1,2-dipalmitoyl-sn-glycero-phosphoethanolamine 
-N-(lissamine rhodamine B sulfonyl) 
RNA ribonucleic acid 
rpm revolutions per minute 
RT room temperature 
RT-PCR reverse transcriptase PCR 
SCID severe combined immunodeficiency 
SDS sodium dodecyl sulphate 
SLO secondary lymphoid organs 
SMAC supramolecular activation clusters 
SSC side scatter 
SSP     single specific primer 
TAP transporter associated with antigen presentation 
       Abbreviations 
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TCM central memory T cells 
TCR T cell receptor 
TEM effector memory T cells 
TEMED tetramethylethylenediamine 
Tet tetramer 
TLR Toll like receptor 
TNF  tumour necrosis factor  
TNFR tumour necrosis factor receptor family 
Tris HCL tris(hydroxymethyl)aminomethane hydrochloride
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1.0.0  INNATE AND ADAPTIVE IMMUNE SYSTEM: 
 
The immune system is a complex organization of cells and molecules specializing in the 
defense against exogenous infections as well as against self-cells that have become 
abnormal or cancerous. Vertebrate organisms demonstrate 2 different types of immune 
responses against pathogens, each mediated by different types of cells and molecular 
effectors: the innate response has the same extent and magnitude every time the 
pathogen is encountered, while the acquired (also called adaptive) response improves 
with every exposure to the pathogen, crucially maintaining memory of past challenges.  
The innate response relies on phagocytic cells such as neutrophils, monocytes and 
macrophages, on cells secreting inflammatory mediators (basophils, mast cells and 
eosinophils) and on natural killer (NK) cells. The acquired response relies instead on the 
proliferation of antigen-specific B and T cells; this phenomenon happens after the 
specialized receptors on their surface engage the antigen (Delves and Roitt, 2000a). 
Whilst the innate response relies upon germ line-encoded receptors, the adaptive is 
dependent upon the rearrangement of a small number of gene segments to constitute a 
large repertoire of receptors each with different specificity (Janeway, 2005). 
 
1.1.0 T CELLS AS KEY PLAYERS IN THE ADAPTIVE IMMUNE 
RESPONSE: 
 
The components of the acquired immune system are B and T cells. Whilst B cells are 
responsible for the secretion of antibodies and fulfil a fundamental role in immune 
response, the focus of this project is on T cells, thus they will be described in more 
detail. All T cells have a T cell receptor (TCR), which is antigen-specific and whose 
complex structure will be described in the next paragraphs. T cells can be subdivided 
into αβ or γδ (Brenner et al., 1986) according to the chains that constitute the TCR. As 
αβ T cells are the most common every T cell mention in the text will always refer to 
them unless explicitly stated.  
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T cells can be divided into 2 subsets, CD4 or CD8, according to the expression of the 
corresponding co-receptor. CD8 T cells are mainly killer cells whereas CD4 T cells are 
mainly helper cells, secreting cytokines and with limited direct cytotoxic activity 
(Delves and Roitt, 2000b). CD4 cells can have various secretion patterns and the most 
common are named Th1 and Th2 (Mosmann and Sad, 1996). Th1 CD4 T cells are 
generated in response to pathogens accumulating in intracellular vesicles in 
macrophages and dendritic cells (DCs). Th1 cells secrete preferentially IL-2 and IFN-γ 
and elicit a strong cytotoxic response aimed at clearing intracellular pathogens (this 
kind of response is fundamental for effective eradication of M. tuberculosis and M. 
leprae infections, amongst others) and of viral-infected cells. Th1 CD4 T cells stimulate 
macrophage antimicrobial activity and promote phagocytosis. Th2 CD4 T cells, on the 
other hand, secrete IL-4, 5, 6, and 10 but not IL-2 or IFN-γ (Delves and Roitt, 2000b). 
This profile is most effective on parasitic infection and promotes mainly a humoral 
response with the production of different antibodies isotypes. 
 
1.1.1  T CELL RECEPTOR (TCR): 
1.1.2  αβ TCR: 
 
Each T lymphocyte expresses on its surface approximately 30.000 identical T cell 
receptors (TCR) (Janeway, 2005). Each TCR is composed of 2 different chains, termed 
TCRα and TCRβ, which are linked by a disulfide chain. The TCR heterodimer is 
responsible for antigen recognition: the TCR αβ is the most frequent isoform in humans 
(up to 95% of circulating lymphocytes) and recognizes major histocompatibility 
complex (MHC) class I-peptide complexes present on the surfaces of all nucleated cells 
and MHC class II-peptide complexes expressed on the surface of antigen presenting 
cells (APCs). Antigen presenting cells constitute a specialised subset of various cell 
types whose main function is to present antigens in an immunogenic form to the cells of 
the immune system; the most important members of the APC family are dendritic cells 
(DCs). The topic of APCs and DCs will be discussed in more detail from section 1.1.4 
onwards. 
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A minority of T cells, 2-10% in adults (Otto et al., 2005), expresses a TCR formed by a 
γδ heterodimer (Brenner et al., 1986). γδ T cells recognize nonclassical MHC-peptide 
molecules, bisphosphonate antigens and other proteins such as NKG2D. They are 
important in innate immunity and seem to have a regulatory function as well, however 
their current physiological role is still unclear and they are the objects of intense 
investigation.  
 
1.1.2.1  αβ TCR GENE REPERTOIRE: 
 
Both the α and β chains are composed of an NH2-terminal variable region, a COOH-
terminal constant region and a short zipper region containing the Cys that forms the 
disulfide bond between the chains (Janeway, 2005). Similarly to what happens for 
antibody chains, both α and β chains are formed from a large number of smaller DNA 
fragments (Davis and Bjorkman, 1988). Their recombination ensures the large number 
of antigen specificities that characterizes the T cell potential for antigen recognition. 
The α chain locus (situated in chromosome 14 in humans) contains between 70 and 80 
V (variable) fragments, 61 J (joining) fragments and a single C (constant) fragment, 
termed respectively Va, Ja and Ca. The β chain locus (situated on chromosome 7 in 
humans) contains 52 V fragments, 6 or 7 J fragments in 2 different positions on the 
chromosome, 2 C regions and 2 D (diversity) fragments, termed respectively Vb, Jb, 
Cb and Db (Janeway, 2005).  
The rearrangements mediated by these gene fragments can generate up to ~1018 
different TCRs; each TCR will be unique to a single T cell, which will be screened for 
absence of self-reactivity in the thymus prior to being released into the periphery. After 
the engagement of a TCR with the ligand it specifically recognizes, T cells will undergo 
activation and possibly clonal expansion. As the ligand for the TCR is always an MHC-
peptide complex, it is logical that the highest variability for the TCR is found in the 
peptide binding region, which is encoded mainly by the V, D and J gene fragments. The 
antigen-binding region of the TCR is subdivided into 3 complementarity determining 
regions (CDR 1, 2, 3). The CDR3 is where the TCR diversity concentrates most, as it 
where the TCR is in contact with the target peptide (Davis and Bjorkman 1988 and 
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Jorgensen et al., 1992), while the CDR1 and 2 binds to the MHC protein, surrounding 
the peptide. 
 
1.1.2.2  αβ TCR GENE REARRANGEMENT: 
 
During the T cell development, the β chain is rearranged and expressed firstly, with the 
union Dβ--> Jβ to form DJβ. This novel gene then rearranges with Vβ  to form VDJβ and 
only at this point a surrogate α chain is attached to the newly formed, rearranged 
β chain to form a pre-TCR to be expressed on the surface of the maturing T cell 
(Janeway, 2005). This step also triggers the co-expression of both CD4 and CD8 co-
receptors and the end of further recombination for the β chain. Therefore, at this stage, 
T cells are called double positive and constitute around 80% of total thymocytes (Petrie 
et al., 1993). A phase of rapid proliferation of double positive cells ensues; at the same 
time, each cell rearranges independently a functional α chain, following a stepwise 
process similar to that observed for the β chain (Malissen et al., 1992). During the 
α chain rearrangement, a complete αβ TCR is expressed for the first time and the T cell 
selection against autologous MHC-peptide is started. Figure 1.1, below, resumes the 
genetic recombination steps leading to the production of a functioning αβ TCR in the 
thymus. 
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1.1.3  γδ TCR:  
 
γδ T cells constitute a minority in the general pool of T cells in adults. Similarly to αβ T 
cells, γδ also undergo various stages of chain formation, with γ chains being always 
assembled via V-J rearrangements and δ chains via V-D-J rearrangements. In contrast, 
their CDR 1 and 2 regions are longer than their homologs in αβ cells (Hayday, 2000). 
They also are usually CD4 and CD8-negative, contrarily to conventional αβ T cells. 
The processes that lead to a formation of the αβ and γδ lineage are still unclear and 
under active investigation (Archbold, 2009); the signal strength, rather than the type, of 
the TCR seems to be the most important factor in deciding which type of receptor will 
be selected and expanded (Hayes et al., 2005).  
 
In healthy adults, the majority of the γδ T cells in peripheral blood –up to 80%- express 
Vγ9 and Vδ2 chains and are, therefore, termed “Vγ9Vδ2” (Schondelmaier et al., 1993 
and Brandes et al., 2009). However, the chain repertoire prevalent in the γδ population 
depends on the tissue examined and its origin (whether from healthy or infected adult or 
from adult or child). γδ T cells can be found in blood and other anatomical locations 
Figure 1.1: scheme of αβ  TCR recombination. Modified from Janeway, 2005. 
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but, strikingly, they are very rarely found in secondary lymphoid organs such as the 
lymph nodes or the spleen (Hein and Mackay, 1991)-i.e., the main locations associated 
with antigen presentation to T cells and where T cell clonal expansion occurs. This 
important feature suggests that γδ T cells do not rely on professional antigen presenting 
cells (APCs) for antigen presentation and recognition, but that they rather may 
recognize antigens directly in tissues. This hypothesis, together with the limited 
diversity of the γδ TCR, is consistent with a role for γδ T cells in the first line of 
defence (Janeway et al., 1988) and suggests that γδ T cells recognize directly stress 
antigens, a hallmark of infected or transformed cells, rather than classical, MHC-
presented microbial antigens (Hayday, 2000).  
 
1.1.4  T CELL ACTIVATION: 
 
All types of T cells require a concerted set of signals before being able to fulfil their 
physiological functions and activities; these signals are usually provided to them by 
APCs. For the complete activation of naïve CD8 and CD4 T cells, more than one input 
is required. The first and foremost requirement is antigen complexed to the relevant 
MHC molecule, leading to MHC-TCR engagement (“signal 1”). Then there is the need 
for costimulation, provided through the CD28-B7 family of molecules (“signal 2”). 
However, even the presence of signal 1 and 2 is not enough to fully activate a naïve T 
cell (Jenkins and Johnson, 1993), as they require in addition a “signal 3” that can be 
provided by a cytokine, usually either IL-12 (Curtsinger et al., 1999) or type I IFN (i.e. 
IFN α or β) (Curtsinger et al., 2005). “Signal 3” performs as a molecular switch and its 
presence determines whether the exposure to antigen will result in tolerance or complete 
activation and development of memory (Curtsinger et al., 2003).  
 
1.1.5  THE IMMUNOLOGICAL SYNAPSE: 
 
T cell activation requires, in most cases, physical contact between T cell and APC to 
bring the TCR and the MHC complexes together. This contact is defined by the sizes of 
the complexes involved (MHC and TCR), which at roughly 13 nm requires widespread 
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interdigitation of the glycocalyx of both T cell and APC (Dustin, 2008). The interaction 
between T cells and APCs causes the formation of specialized signalling areas, termed 
immunological synapses. Immunological synapses were first defined as such in the late 
1990’s (Grakoui et al., 1999), even if their existence as conjugate or cell pairs was first 
described and studied in the late 1970s. Micrometer-scale molecular complexes that 
form within minutes after the T cell-APC interaction are present at the immunological 
synapse; they are called supramolecular activation clusters or SMACs (Monks et al., 
1998). A SMAC is composed of 2 concentric regions: the inner one is termed central 
SMAC (cSMAC) and is the region with the highest concentration of TCR, while the 
outer one is called peripheral SMAC (pSMAC) and is enriched in the integrin LFA-1 
(on the T cell side) and in its ligand ICAM-1 (on the APC side). Also a distal SMAC 
(dSMAC) has been characterized and the signature molecule of this region is CD45 
(Freiberg et al., 2002). The immunological synapse fulfils various useful functions for T 
cell activation, among them: 
 
• It acts as a braking mechanism, effectively ceasing rapid T-cell migration and 
allowing T cells to remain in contact with APC or target cells for hours. 
• It is important as a spatial marker, setting up an actin-depleted central secretory 
domain allowing membrane traffic in both directions from the centre of the 
synapse. It also acts as a gasket surrounding the secretory domain, retaining 
macromolecular complexes in the SMAC. 
• It contributes to set an axis of asymmetry, which may be important for 
prolonged signal transduction and asymmetric cell division, such as occurs 
during differentiation processes.  
• The immunological synapse stability may finally play a role in deciding other 
aspects of T cell fate, like Th1-Th2 switch (Monks et al., 1998 and Dustin, 
2008). 
 
The role of cSMAC and pSMAC in the immunological synapse is still the subject of 
active debate. When it was first discovered it was thought that the peculiar molecular 
segregation observed could be linked to T cell activation. In particular it was speculated 
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that the cSMAC would boost signalling and allow a few MHC-peptide complexes to 
promote T cell activation (Monks et al., 1998). This very reasonable hypothesis was 
challenged by the fact that TCR signalling begins in the periphery and is precedent to 
TCR clustering in the cSMAC. It was then proposed that molecular segregation in the 
SMAC reflected another type of functional distinction, with the peripheral area 
(pSMAC) corresponding to an area of productive signalling and the central area 
(cSMAC) not contributing to the signalling, but rather being a site for TCR 
internalization and degradation (Lee et al., 2003 and Varma et al., 2006). This 
hypothesis was initially suggested since the intensity of signalling was lower in the 
cSMAC than in the pSMAC (Lee et al., 2003). Recently this model has been amended 
taking into account the strength of the antigen binding as a factor. Shaw’s group 
(Cemerski et al., 2008) found that a weak antigenic stimulus (for example, a suboptimal 
concentration of antigenic peptide or a peptide-MHC complex with a short half-life, 
therefore unable to form sustained interaction with the TCR) triggered sustained TCR 
signalling, as measured by protein tyrosine phosphorylation, in the cSMAC. Using a 
strong antigenic stimulus (in this case, optimal peptide concentration), the readout 
system gave a lower signalling level, possibly due to TCR down-regulation. However, 
when TCR down-regulation was blocked, signalling markers were detected in the 
cSMAC. This and other data suggested that the cSMAC could work as an adaptive 
controller of T cell activation and promote enhancement of weak signals and attenuation 
of strong ones (Cemerski et al., 2007). The evidence from Cemerski et al., 2008, 
suggests that, although TCR signalling is initiated in the immunological synapse 
periphery, its continuation evolves differently according to the strength of the antigen. If 
the antigen stimulus is strong the TCR will be rapidly degraded. As such, although 
productive signalling occurs in the cSMAC, its effective readout will be hampered by 
the rapid degradation of the signalling pathway components. If the antigen stimulus is 
weak, instead, the rate of TCR degradation is slow and signalling is more easily 
detected in the cSMAC. A representative example of immunological synapse between a 
DCs and a T cell is presented below in Figure 1.2. 
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1.1.6  THE IMPORTANCE OF COSTIMULATION: 
 
T cells can be subdivided into various subsets according to their phenotype and 
functionality. “Naïve” T cells are cells that have not yet encountered their cognate 
antigen; once they have been activated by antigen-specific APCs they will undergo a 
robust expansion, resulting in the generation of a large “effector” T cell population. 
After the rapid expansion, and the clearance of the infection, the effector population 
will contract (up to 95% of effector cells die by apoptosis) and the surviving pathogen-
specific T cells form the “memory” population (Obar and Lefrançois, 2010). The 
generation and phenotype of these subsets will be discussed in more detail in section 
1.1.7.  
 
1.1.6  THE IMPORTANCE OF COSTIMULATION: 
 
Effector T cells can be activated simply by TCR engagement with the specific MHC-
peptide complex. Once the TCR is engaged with the MHC molecule, it is complexed 
with an ensemble of molecules acting as coreceptors and collectively termed CD3. The 
CD3 is a signal transmission complex and its components are one CD3γ, one CD3δ and 
two CD3ε chains, together with a disulphide-linked ζ chain homodimer. When TCRs 
Figure 1.2: representation of an immunological synapse between a T cell (in blue) and a dendritic 
cell (in grey, in the lower part of the picture). The immunological synapse is in the centre of the 
figure (red = adhesion, bright green = foreign antigen). This is a composite image of a scanning electron 
micrograph and a fluorescence image. Picture taken by Michael Dustin. 
 
                                                                                                                                        Chapter 1 
  
  
 
   33 
cluster, which happens when the TCR molecules engage the peptide-MHC complexes 
on the cell surface, the activation signal cascade is initiated via the phosphorylation of 
the tyrosines in the cytoplasmic segments of the CD3 complex. The activation of the 
CD3 leads to a downstream signal to the nucleus that initiates various transcriptional 
responses including the up-regulation of cytokines that stimulate proliferation and 
survival of T cells.  
 
Naïve T cell activation occurs only if additional signals, such as costimulatory 
molecules (“signal 2”) and cytokines (“signal 3”) are present. In fact, costimulatory 
molecules (either positive or negative) are crucial players in all stages of T cell 
response. The majority of the costimulatory molecules belong to one of three groups: 
immunoglobulin superfamily (IgSF), tumour necrosis factor receptor (TNFR) family 
and integrin family.  
 
The IgSF superfamily is also known as B7 family and counts six members: the 
fundamental CD80 (also known as B7-1) and CD86 (B7-2), then B7-H1/PDL1, B7-
DC/PDL2, B7-RP-1 and B7-RP-2. Various ligands for the B7 molecules have been 
identified on T cells but the most important are CD28 (for positive costimulation) and 
CTLA-4 (for negative costimulation) recognized by both CD80 and CD86 (Song et al., 
2008). CD80 and CD86 share about 25% sequence homology and, while interacting 
with their receptors, the binding of CD80 is stronger, as measured by equilibrium 
dissociation constant (Van Der Merwe and Davis, 2003). CD80 and CD86 also differ in 
their presentation on the cell surface, with CD80 reported to exist as a dimer (Ikemizu et 
al., 2000), while crystallographic data indicate that CD86 is unlikely to form a stable 
dimer (Collins et al., 2002). While CD80 and CD86 are generally considered to have 
overlapping roles, data from Davis’s group (Collins et al., 2002) suggest that CD80 is 
likely to be a more potent ligand for CTLA-4, based on both higher affinity and avidity, 
thereby resulting in an inhibitory effect/phenotype. Conversely, CD86 is probably a 
more effective ligand for CD28 than CD80, at least in some circumstances, as its effects 
seem to be less opposed by CTLA-4 (Sansom et al., 2003). These considerations 
suggest that cells expressing both CD80 and CD86 (i.e., APCs) have the potential to 
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promote stimulation of T cells as well as its opposite-tolerization. Therefore, the 
possibility of a tolerogenic phenotype when generating APCs should be evaluated. 
 
The TNFR family, expressed on T cells, includes 4-1BB ligand (also known as CD137) 
and OX40 (CD134) and bind Tumour necrosis factor (TNF) molecules expressed by 
APC. Finally, integrin molecules, which are a family of heterodimers formed by two 
chain (α and β) covalently linked, forming LFA-1, are a fundamental component of the 
immunological synapse (Song et al., 2008). Costimulatory signals can have many 
different functions, including increasing IL-2 production, promoting progression 
through the cell cycle or inducing cytokine synthesis and secretion. The CD28-B7 
binding provides the most important effect of costimulation, which is the increase of IL-
2 production via both mRNA stabilization and activation of nuclear transcription factors 
AP-1 and NF-kB (Zhou et al., 2002). When T cells engage their TCR without 
concomitant CD28-B7 binding, IL-2 production is very limited and T cells do not 
proliferate, becoming anergic instead. The crucial relevance of IL-2 in acquired 
immunity is well explained by the immunosuppressive drugs used to prevent transplant 
rejection: cyclosporin A and tacrolimus both inhibit IL-2 production by blocking the 
TCR-transmitted signals, while rapamycin inhibits the signal transmission mediated by 
IL-2 receptor (Janeway, 2005). A scheme summarising the signals required for full T 
cell activation is shown below in Figure 1.3. 
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1.1.7 CD8 T CELL SUBSETS: 
 
1.1.7  CD8 AND CD4 T CELL SUBSETS: 
 
CD8 T cells can be subdivided into various types according to their maturation -effector 
vs memory T cell, for example. All T cells, when they leave the thymus after their 
education (positive and negative selection), are naïve- i.e. they have not encountered 
any antigen yet. Naïve CD8 T cells usually migrate through secondary lymphoid 
tissues, the location where they come across their cognate antigen and the appropriate 
costimulatory molecules (both provided by a professional APCs), to be primed. This 
occurrence triggers clonal expansion, which mediates an enormous increase in a given 
antigen-specific T cell population during the subsequent effector phase and also results 
in the generation of T cells subpopulations with different phenotypes and distinct 
functions (Williams and Bevan, 2007). Effector cells are predominant in the clonal 
Figure 1.3: scheme resuming all the signals required for full T cell activation. Modified from 
Steenblock et al., 2009. The numbers on the arrows refer to the type of signal mediated by the indicated 
molecules.  
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expansion and they are characterized by a cytotoxic potential and by the secretion on 
IFN-γ, TNF-α, and/or IL-2.  
 
Following clearance of the pathogen and contraction of the overall T cell population a 
small percentage of long-lived cells can survive for a long time. Those cells are 
generically termed “memory cells” and, in contrast to naïve cells, can reactivate specific 
effector functionality extremely quickly when challenged, even within minutes. 
Moreover, an effector cell population can expand rapidly starting from memory T cells 
(Stemberger et al., 2007). The “readiness” of memory T cell to respond to secondary 
infections results from their persistence in a pro-growth state, with high levels of cyclin-
dependent kinase 6 (CDK6)-cyclin D3 complex (Badovinac et al., 2002), and from the 
maintenance of mRNA expression of cytotoxic proteins, cytokines and chemokines.  
 
CD4 T cells can also be subdivided in various subsets, according to their cytokine 
secretion pattern and function. Historically, Coffman’s group described 2 subsets of 
CD4 T cells according to the secretion of IFN-γ or IL-4 (Mosmann et al., 1986), 
however it is now acknowledged that naïve CD T cells have at least 4 different fates 
that are determined by the combination of signals they receive upon the initial 
interaction with the antigen and are termed Th1, Th2, Th17 and induced regulatory 
(iTreg) cells (Zhu and Paul, 2008). Th1 cells mediate responses against intracellular 
pathogens and have a fundamental role in the response to mycobacterial infections in 
humans. The predominant cytokines secreted by Th1 cells are IFN-γ, IL-2 and 
lymphotoxin α (LT-α) (Mosmann and Coffman 1989). Th2 cells mediate the adaptive 
immune response against extracellular pathogens (including multicellar parasites such 
as helminths) and have been implicated in playing an important role in the induction 
and persistence of asthma and allergic diseases. Their main cytokine products are IL-4, 
IL-5, IL-9, IL-10, IL-13, IL-25 and amphiregulin (Zhu and Paul, 2008). Th17 cells 
promote the immune responses against extracellular bacteria or fungi (Weaver et al., 
2006), but are also important in the induction of many organ-specific autoimmune 
diseases. They secrete IL-17a, IL-17f, IL-21 and IL-22. Finally, iTreg cells secrete 
TGFβ, IL-10 and IL-35; like all Tregs, irrespective of their origin, they are fundamental 
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both in maintaining self-tolerance and regulating the immune response (Sakaguchi, 
2004). An increase in their numbers or suppressive activity could be beneficial to treat 
autoimmune pathologies and to prevent allograft rejection (Zhu and Paul, 2008). 
 
1.1.8  KINETICS OF T CELL ACTIVATION: 
 
T cells become activated following their interaction with an APC presenting a peptide-
MHC complex and costimulatory molecules of the B7 family, able to bind to the CD28 
expressed on T cells. The number of naïve T cells specific for each distinct epitope is 
very low (1 in 106-107), so each T cell must contact and interrogate many different APC 
to find the one presenting its cognate antigen on its surface (Henrickson and von 
Andrian, 2007). To maximize a positive antigen encounter, the half-life of T cells in the 
bloodstream is limited (approx 30 min) as circulating lymphocytes are continuously 
recruited into the secondary lymphoid organs (SLO), where the professional APCs 
reside. SLOs include the spleen, which collects antigens from the blood, lymph nodes, 
which collect antigens from the skin and solid organs, and Peyer’s patches, where 
antigens from the gut lumen are collected and presented. T cells remain in the SLOs for 
approximately one day before returning to the bloodstream and during this period they 
crawl in an amoeboid manner displaying a cellwalk-like behaviour (Miller et al., 2003). 
It has been calculated that the average speed of naïve T cells is approx 12 µm/minute 
(Mempel et al., 2004b). Assuming a 23h/day permanence in the SLO, each T cell would 
cover more than 6 meters/year.  
 
In an experiment aimed to elucidate the kinetics and timings of antigen presentation in 
an in vivo model (Mempel et al., 2004a), it was found that T cells priming in lymph 
nodes occurs in three distinct phases. After DCs and T cell injections in recipient mice, 
and following injection of anti L-selectin (that blocked further lymphocyte homing to 
the lymph nodes), the first phase of T cell priming lasted approximately 8 hours and 
was characterized by brief T cell-DC encounters where T cells moved rapidly and 
scanned many APC. Phase two covered the period between 8 and 24 hours after the 
adoptive cell transfer. In this phase the T cell-DCs conjugates became more stable and 
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lasted for more than 1 hour. T cell velocity slowed down and by the 20th hour T cell 
started secreting IL-2 and IFN-γ: expression of activation marker was abundant but no 
cell division occurred yet. Phase three started 1 day after T cell homing; in this phase T 
cells detached from the DCs, started a massive proliferation and left the lymph nodes 
(Mempel et al., 2004a). The expression of the activation markers CD25 and CD69 
diminished, whilst CD44 expression remained high. T cells still made contacts with 
DCs at late time points (44-48 hours), but it is not clear if such interactions are 
productive, as DCs may not have any more antigenic peptide at that time. This pattern 
was followed also when DCs did not present any antigen, even if in this case phase two 
was shorter than with antigen-bearing DCs (Mempel et al., 2004a).  
 
1.1.9  MEMORY T CELL EXPANSION: 
 
Lanzavecchia’s group showed the difference between effector and naïve T cells in their 
requirements for activation during a study aimed at highlighting the importance of the 
duration of antigen stimulation in determining the fate of naïve and effector T cells 
(Iezzi et al., 1998). They found that naïve T cells require a very long antigenic 
stimulation (20 hours) to become committed. In contrast effector T cells require 1 hour 
only (Iezzi et al., 1998). However, the latter undergo activation-induced cell death if 
stimulation is prolonged. High levels of antigens and the presence of CD28 
costimulation shortened the time required by naïve T cells for commitment. However, 
even under the best conditions, there is a 20-fold difference in the time required for 
commitment between effector and naïve T cells. Also their reaction to high antigen dose 
is different; it increases activation-induced cell death for effector T cells, while 
costimulation reduces it. Costimulation via CD28 has been shown to enhance massively 
the response of naïve T cells to low doses of antigen, where no T cell activation could 
be detected even in the presence of maximal TCR engagement. It has been shown that 
IL-2 also plays an important role in T cell activation but, even in presence of IL-2 in the 
culture medium, naïve T cells still have a minimum 6 hr commitment time. In fact, the 6 
hours required for commitment correlate with the slow kinetics of IL-2 receptor α chain 
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expression, whose up-regulation occurs indeed after 6 hours of antigenic stimulation 
(Iezzi et al., 1998).  
 
1.1.10  THE PHENOTYPE OF MEMORY T CELLS: 
 
Memory cells can be subdivided into 2 different types: effector memory T cells (TEM) 
and central memory T cells (TCM). TEM are preferentially found in peripheral tissue, they 
have immediate effector functions upon encounter with an antigen but have poor 
proliferative potential. TCM, on the other hand, usually reside in lymphoid organs, can 
produce large amounts of IL-2 and are able to expand massively upon antigen encounter 
(Sallusto et al., 2004). The various classes of effectors cells can be discriminated 
according to the expression of CD62L, the lymph node homing receptor, CD127, the α 
chain of the IL-7 receptor, and CD27, a member of the TNF receptor superfamily. The 
expression of the said markers correlates well with the functional properties of the cells 
types they are expressed on: TCM are CD127/CD27highCD62Lhigh and TEM are 
CD127/CD27highCD62Llow. Memory T cells can also be subdivided according to the 
expression of C-chemokine receptor 7 (CCR7), which is present on various lymphoid 
tissues and promotes the activation of B and T cells. CCR7 expression correlated with 
CD62L expression, and they are both expressed by TCM, while TEM are negative for 
both markers (von Andrian and Mackay, 2000). 
 
1.1.11  THE EFFECTOR MECHANISMS OF T CELLS: 
 
How do cytotoxic T cells exert their action? The cytotoxic activity of T cells is 
mediated either by the secretion of proteins by the T cells or by the activation of 
specific pathways in the target cell. Cytotoxic molecules belong to two groups: 
cytotoxins, which are stored in lytic granules in the cytosol, and cytokines, which are 
synthesized de novo by all effector T cells (Janeway, 2005).  
Cytotoxins are the main effector molecules and their release needs to be tightly 
controlled as their actions are unspecific and can exert their cytotoxic effects on any cell 
within their range of action, not necessarily on the target only. Cytokines, on the other 
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hand, have a receptor-specific effect. The principal cytokine released by CD8 effector 
cells is IFN-γ (Harty et al., 2000), which can block viral replication and even eliminate 
the virus without killing the cell hosting it.  
 
Cytotoxic T cells can kill directly their target cell or induce its apoptosis. The first 
mechanism is mediated by the release of the proteins stored in the lytic granules, 
following the recognition of the antigen in the surface of the target cells. Lytic granules 
are modified lisosomes and contain three different classes of cytotoxic proteins 
(perforin, granzymes and granulolysin). The perforin, as the name suggests, polymerises 
and creates pores in the membrane of the target cells, leading to water entry and 
disruption of cell integrity. Granzymes and granulolysin can both induce apoptosis once 
in the target cells and the same effect is mediated by the Fas ligand (CD178) (Shresta et 
al., 1998), which induces apoptosis of target cells expressing the Fas receptor (CD95) 
(Harty et al., 2000).  
 
1.2.0  ANTIGENS AND EPITOPES-DEFINITION: 
 
The immune system in humans is able to mount a protective response against anything 
that can be bound by the receptors of either the innate or adaptive immune system. A 
compound is generically termed “immunogen” if the cells of the immune system can 
mount a response against it, regardless of the subtype of cell involved. An “antigen” is 
any compound or substance that can bind an antibody. Antigen size and chemical 
composition can vary greatly. An antigen that triggers an immune response is called 
immunogenic, but there are also antigens, called haptens, that are not immunogenic 
(Delves and Roitt, 2000a). Haptens need to be coupled to larger immunogenic 
molecules termed carriers to be rendered immunogenic (Mitchison, 1971). Large 
proteins are usually immunogenic on their own; carbohydrates, on the other hand, 
require often to be joined to proteins to elicit an immune response, for example in 
vaccine preparation. In the case of T cells, the overall length of the antigen recognized 
by the TCR is usually between 9-15 aa. As such, T cell receptors recognize only a part 
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of a complex antigen (such as a whole viral protein, as it might be the case of 
cytomegalovirus pp65), which is called an epitope. 
 
1.2.1  MHC: 
 
The αβ TCR –and, by extension, any CD4+ve or CD8+ve T cell- can mount a response 
against an antigenic peptide only if this is presented by a molecule of the MHC family. 
As a consequence, every pathogen able to evolve and escape MHC presentation would 
have a strong selective advantage. However MHC genes, which in human are called 
Human Leukocyte Antigen (HLA), are polygenic and extremely polymorphic. In fact, 
they are the most polymorphic set of genes in the entire human genome and this marked 
variability results in complete MHC escape being more difficult. The number of HLA 
alleles is continuously growing and, up to October 2010, there are 5,674 total class I and 
class II HLA alleles divided in HLA-A, B and C (class I HLA alleles) and HLA-DP, 
DQ, DR (class II HLA alleles). Any individual can either be homozygous or 
heterozygous for each of the alleles stated above. Peptides bind to a MHC molecule 
according to their origin, as follows: 
 
• Peptides coming from the cytosol, derived from intracellular pathogens, are 
presented by MHC class I molecules, which are expressed on every nucleated 
cell in the organism, to CD8 T cells. The MHC class I pathway provides a 
system to display a sample of the proteome synthesized by every cell at any 
given time. This enables CD8 T cells to kill cells that express viral proteins as a 
result of viral infection and tumour antigens as result of cancer transformation. 
• Extra-cellular peptides, which have been internalized and processed, or peptides 
derived from pathogens proliferating in intracellular vesicles, are instead 
presented on MHC class II molecules to CD4 T cells. The expression of MHC 
class II molecules is restricted to APCs such as DCs, B cells, macrophages and 
thymic epithelial cells. Since CD4 T cells can stimulate other subsets of the 
immune system, it seems appropriate that only cells that can regulate an immune 
response (ie. APCs) can activate them. In fact, the surface presentation of MHC 
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class II molecules and the expression of costimulatory molecules are tightly 
regulated processes, reflecting the importance CD4 T cells have in adaptive 
immunity (Jensen, 2007). 
 
According to this model extracellular peptides should not be presented on MHC class I 
molecules for recognition by CD8 T cells: however, dendritic cells (DCs) are able to 
present extracellular peptides on MHC class I molecules (cross presentation) for 
recognition by CD8 T cells (cross priming) (Albert et al., 1998, and Mellman and 
Steinman, 2001).  
 
1.2.1.1  MHC CLASS I AND II: 
 
The MHC class I protein is a heterodimer formed by 2 different polypeptidic chains. 
The larger one is termed MHC class I heavy chain and is coded on the MHC locus on 
chromosome 6; the variability imparted to the MHC molecule derives from the heavy 
chain. The second and smaller polypeptidic chain is termed β2-microglobulin (β2m), is 
coded on chromosome 15 and is conserved. The MHC heterodimer consists of 4 protein 
domains, 3 of which (α1, 2 and 3) are derived from the heavy chain, while the 4th is 
formed by the β2m. The α1 and α2 domains form the peptide-binding groove and, not 
surprisingly, are also the sites where the polymorphisms are mostly concentrated 
(Bjorkman et al., 1987).  
 
The MHC class II molecules are heterodimers as well. They are formed by 2 chains 
(α and β), both coded on the MHC locus on chromosome 6. The crystallographic 
conformation is quite similar to that of MHC class I: in this case, as well, the 
polymorphism is maximal on the peptide binding groove, which is formed by the 
domains α1 and β1 (Fremont et al., 1996). 
 
With both MHC class I and II molecules, the bound peptides constitute an integral part 
of the correctly folded molecule and are buried in the peptide-binding groove, held in 
place by noncovalent interactions, mainly hydrogen bonds. In MHC class I proteins the 
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length of the bound peptide is limited to 8-10 residues by conserved hydrogen bonds at 
each end of the peptide-binding groove. However, some bulge in the middle of the 
peptide-binding groove is allowed. In MHC class II molecules the peptide is instead not 
restricted to a specific length as the ends of the peptide-binding groove are open 
(Rammensee, 1995). 
 
1.2.1.2  NON-CLASSICAL MHC: 
 
In addition to MHC class I and II molecules there are also other proteins that are very 
similar to MHC class I and II but display less polymorphisms and usually have a far 
more restricted tissue distribution. These proteins have been called, collectively, MHC 
class Ib and are also currently termed nonclassical MHC. Between the nonclassical 
MHC, the proteins expressed from the MIC genes are peculiar, as they are not 
constitutively expressed, as the classical MHC class I molecule is, but instead is 
induced upon cellular stress. Moreover, if they bind peptide products they tend not to be 
the classical microbial products as seen with MHC class I and II. MICA and MICB, for 
example, are heavily glycosylated proteins with low homology (18-30%) with MHC 
class I molecules, but a relatively high level of polymorphisms. Their expression is 
limited to epithelial surfaces, mainly gastrointestinal system and thymic cortex, and 
their expression is up-regulated upon heat shock, cell transformation and infection 
(Braud et al., 1999). MICA and MICB are recognized by NK cells via their NKG2D 
receptor and can activate them to kill the MICA-expressing cells. Other MHC Ib 
molecules, such as HLA-G, result instead in an inhibitory signal, so that NK cells do not 
kill the uterine cells expressing them. HLA-E is the least polymorphic of all MHC class 
Ib genes and is also has the widest tissue distribution, albeit with a lower level of 
expression than classical MHC molecules. It preferentially, but not exclusively, binds 
peptide sequences derived from MHC-class-I derived leader peptides. HLA-E can 
produce inhibitory responses, when interacting with CD94-NKG2A, or activating 
responses, when interacting with CD94-NKG2C and TCR, thus exerting a wide range 
of actions depending on the cellular context (Sullivan et al., 2008).  
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Finally, CD1 molecules are similar to MHC proteins in structure, as they share both 
limited sequence homology and domain organization (a heavy chain composed of three 
distinct α1, 2 and 3 parts, non-covalently associated with β2m). However, they have a 
very distinct functionality as they bind and present lipid antigens to elicit T-cell 
mediated immunity (Odyniec et al., 2010). Recently DC-expressed CD1b and CD1c 
have been shown to mediate the recognition of lipid A, the most conserved membrane 
anchor of LPS, by γδ T cells, promoting their proliferation (Cui et al., 2009). Figure 1.4, 
below, represents the three types of MHC molecules (class I and II plus CD1 as an 
example for class Ib) described in this chapter.  
 
 
 
 
1.2.2  MHC CLASS I PRESENTATION: 
 
MHC class I molecules bind their peptide in the endoplasmic reticulum (ER). The 
peptide supply is generated in the cytosol via the proteasome degradation of 
endogenous proteins. The peptides are then carried into the lumen of the ER by the 
transporter associated with antigen processing (TAP). However, the peptides generated 
by the proteasome are between 2 and 25 aa in length, so they may exceed the maximum 
length admitted by MHC class I molecules (Kloetzel, 2004). A further trimming step is 
then performed in the ER by the ubiquitously expressed ER aminopeptidase ERAAP 
(also called ERAP1). ERAAP recognizes the COOH-end of the peptide and trims the 
Figure 1.4: MHC molecules, classical and nonclassical. Modified from Porcelli, 2005.  
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NH2-end to form 8-10mer (Chang et al., 2005). The chaperone is then released and the 
MHC class I molecule, still without peptide, is joined to the MHC class I peptide 
loading complex for loading and exposure on the cell surface. This complex comprises 
many different proteins, including TAP, tapasin, the chaperone calreticulin, protein 
disulfide isomerase (PDI) and ERp57 and has two distinct functions, as it both regulates 
the final assembly MHC class I-peptide and provides quality control for the MHC-class 
I loaded molecules to be exported. TAP associates to the MHC class I heavy chain via 
tapasin and provides a topological advantage (i.e. it brings peptide and MHC heavy 
chain in close proximity) but it does not seem to be a necessary part of the peptide-
loading complex (Flutter and Gao, 2004). On the other hand, tapasin is a fundamental 
player in the formation of the peptide-loading complex, its role being a bridge between 
TAP and the yet-unloaded MHC class I. Calreticulin is both an essential effector in 
intracellular calcium homeostasis (its deletion is lethal in embryogenesis, (Mesaeli et 
al., 1999)) and an important ER chaperone involved in glycoprotein -such as MHC 
class I- folding (Flutter and Gao, 2004). ERp57 is a thiol oxidoreductase whose role is 
to form a disulfide bond with tapasin (Dick et al., 2002). In fact, tapasin acts as a sink 
for ERp57 sequestration: when tapasin is absent, ERp57 catalyses the reduction of a 
disulfide bond in the MHC class I heavy chain (Kienast et al., 2007). PDI is the latest 
candidate for addition to the peptide-loading complex and its general function is 
catalysing the formation of native disulfide bonds in the initial phases of protein folding 
in the ER (Jensen, 2007). A scheme resuming the main players in class I presentation is 
presented below in Figure 1.5. 
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1.2.3  MHC CLASS II PRESENTATION: 
 
The peptide loading of MHC class II monomers relies on the action of a specialized 
chaperone protein termed the invariant chain (Ii) for its assembly in the ER (Watts, 
2004). Ii mediates the stable assembly of MHC class II in the endoplasmic reticulum via 
a protein fragment that fits into the MHC class II peptide-binding groove and acts as a 
surrogate peptide to stabilize the protein. Ii release from the MHC class II involves a 
series of proteolytic cleavages, the key one being mediated by cathepsin S, which leaves 
only a short peptide (MHC class II-associated invariant-chain peptide or CLIP) in the 
peptide-binding groove. This results in each MHC class II molecule starting with the 
same self-peptide -CLIP- that needs to be displaced and substituted by other peptides 
for the antigen presentation system to work. Without enzymatic help the rate of 
dissociation of CLIP from most MHC class II molecules is too slow to allow effective 
peptide substitution before presentation on the cell surface. A fundamental role in MHC 
class II presentation is, therefore, performed by the chaperone protein HLA-DM. This 
accelerates the rate of CLIP release and peptide exchange in the MHC class II 
compartment. HLA-DM is a nonpolymorphic MHC class II heterodimer: it does not 
Figure 1.5: scheme of MHC class I presentation. Taken from Jensen, 2007. 
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directly bind peptides itself but interacts with peptide-MHC class II molecules and 
facilitated peptide exchange. It is also thought that HLA-DM has a role in peptide 
editing by catalyzing multiple events of peptide exchange, possibly with a bias towards 
the most stable complexes (Jensen, 2007). Class II MHC molecules, following their 
association with Ii, are concentrated in multivesicular, late endosomal compartments 
called “MHC II compartments” (Vyas et al., 2008). As such, the MHC class II peptide 
supply must be able to access this compartment. Extracellular material including 
antigens and whole microorganisms is taken up by the APC cells and enclosed in a 
phagosome, a membrane-bound compartment to confine ingested material. The 
phagosome then undergoes various modifications, whose nature can depend on the 
content of the phagosome itself, and fuses with a lysosome to form a phagolysosome 
(Vyas et al., 2008). At this stage the phagolysosome can interact with the MHC class II 
molecules for peptide loading. Figure 1.6, below, summarizes some of the possible 
sources of materials for loading on MHC class II molecules.  
 
 
Figure 1.6: scheme resuming the various possible sources of antigen for MHC class II presentation. 
Taken from Vyas et al., 2008. 
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The final step in MHC class II antigen presentation requires the transportation of the 
vesicles containing the MHC class II peptide-loaded molecules to the cell surface. This 
process is thought to involve the transformation of MHC class II-containing vesicles 
into tubular structures directed towards the plasma membrane in the site of the 
interaction with the T cell (Vyas et al., 2007). Such a targeting is thought to enhance 
MHC class II clustering at the site of T cell contact and might play a role in the 
formation of the immunological synapse.  
 
1.2.4  CROSS PRESENTATION: 
 
For a long time MHC class I and II pathways of antigen presentation have been 
considered strictly distinct, with antigens of exogenous origin (i.e., phagocytosed or 
otherwise acquired by the cells and not naturally present in the cytosol) presented only 
on MHC class II molecules. The need for such a tight regulation of MHC class I 
restriction to endogenous antigens only appear clear when considering that otherwise 
healthy cells might become a target for CD8 cytotoxic T cells. However, if MHC class I 
presentation was indeed completely restricted to endogenous antigens, this would raise 
the question on how it would be possible to mount a cytotoxic response against 
pathogens that do not infect APCs. If APCs were not infected, in fact, they would not 
present the pathogen’s antigen on their MHC class I and, therefore, it would not be 
possible to mount a cytotoxic response against any other cell infected/transformed in the 
same way. Such a response is made possible by the cross presentation pathway, where 
DCs present exogenous antigens on MHC class I molecules.  
 
Cross presentation is fundamental to triggering a cytotoxic response against bacteria, 
tumour, and certain viruses, and for the tolerance to self-antigens (Savina and 
Amigorena, 2007). In vivo cross presentation has been attributed mainly to DCs, 
however in vitro experiments have shown that also other cell types including B cells 
and macrophages can cross present, albeit with a low level of efficiency (Reis e Sousa 
and Germain, 1995). There are many pathways available for cross-presentation, with 
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phagocytosis and macropinocytosis being the main routes for antigen uptake. However, 
the intracellular compartments responsible for cross presentation are still not well 
defined, even in DCs. Some antigens are presented through the so-called “cytosolic 
pathway”; following internalization in endosomes, protein antigens are partially 
digested to form large fragments, which are then exported in the cytosol and subjected 
to further degradation in the proteasome. Finally they are bound by TAP, transported 
into the ER and loaded onto MHC class I molecules (Ackerman and Cresswell, 2004). 
However, a “vacuolar pathway”, similar to MHC class II presentation and presumably 
independent from any cytosolic step, has also been reported (and reviewed in 
Ramachandra et al., 2009). As for the type of antigens used in cross-presentation, 
peptides derived from particulate antigens (cell- or particle- associated) are much more 
efficiently presented than soluble ones. This and other evidences suggest that 
phagocytosis enhances antigen delivery into the MHC class I pathway (Ackerman and 
Cresswell, 2004). It has also been demonstrated that export to the cytosol in DCs is 
more rapid for small than for large molecules (Rodriguez et al., 1999). While the 
evidence for phagosome/endosome-contained antigens being released in the cytosol is 
quite strong (Kovacsovics-Bankowski and Rock, 1995), the fusion of ER with the 
phagosome system has been a topic of hot debate for some years. This was consistently 
clarified by Cresswell’s group (Ackerman et al., 2006), as they published that a bead-
bound protein with a specific site for N-glycosylation underwent glycosylation after 
phagocytosis from DCs while still being attached to the bead. As N-glycosylation is a 
peculiar feature of the ER, this provides quite strong evidence for ER-phagosome 
interaction in DCs. To summarize, cross presentation is still very much an open field 
and new substantial developments are to be expected.  
 
1.3.0  ANTIGEN PRESENTING CELLS: 
 
A critical factor, possibly the most important factor for the generation of effective T cell 
lines, is the interaction between the T cell and the antigen–presenting cell (APC), in 
which peptides derived from the antigen are loaded on MHC molecules and presented 
on the APC surface to the TCR. Controlling and fine-tuning the APC functionality is 
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hence fundamental for any therapeutic strategy requiring T cells stimulation, either in 
vitro or in vivo (Oelke et al., 2005). Many types of cell in the body can exert APC 
function; in fact, virtually any cell carrying an HLA molecule loaded with a peptide 
would be able to elicit a memory T cell response. However, only professional APC–
mainly dendritic cells (DCs)- are able to prime effectively naïve T cells to promote a 
full primary response (Banchereau et al., 2000). The success of any adoptive transfer 
immunotherapy protocol requires that the lymphocytes be presented the relevant 
antigen(s) and that, after antigen presentation, they mature and undergo activation, 
expansion and differentiation. 
 
1.3.1  B CELLS, MACROPHAGES: 
 
While DCs are the most efficient APCs in humans other cell types, mainly B cells and 
macrophages, can have antigen-presenting activity. B cells, in particular, show a 
constitutive expression of MHC class II that begins during B cell development and is 
maintained throughout differentiation and maturation (Chen and Jensen, 2004). 
However, the expression of CD80 and CD86 is very low upon B cell maturation, thus 
rendering them unable of providing normal co-stimulation during antigen presentation. 
This feature is consistent with B cells at this stage being able to induce T cell tolerance 
rather than activation (Chen and Jensen, 2008). B cells are not very efficient in the 
capture and processing of pinocytosed or endogenous antigens which, combined to their 
lack of costimulatory molecules prior to activation, renders them poor presenters of 
non-specific antigens compared to, for example, DCs or macrophages (Chen and 
Jensen, 2008). However, once they encounter a specific antigen via their BCR they are 
then able to present with very high efficiency. 
Macrophages were initially identified by E. Metchnikoff in the early 1900 as highly 
phagocytic cells that were able to eliminate pathogens and perform general 
housekeeping functions in a wide range of organisms (Martinez et al., 2009). Later on it 
was discovered that IFN-γ, which is secreted by both NK and T cells, can convert 
macrophages in cells with a clear antigen presenting activity, an increased rate of 
synthesis of proinflammatory cytokines and an increase in phagocytosis too (Martinez 
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et al., 2009). However, both the cell types described above cannot match dendritic cells 
in terms of efficacy of antigen presentation. 
 
1.3.2  DENDRITIC CELLS:  
 
DCs are the most potent APCs and they have a unique ability to stimulate naïve T cells 
(Banchereau and Steinman, 1998). DCs are present in low numbers throughout the 
body, both in lymphoid and nonlymphoid tissues. In peripheral tissues they reside 
particularly in skin and mucosae, the sites of interface with the external environment. 
Their distribution -they are abundant in pharynx, upper oesophagus and gastrointestinal 
system, vagina and anus, in brief at all sites where exogenous pathogens could be 
present- makes them the predominant cell to respond to disease-related stimuli 
(Steinman and Banchereau, 2007). DCs are also able to extend their processes –and as 
such their antigen-sampling ability- through the tight junctions of the epithelia without 
altering its barrier function (Rescigno et al., 2001). This feature probably enables the 
silencing of the immune system towards harmless environmental pathogens.  
 
DCs are involved in the establishment of both innate and adaptive immunity 
(Banchereau et al., 2000) and can promote Th1 (Pulendran et al., 1999) and Th2 
differentiation in helper T cells. They are able to induce memory in specific T cell 
clones, thus allowing its long-term persistence and a rapid response upon re-exposure to 
the original antigen (Badovinac et al., 2005). The key features DCs possess regarding 
their antigen presentation and T cell activation potential are summarized in Figure 1.7, 
below. 
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However, DCs also contribute to the differentiation of regulatory T cells required for 
the maintenance of self-tolerance (Steinman and Nussenzweig 2002) and/or to the 
dampening of an immune response, as it will be described also in sections 1.3.2.1 and 
1.3.2.2. DCs can be tolerogenic in their immature state, as explained in section 1.3.2.2, 
but this phenotype can also be induced by exposing them to various immunosuppressive 
and anti-inflammatory agents such as IL-10, TGF-β1 or compounds as prostaglandin E2 
(Morelli and Thomson, 2007). DCs can also induce tolerance, rather than activation, 
upon capture of harmless self-antigens, environmental antigens, or in some cases 
antigens from dying cells (Morelli and Thomson, 2007). 
 
1.3.2.1  MAIN DCs SUBTYPES: 
 
DCs are a unique subset of cells and their heterogeneity is partly reflected by their 
widespread distribution in the body. All human DCs are leukocytes arising from the 
bone marrow and DCs and DCs precursor make up around 1% of circulating PBMCs 
(Sato and Fujita, 2007).  
The main subdivision in DCs subsets is between conventional (cDCs) and plasmacytoid 
(pDCs) DCs. There is also a subset of cells termed follicular DCs, but these are non-
haematopoietic in origin, do not express MHC class II on their surface and reside in 
follicles and germinal centres (hence the name). They have long dendrites but do not 
Figure 1.7: main features of DCs. Taken from Steinman and Banchereau, 2007. 
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process the antigen, carrying it intact on their surface instead, and are not related to 
classical dendritic cells.  
 
Human DCs are defined as lineage-ve MHC class II+ve cells; moreover, all human DCs 
express CD4. cDCs are defined as CD11c+ve while pDCs are CD11c-ve in humans, 
whereas in mouse all DCs are CD11c+ve regardless of the subtype (Sato and Fujita, 
2007). pDCs derive their name by their cytologic similarities with antibody-producing 
B (plasma) cells, can be involved in tolerance when in their immature state and, 
contrarily to cDCs, are long-lived. Upon maturation, they express Toll-like receptor 
(TLR) 7 and 9 and are known to express large amounts of type I IFN (Steinman and 
Banchereau, 2007) in response to viral infections, which is their main physiological 
role. They can also act as APC and control T cell responses once they have undergone 
maturation (Colonna et al., 2004); however, as the level of MHC and costimulatory 
molecules is not as high as in classical cDCs, this is probably the reason for their minor 
efficiency in T cell priming (Villadangos and Young, 2008). pDCs have also been 
shown to be able to induce Tregs (Moseman et al., 2004). 
 
cDCs are more common than pDCs, are highly mobile between various body 
compartments and can be further sub-divided according to the tissue of residency. cDCs 
in the epidermis, for example, are called Langerhans cells and express langerin and 
CD205, while some of the DCs in the dermis express CD209 and can activate antibody-
producing B cells (Steinman and Banchereau, 2007). Dendritic cells in the intestine are 
characterized by the common marked CD11c and can be divided into two further 
subsets according to CD103 or CX3CR1 expression (Laffont and Powrie, 2009). DCs of 
either type are closely related to macrophages and monocytes so it is not surprising that 
DCs are derived from a macrophage/DCs precursor population (MDPs) residing in the 
bone marrow, which subsequently differentiates into monocytes and common DCs 
precursors (CDPs). CDPs would then differentiate into DCs but not into monocytes. Of 
note, in fact, while differentiation of DCs from monocytes is well-established in vitro 
(Sallusto and Lanzavecchia, 1994) and is possibly the preferred technique for DCs 
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generation in laboratories worldwide, in vivo this seems not to be the preferred pathway 
for DCs differentiation (Fogg et al., 2006).  
 
1.3.2.2  PHENOTYPE OF IMMATURE AND MATURE DCs: 
 
When in non-lymphoid tissues, DCs are in an ‘immature’ state ie. they do not express 
the costimulatory signals required for T cell activation. During their time in non-
lymphoid tissues, in fact, DCs tend to sample their environment and display a 
phenotype characterized by high phagocytosis and continuous internalization of 
antigens (Banchereau et al., 2000), either particulate or soluble, via phagocytosis, 
endocytosis or macropinocytosis. They can also acquire microbial pathogens, dead or 
dying cells, and immune complexes (Rossi and Young, 2005). DCs are actually able to 
recognize different pathogens through the expression of pattern recognition receptors 
(PRR), which interact with specific microbial structures called pathogen-associated 
molecular patterns (PAMPs). Immature DCs can present antigens to T cells but this 
presentation is inefficient and results either in an abortive T-cell activation and 
induction of anergy (Sotomayor et al., 2001) or differentiation of regulatory T cells 
(Jonuleit et al., 2001). In fact, it has been shown that immature mDCs, characterised by 
a low expression of costimulatory molecules (CD80, CD86 and inducible costimulatory 
ligand or ICOSL) have the potential to induce suboptimal T cell priming, thus often 
leading to T cell tolerance (Steinman and Nussenzweig, 2002), and to inhibit 
alloantigen-specific T cell responses. These immature DCs are able to improve the 
survival of grafted organs after their transfer across an MHC barrier (Fu et al., 1996). 
Therefore, the full maturation of DCs prior to its interaction with T cells is an important 
requisite for T cell activation.  
 
Antigen uptake, together with exposition to inflammatory cytokines, provokes DCs 
maturation, which is usually completed in 24 hours. The maturation of DCs involves 
downregulation of antigen uptake and processing, upregulation of antigen presentation 
and migration to the local draining lymphoid tissue. DCs maturation is also 
characterised by an increase in the expression of MHC I and II molecules on the cell 
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surface. This feature results from both an increase in the efficiency of antigen 
processing for both MHC class I and II pathways (Guermonprez et al., 2002) and a 
longer persistence on the cell surface for the peptide MHC class II complexes, which 
would be otherwise rapidly recycled (Shin et al., 2006). The costimulatory molecules 
CD80 and CD86 and the marker of cell activation CD83, required for T cell activation, 
are also up-regulated (Banchereau et al., 2000). The extent and type of innate and 
adaptive immune response elicited by the activated DCs depends on the type of signal 
that activated them. The maturation of DCs involves several stages each with its 
specific kinetic of expression of cytokines and surface molecules critical for initiation 
and control of both innate and adaptive immune responses (Langenkamp et al., 2000 
and Granucci et al., 2001). In particular, inflammatory molecules such as the tumour 
necrosis factor (TNF) are strongly upregulated immediately after bacteria stimulation, 
but subsequently downregulated. This suggests that inflammatory activity of DCs takes 
place, in its main part, early after activation, before DCs left the inflammatory site.  
 
1.3.3  γδ T CELLS AS APC FOR STRESS-RELATED RESPONSES: 
 
The antigen presentation system in which the key players are DCs and macrophages 
provides a good description of the immune surveillance targeting microbial/viral 
pathogens. However, the immune surveillance dealing with nonmicrobial stress is less 
well known, at the moment, and is the focus of active investigation. While DCs and 
monocytes should be able to mount a response against some stress signals released from 
dying cells, such as ATP (Rock and Kono, 2008), they may not be able to recognize a 
more diverse range of molecules such as MICA, which is up-regulated on epithelial 
cells following various physicochemical perturbations, is expressed by tumour cells and 
is present at inflammatory sites (Groh et al., 1996 and Groh et al., 1999). These 
antigens are recognised by NK cells and “nonconventional” T cells, of which γδ T cells 
are the main representatives (Hayday, 2000). After one of their receptors, including the 
TCR, is engaged with a stress-related antigen, γδ T cells are able to initiate a fast-acting 
lymphoid stress-related response that is not constrained by either clonal expansion or de 
novo differentiation (Strid et al., 2008). Such a quick response would necessitate a high 
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frequency of γδ T cells ready to react upon activation mediated by autologous stress 
antigens, common pathogens, or a combination of both. The full range of ligands able to 
engage the TCR γδ receptor has not been fully established; however, it has been 
ascertained that most of the ligands are not β2m-dependent. Two murine MHC-I-related 
proteins termed T10 and T22 have been shown to ligate two independently derived γδ 
TCR (Adams et al., 2008).  
Better known, at the moment, is the reactivity of human Vγ9Vδ2 cells to low molecular 
mass phosphoantigens (Hayday, 2000). In accordance with the stress surveillance 
model, phosphoantigens can be either of autologous origin, such as 
isoprenylpyrophosphate (IPP), which is accumulated in virus-infected and transformed 
cells (Hayday, 2000), or pathogen-derived such as hydroxymethyl but-2-enyl 
pyrophosphate (HMBPP), an intermediate of the MEP pathway of isoprenoid synthesis 
shared by many prokaryotes and pathogens (Eberl et al., 2003), including the malarial 
parasites. Of interest, aminobisphosphonates, which are currently used in therapy 
against osteoporosis and myeloma, inhibit farnesyl pyrophosphate synthase in patients 
and this results in IPP accumulation and Vγ9Vδ2 activation (Kunzmann et al., 1999). A 
scheme summarising all the known ligands for γδ T cells, together with the possible 
activation outcomes, is presented below in Figure 1.8. 
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γδ T cells are able to exert a wide range of functions. They are effector cells and among 
the first IFN-γ-secreting cells both in mice and human and as such are essential 
contributors to host survival in early life (Gibbons et al., 2009). In fact, in adults γδ T 
cell exert a cytotoxic effect towards various malignancies, including leukaemias (Lamb 
et al., 2001), and respond to virus, parasites and bacteria (Boismenu and Havran, 1998). 
It was recently shown that γδ T cells produced IFN-γ and proliferated in response to a 
M. tuberculosis-derived antigen (Li and Wu, 2008). An effector/cytotoxic phenotype 
has been suggested in CB as well (Engelmann et al., 2005 and Campos Alberto et al., 
2009). Finally, Moser’s group showed unequivocal antigen presenting activity for the 
Vγ9Vδ2 subset in adults, thus broadening γδ T cell functionality (Brandes et al., 2005 
and Brandes et al., 2009).  
Figure 1.8: scheme resuming the main activatory ligands, and possible outcomes of activation, for 
γδ  T cells. Modified from Hayday, 2009.  
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1.4.0  ARTIFICIAL APCs: 
 
As described above, DCs are the most effective APCs and as such they would be ideal 
candidates for immunotherapeutic applications. However, preparing DCs cells for 
clinical use is extremely challenging (Kim et al., 2004). DCs generation is cumbersome 
in itself due to the need for autologous cells. The task is also technically difficult due to 
the requirement of a sufficient number of activated cells, suitably differentiated and 
rapidly and reproducibly generated (Oelke et al., 2003). This is a more acute problem in 
patients with advanced disease (Steenblock et al., 2009). Moreover, the APCs should be 
unaffected by tumour and viral immune evasion strategies responsible either for the 
disease itself or the malfunctioning of the physiological APC in the first place.  
 
An artificial system for antigen presentation would solve many of the problems 
presented by DCs generation. Ideally an artificial APC (aAPC) platform should have 
the following characteristics: it should be able to traffic the human body safely, it 
should be biodegradable, cell compatible, inert (non toxic and non tumourigenic), it 
should be capable of forming T immunological synapse and delivering adequate T cell 
signal and finally be as small as possible and yet traceable in vivo. Another ideal 
requirement would be the “one-type-fits-all” quality, i.e. it should be possible for the 
same aAPC to be loaded with different peptides/molecules and therefore be used for a 
large variety of diseases (Oelke et al., 2005). These requisites would be best satisfied by 
a non-cell based aAPCs system, which would also offer the further advantage of 
ensuring its efficacy is unaffected by the pathology, whatever may happen to the 
endogenous APC. Non-cell based systems offer also complete “off-the-shelf” 
availability, while it is more difficult envisaging a way to avoid the culture requirements 
of any cell-based aAPC. There are many features of a T cell that should be elicited by 
an ideal aAPC: the signals received from T cells during the ex vivo expansion affect 
their specificity but also the potential survival, their tropism, their differentiation into 
functional subsets and the generation of memory cells. Ideally all these characteristics 
should be elicited by an aAPC. 
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1.4.1  CELL-BASED ARTIFICIAL APCs: 
 
A number of cell-based and acellular APCs systems fulfil part of the requirements 
quoted in the paragraph above. Mouse fibroblasts, engineered to express an HLA 
molecule and 3 costimulatory molecules (CD58, CD80, CD54), proved to be as 
effective as autologous APCs (Latouche and Sadelain, 2000). Insect APCs cells from 
Drosophila melanogaster, pulsed with a melanocyte-derived peptide, were able to 
generate 109 cytotoxic T lymphocytes within one month starting from 1010 PBMCs 
(Mitchell et al., 2002). A human leukemia cell line, K32, has been transformed in a 
potent amplifier cell following transfection with CD32 (low affinity Fcγ receptor) and 
subsequent incubation with anti-CD3 and anti-CD28 antibodies: these cells were 
capable of promoting a 1,000 fold increase in the T cell population, getting up to 1010 
polyclonal T lymphocytes after starting from 500 ml of blood (Maus et al., 2002). More 
recently, Barber et al., 2006, developed a cell-based APC system where Daudi B cells, 
which do not naturally express HLA class I, were coated with fixed amount of HLA 
class I monomers and used to stimulate PBMCs in vitro. These modified Daudi cells 
promoted the expansion of CMV epitope-specific CD8 T cells from 0.03% to 30.6% in 
two weeks, a result comparable to the use of peptide-loaded dendritic cells (Barber et 
al., 2006).  
 
All the systems here described, although effective, would not be appropriate for an in 
vivo use due to the origin of the cells employed. In fact, any cell-based aAPC system 
would be unsuitable for an in vivo destination, regardless of the origin of the APCs cells 
employed, as there would be a rejection of the exogenous cell product once transferred 
in the patient. A more appropriate option for an in vivo compatible aAPC would then be 
an acellular platform. In the next paragraphs an overview on the state-of-the-art aAPC 
will be presented. Exosomes will be presented first, as they are at the interface between 
physiological and artificial APC.  
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1.4.2.  NON-CELL-BASED ARTIFICIAL APCs: 
1.4.2.1  EXOSOMES: 
 
A possible aAPC acellular system is represented by exosomes, small (30-100 nm) cell-
derived vesicles enclosed by a lipid bilayer and secreted in the extracellular space 
(Thery et al., 2002b and Thery et al., 2009). There is a wide range of vesicles that can 
be secreted either directly from the plasma membrane or after the fusion of cytosol 
compartments that contain intraluminal vesicles with the plasma membrane. The term 
exosome has been specifically used since 1987 for only this second group of vesicles –
i.e., exocytosed vacuoles of endosomal origin (Pan et al., 1985 and Thery et al., 2009). 
Exosomes are secreted exclusively by living cells (Thery et al., 2001). Moreover, 
exosomes derived from various cell types (murine DCs, human intestinal epithelial cells 
and EBV-transformed B cells) displayed similar characteristics; all were enriched in 
MHC class II molecules and contained heat shock proteins, annexins, integrins, 
cytoskeleton proteins and MHC class I molecules (Mignot et al., 2006). True exosomes 
share physical and chemical characteristics with the late endocytic compartments, 
however the precise nature of the intracellular location/organelle from which they 
derive is still unknown. Their secretion by the parent cell depends on the type of cell 
involved; while in T (Blanchard et al., 2002) and resting B lymphocytes (Saunderson et 
al., 2008) the secretion is inducible, in DCs (Zitvogel et al., 1998) and EBV 
transformed B cells (Raposo et al., 1996) it is constitutive, as it is in most tumour cell 
lines. In the case of DCs, it has been shown that exosome secretion is more relevant in 
immature rather than mature DCs (Thery et al., 1999). This suggests that exosome 
secretion is modulated by both cell types and environmental changes; it is possible that 
such a feature is one of the means cells use to adapt to these changes (Thery et al., 
2009).  
 
As both antigenic material and MHC-peptide complexes are present on the exosome 
surface, they have sparked the interest of immunologists regarding their possible role in 
eliciting immune responses. Exosomes purified from tumour cell lines (Wolfers et al., 
2001) can induce the activation of antigen-specific T cells in vitro in presence of 
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recipient DCs, even if the professional APCs have not encountered the antigen 
previously. This indirect activation of recipient DCs has also been shown in the case of 
bacterial infection, for both M. tuberculosis and M. bovis (Giri and Schorey, 2008) and 
CMV (Walker et al., 2009). In some circumstances, moreover, the MHC-peptide 
complexes on the exosomes surface can be directly presented to T cells.  
 
Minami’s group, among others, reported that DCs-derived exosomes were able to 
activate CD8+ve T cell clones on their own (Utsugi-Kobukai et al., 2003), while 
Zitvogel’s group showed the same outcome even when exosomes were incubated with 
DCs bearing allogeneic MHC class I complexes, thus indicating that the exosomes-
derived MHC molecules were functional (Chaput et al., 2004). However, tumour-
derived exosomes seem to be able to activate CD8+ve T cells only when incubated with 
recipient DCs bearing the correct MHC haplotype (Wolfers et al., 2001). When derived 
from a B cell, exosomes can provoke CD4+ T cell proliferation, in vivo, but the 
efficiency is not optimal (Raposo et al., 1996). More interestingly, purified exosomes 
can be loaded with antigenic peptides and tumour-derived exosomes can be used for 
immunization, resulting in a better efficiency than immunization with irradiated tumour 
(Wolfers et al., 2001).  
 
1.4.2.2  OTHER ACELLULAR OPTIONS: 
 
The aAPCs described in literature so far belong to four different types: latex beads, 
magnetic beads, biodegradable polymers and liposomes (Steenblock et al., 2009).  
 
1.4.2.3  LATEX BEADS: 
 
Latex beads are rigid spheres that can be coated, via nonspecific interactions, with 
different ligands and as such perform as aAPCs. They are non-physiological and do not 
have a fluidic interphase, but despite these main disadvantages they have been proven 
very useful to study APC-T cell interactions (Curtsinger et al., 1997). Latex bead-based 
aAPCs were first used to prove that the size of the antigen-presenting particle is a 
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crucial factor for T cells stimulation (Mescher, 1992). Latex microbeads covered with 
either MHC class I molecules or tumour cells-derived membranes were used to activate 
splenocytes and it was found that the degree of activation depended on size, with 4-5 
µm diameter aAPCs resulting the most effective (Mescher, 1992). Crucially, it was also 
discovered that T cell responses were dependent on the density of ligands per bead, 
rather than to the number of beads presenting at lower densities (Deeths and Mescher, 
1997). It was discovered, as well, that T cells responses were dependent on exogenous 
cytokines for a sustained proliferation, despite acquiring effector phenotype after three 
days of stimulation (Deeths and Mescher, 1999). Oosten et al., 2004, used latex beads 
coated with costimulatory molecules and minor histocompatibility antigens-MHC 
complexes to expand peptide-specific CTL cell lines while Whitelegg et al., 2005, 
employed CD54, CD80 and MHC class I coated-latex beads to study peptide-
independent allorecognition. Finally, latex bead-based aAPCs were also used for 
clinically relevant studies: the stimulation of PBMCs from healthy donors with latex 
beads covered with MHC and a glioma epitope, CD28 and CD83 lead to an expansion 
of glioma antigen-specific cells of 50-60 folds over 4 weeks (Jiang et al., 2007).  
 
1.4.2.4  MAGNETIC BEADS: 
 
When the aAPCs are large (5 µm or more) their separation from the expanded T cells 
becomes a fundamental step to prevent in vivo complications such as embolism. This 
size prerequisite makes magnetic beads very attractive; in addition to the ease in 
coupling T cell ligands via biochemical techniques, they can be removed from the cell 
suspension simply using a magnet.  
Non-antigen-specific CD4+ve and CD8+ve expansion was obtained when cells were 
stimulated with magnetic beads coated with anti-CD3 and anti-CD28 particles (Levine 
et al., 1997). Magnetic beads also showed potential in an antigen-specific system, where 
influenza-specific tetramers coupled to the beads were able to maintain antigen 
specificity in CD4+ve sorted cells over 9 weeks of culture (Maus et al., 2003). When 
MHC dimers coupled to magnetic beads were used in a melanoma-specific system, up 
to 109 MART-1 specific cells were obtained in less than 2 months (Oelke et al., 2003).  
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1.4.2.5  BIODEGRADABLE PARTICLES: 
 
While biodegradable polymers (BPs) are particularly suitable as vehicles due to their 
flexibility in size and to the ability of encapsulating cytokines, they present a particular 
challenge for antigen presentation, as their biodegradable nature compromises long-
term surface ligand presentation. This may result in insufficient time of ligands being 
exposed on the surface to attain successful antigen presentation. However, the most 
widely used polymers -aliphatic polyesters- have a degradation rate ranging from days 
to months (Steenblock et al., 2009).  
Three years ago it was published that the stimulation of unsorted murine splenocytes 
using poly(lactide-co-glycolide) (PLGA) particles that presented anti-CD3 and anti-
CD28 and released IL-2 resulted in a marked skewing to 100% CD8+ve cells by day 4 
(Steenblock and Fahmy, 2008). This population expanded 45-fold in one week and this 
effect was not observed without encapsulation of IL-2. Few studies have used any of the 
aAPC platforms described above, or liposome-based systems, as APC in vivo. Among 
these studies, the focus has been on latex and magnetic beads and on biodegradable 
polymers as aAPC. Very little has been accomplished when using liposomes as aAPC in 
vivo (Steenblock et al., 2009).  
 
1.4.3  LIPOSOMES: 
 
The fourth acellular APCs system is based on liposomes, small (up to 150 nm) vesicles 
made up of a lipid bilayer. Liposomes are similar to very small empty cells, having a 
cell membrane with a hydrophilic-based internal cavity but no organelles. The lipid 
molecules used to build liposomes are usually phospholipids with or without additional 
additives. For example, cholesterol is a common component as it improves the lipid 
bilayer’ characteristics: it helps increasing the microviscosity of the lipidic vesicle and 
stabilizing the membrane (Vemuri and Rhodes, 1995). Liposomes’ long-standing 
popularity as biological vehicles can be ascribed to their ease of preparation; they self-
assemble easily in aqueous buffers and their sizes can be adjusted from 60 nm to 1 µm 
via mechanical methods (Steenblock et al., 2009).  
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The first research involving liposomes date back to the late 1970s when they were 
studied to encapsulate and deliver chemotherapy (Gregoriadis, 1976). Although 
liposomes were not defined nanoparticles at that time and despite their dimensions 
being slightly bigger than what would qualify them as nanotechnology (minor or equal 
than 100 nm), their research was propelled by the current “nanotechnology moment”. 
Today a significant portion of nanotechnology research in biomedicine is focused on 
liposomes (Kim et al., 2004).  
  
1.4.3.1  LIPOSOMES AND DRUG DELIVERY: 
 
Recently liposomes have been widely employed for drug delivery purposes (Park, 2002 
and Mamot et al., 2003, review the topic), where the drug is enclosed in the liposome 
thus increasing its half-life in the organism. Among the best characterized uses for 
liposomes is the encapsulation of doxorubicin, a member of the anthracyclines class of 
drugs, whose use is severely limited by systemic toxicity (Park, 2002). In particular, 
pegylated liposomal doxorubicin (Doxil®) is characterized by a prolonged circulation in 
the organism, with a terminal half-life of 55 hours, due to the reduced interaction with 
plasma protein and phagocytes conferred by the pegylated lipids on the surface (Park, 
2002). Liposomal daunorubicin (DaunoXome®) too has been approved for cancer 
treatment. Manipulating their lipid formulation, the liposomes can be made temperature 
or pH sensitive, to allow controlled release of their content. Mills and Needham, 2004, 
managed to construct temperature-sensitive liposomes that released their drug content in 
tens of seconds at clinically feasible hyperthermia (39-42°).  
 
1.4.3.2  IMMUNOLIPOSOMES: 
 
Immunoliposomes –liposomes in which fragments of monoclonal antibody (Fab) are 
conjugated to the surface- are an important component in the development of new, 
molecularly-targeted drug delivery systems. They can be engineered to promote specific 
binding to a target antigen followed by receptor-mediated endocytosis (Mamot et al., 
2005). In addition to targeting, the drug delivery is also rendered more efficient by the 
                                                                                                                                        Chapter 1 
  
  
 
   65 
immunoliposome and a drug delivery in the cytoplasm can potentially overcome the 
chemotherapeutic resistance due to membrane efflux system (common in cancer 
settings). So far, immunoliposomes have been used mainly for drug delivery purposes. 
Promising results have been achieved targeting the liposomal doxorubicin to specific 
receptors; immunoliposomes targeted to HER-2 overexpressing tumour cells show 
increased therapeutic efficacy in delivering the drug in preclinical model (Park, 2002) 
and they can be prepared from existing liposomal doxorubicin. Immunoliposomes have 
also been directed against the epidermal growth factor receptor (EGFR) and in vitro 
experiments showed a massive internalization in the cytoplasm of EGFR-
overexpressing cells. The same immunoliposomes showed also a marked cytotoxicity 
when encapsulating a chemotherapeutic drug such as doxorubicin or methotrexate 
(Mamot et al., 2003). Also, non-antibody mediated targeting of liposomes have been 
attempted: one example is folate targeting, pursued conjugating liposomes to folic acid 
and then exploiting the folate receptor pathway in cancer cells. Studies in a murine 
resistant lung carcinoma model showed that folate-targeted liposomal doxorubicin had a 
superior efficacy compared to non-targeted doxorubicin when assayed in an in vivo 
model (Goren et al., 2000).  
 
1.4.3.3  LIPOSOMES AND ANTIGEN PRESENTATION: 
 
The enhanced efficiency of molecular interactions, when occurring within fluid 
biological membrane, was first highlighted by A. Delbrueck (1968). It has also been 
shown that antigen presentation is more efficient if the antigens are taken up within 
particles rather than from a solution (Shen et al., 1997). As the formation of the immune 
synapse requires that the molecular interaction progress in an orderly configuration of 
which the lipid bilayer is an essential component, it can occur also via liposomes. The 
first mention for liposome-based antigen presentation dates back to 1978, when 
Burakoff’s group prepared liposomes derived from cell membranes and used them as an 
aAPC for the stimulation of polyclonal murine lymphocytes (Engelhard et al., 1978). 
Subsequent works used liposomal aAPCs prepared using different lipids formulations 
and tumour cells or viral membranes (Finberg et al., 1978 and Weinberger et al., 1985). 
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As already seen for magnetic beads, it was found that the level of stimulations depended 
on the density of T cell antigens on the liposome’ surface.  
Albani’s group embedded MHC class II molecules in unilamellar liposomes and mixed 
it with CD4+ T cells; this resulted in IL-2 secretion (Prakken et al., 2000). Moreover, 
the MHC clusters induced on liposome-stimulated cells were very similar to the 
physiological clusters induced by natural APCs (Prakken et al., 2000). It was also 
shown that the preliminary clustering of T cells antigens into microdomains in the 
liposomes improved aAPC function (Giannoni et al., 2005). In fact, when incubated 
with human T cells for polyclonal expansion, liposome-based aAPC where antigens had 
been previously clustered in microdomains achieved preferential CD8+ve T cells 
expansion and avoided terminal differentiation in vitro. Moreover, a robust expansion 
of MelanA-specific T cells was observed after 2 weeks of stimulation using liposome-
based aAPCs and IL-2 and IL-15 in the culture; however, the aAPCs themselves were 
not antigen-specific and the cells had been incubated with MelanA-pulsed T2 cells prior 
aAPC expansion (Zappasodi et al., 2008).  
 
1.5.0  ARTIFICIAL ANTIGEN PRESENTATION AND ITS CLINICAL 
APPLICATION: 
 
This PhD project will focus on the development and characterization of artificial 
antigen presentation systems to be used in clinical settings. In particular, it will 
concentrate on hematopoietic stem cell transplantation (HSCT) and on how to target 
post-transplantation infections and improve the outcome via immunotherapy. Therefore, 
a brief overview of HSCT, immunotherapy and cytomegalovirus infection, which is one 
the main complication occurring after HSCT, will be now presented.  
 
1.6.0  HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): 
 
Hematopoietic stem cell transplantation (HSCT) is now the most effective treatment for 
a variety of haematological diseases, such as myelomas, non-Hodgkin’s lymphoma, 
acute and chronic myeloid leukaemia, acute lymphoblastic leukaemia, aplastic anaemia, 
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Fanconi’s anaemia and SCID (Copelan, 2006). Prior to undergoing transplant, patients 
who are eligible for HSCT –regardless of the underlying disease- need a preparatory 
treatment, or regimen, which can consist of chemotherapy, total body irradiation, or a 
combination of the two. This is performed in an attempt to remove the underlying 
condition and, in the case of allogeneic HSCT, to establish the immunosuppressed state 
that will allow a successful engraftment. Once the transplantation has been performed, 
T cells from the recipient will recognize donor antigens (especially MHC molecules –
see below) and this can cause graft failure. On the other hand, donor T cells will 
recognize recipient MHC-mismatched antigens; this process is responsible for both 
graft-versus-host-disease (GvHD) and graft-versus-tumour (GvT) activity, which are 
tightly related effects.  
 
Both graft failure and GvHD are the clinical manifestation of the immune response to 
allogeneic cells (i.e, cells that have different alleles at one or more loci, especially 
MHC). Cells of donor origin can be recognised by the B, NK and T cells of the 
recipient as they do not express the same MHC alleles and this can result in graft 
failure, while the recognition of recipient cells by the donor effector cells (mainly T 
cells) is responsible for the beneficial GvT/L effect. T cells are the most relevant 
players in alloreactivity (i.e, an immune response against cells with a mismatched 
MHC), as shown by the fact that T cell suppression is the main approach to control 
alloreactivity in transplant patients (Whitelegg and Barber, 2004). During thymic 
maturation, T cells are selected to form a repertoire of lymphocytes that interact 
preferentially with the MHC molecules expressed by the same individual (Kisielow and 
Von Boehmer, 1995). The phenomenon where T cells recognise MHC molecules they 
have not been previously exposed to is termed allorecognition and could be considered 
a paradox in the context of thymic selection. Alloreactive T cells (around 1-10% of total 
T cells, Suchin et al., 2001) are able to elicit a very strong immune reaction; the 
phenomenon was firstly shown by the protocol of mixed leukocyte reaction, or MLR, 
where T cells from two different individuals are co-cultured to assess the proliferation 
of the T cells from one donor against the other (Janeway, 2005). 
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GvHD is highly detrimental, while GvT/L is very effective in eradicating the 
malignancy and is the main mechanism accounting for the use of transplant as a 
therapy. GvHD is one of main complications when performing HSCT; it can be 
localized and easily treated or develop into a multisystemic syndrome affecting skin, 
gut and liver. When not prevented by appropriate prophylactic chemotherapy 
(methotrexate and cyclosporine, for example) almost all HSCT recipients are affected 
by GvHD (Sullivan et al., 1986). The main risk for GvHD occurrence is HLA 
mismatch, however it can occur also in HLA-matched patients and despite preventative 
measures. Depleting T cell in the graft prior transplantation can reduce GvHD, but this 
results in an increased rate of graft failure, opportunistic infections and relapse (Wagner 
et al., 2005), so the disease-free survival rate is not improved. The GvT/L effect can 
explain the reduced rate of relapse after either allogeneic HSCT (as compared to HSCT 
where the donor is an identical twin) and in patients who develop GvHD compared to 
those who do not (Horowitz et al., 1990).  
 
The source of stem cells available for HSCT is varied. Traditionally stem cells of bone 
marrow origin (obtained by repeated aspiration from the iliac crests while the donor is 
under local or general anaesthesia) were the first to be employed. Moreover, stem cells 
can also be found in peripheral blood, due to their recirculation between blood and bone 
marrow. The number of stem cells can be estimated from the expression of CD34+ve 
cells and in peripheral blood they are very few, less than 0.06% of total nucleated cells 
(Korbling and Anderlini, 2001). However, stem cells can be successfully mobilized 
from the bone marrow into the blood using the granulocyte colony-stimulating factor 
(G-CSF). Compared with bone marrow-derived cells, stem cells of peripheral blood 
origin contain more T cells, resulting in a more rapid reconstitution but increasing the 
incidence of chronic GvHD (Cutler et al., 2001). However, both these sources rely on 
adult donors; it is estimated that international registries (for all patients who do not have 
an HLA-matched sibling or relative) can find a suitable donor for more than 50% of the 
patients. As such, there is a dire need for alternative sources of stem cells to find a 
match for the remaining patients awaiting transplantation.  
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1.6.1  CORD BLOOD TRANSPLANTATION:  
 
Cord blood (CB) has been used as a source of hematopoietic stem cells (HSC) 
alternative to bone marrow and mobilized peripheral stem cells for a variety of diseases. 
The proof of principle for CB-derived HSCT came in 1988, when E. Gluckman and her 
team successfully transplanted an 8-years-old boy suffering from Fanconi’s anaemia, 
reaching complete chimerism one month after transplantation (Gluckman et al., 1989). 
This first milestone proved that one CB contained enough HSC to guarantee 
engraftment, at least in paediatric patients. Since then, CB has now been used to 
transplant more than 20000 patients both adults and paediatric (data referred to 2009).  
 
Three potential advantages of CB use in HCST were clear from the beginning: firstly, 
CB was most likely to be free from herpes virus contamination. Secondly, CB 
collection could be targeted –a feasible and practical strategy to increase the 
representation of ethnic minorities samples in the registry- and, most importantly, HLA-
typed, frozen CB was ready to use as and when required, without the delays required for 
typing and collecting compatible adult donors samples (Wagner and Gluckman, 2010). 
The lack of collection-related risks for the donor (i.e. the mother/baby after delivery) 
was another attractive feature (Gluckman, 2009), as it was the ease of collection. So far 
cord blood transplantation (CBT) has been shown to have a delayed engraftment and 
lower GvHD compared to HLA-identical sibling transplant (Rocha et al., 2000). This is 
possibly due to the low number of CD34+ve cells in CB (if compared with adult HSC) 
(Rocha et al., 2000); this feature is a limitation to the use of CB in transplantation, 
especially in adult patients. However mismatched CB, if compared with matched 
unrelated bone marrow, can promote a similar long-term leukaemia-free survival in 
both children (Rocha et al., 2001) and adults (Takahashi et al., 2007). Improvements in 
adults transplantation were also obtained with strategies designed to increase the 
CD34+ cell dose, such as the use of double CB transplant (Ballen et al., 2007) and the 
combination of single-unit CB transplant with the co-infusion of mobilized 
haematopoietic stem cells (MHSC) from a third party donor (Bautista et al., 2009; 
Martin-Donaire et al., 2009).  
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As general features, the decrease in GvHD observed in CB transplantation is 
accompanied by a higher rate of post-transplant infections, especially CMV 
reactivation, and by a slowed immune reconstitution when compared to HSCT using 
adult-derived stem cells. More specifically, neutrophils and NK cells return to 
physiological levels in the first 2 months after transplantation but CD4 and CD8 T cells 
remain low for 6-12 months (Komanduri et al., 2007), resulting in a longer period of 
immunodepression compared to adult HSC recipients. CB transplanted patients also 
experience a slower engraftment when compared to adult-derived HSCT. The increased 
naivety/immaturity of CB cells may account for all these observations.  
 
To summarize, HSCT is more effective in establishing cure and remission than 
alternative chemotherapy-based treatments, but is also responsible for a substantial 
treatment-related morbidity and mortality (Wagner and Gluckman, 2010). Even if the 
transplant-related mortality of some allogeneic HSCT is less than 10%, there will be an 
approximate rate of 40% fatality among the patients with established malignancy who 
undergo HSCT, and this will depend on complications related to the transplant. 
Transplant-related infections, mainly of fungal and viral origin, play a major role in 
this; therefore, any treatment against them (including immunotherapy) has great 
importance in HSCT. 
 
1.6.2  IMMUNOTHERAPY:  
 
Immunotherapy is defined as a treatment that elicits therapeutic responses against a 
disease primarily through the host immune defence mechanisms, either innate or 
adaptive (Kim et al., 2004). The aim of immunotherapy may vary depending on the 
ongoing pathology: it can be elimination of damaging cells, either cancer or virus-
infected ones, or protection of healthy tissue from immune destruction, as can happen in 
graft rejection or autoimmune diseases. These objectives can be reached via either cells- 
and/or cytokines-mediated action, as shown below in Figure 1.9. Concentrating on 
cellular-mediated immunotherapy only, broadly speaking it can belong to one of two 
categories: the active one aims at the introduction of antigens into the patient in an 
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immunogenic form, either to break tolerance or to activate T cell subsets; vaccination is 
a well known and very successful form of active cellular immunotherapy (Mocellin et 
al., 2004). In the adoptive immunotherapy immune cells are instead collected, 
stimulated and expanded ex vivo and then infused in the patient. Figure 1.9, below, is a 
scheme resuming all the main types of immunotherapy available, with examples for 
each major subtype. 
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Figure 1.9: scheme of all types of immunotherapy. Modified from Van Den Bosch et al., 2006.  
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1.6.3  CYTOMEGALOVIRUS (CMV): 
 
CMV is one of the largest and most complex viruses known so far. Belonging to the 
herpes virus family, CMV is a double stranded DNA virus whose genome (230 Kb), 
enclosed in an icosahedral nucleocapsid, is surrounded by both a matrix and a lipid 
bilayer containing a variety of viral glycoproteins. A large proportion of the matrix 
proteins are phosphorylated and potently immunogenic; the most abundant are pp150 
(UL32) and pp65 (UL83) that is one of the main CMV antigens. pp65 is synthesized 
early in the lytic cycle and the regulation of its production is likely to play a major role 
in controlling the latent state (Peggs, 2009). CMV is a species-specific ubiquitous 
pathogen and the co-evolution occurred within its human host led to the development of 
a number of immune evasion strategies that allow the survival of a significant viral 
reservoir in infected individuals, mainly in the mononuclear leukocytes subset. Around 
50 to 80% of the USA adult population is infected with CMV by the 40th year of life 
(from http://www.cdc.gov/cmv/facts.htm), yet the infection is asymptomatic in the 
majority of cases. Despite its lack of clinical symptoms in healthy patients, the 
percentage of the host immune system devoted to CMV control is remarkable, as up to 
1-2% of both the CD4 and CD8 compartments in young samples’ cohort and up to 30-
40% in elder cohorts are CMV-reactive (Pourgheysari et al., 2007).  
 
1.6.4  THE IMPACT OF CMV IN HSCT: 
 
In some cases, symptoms that are indistinguishable from those of infectious 
mononucleosis occur in the host upon primary CMV infection. However, viral 
replication is in most cases not clinically relevant in healthy patients. This may allow 
the virus to spread both horizontally and vertically but, even so, systematic 
dissemination events remain rare in immunocompetent hosts, as the virus is kept in 
check by both innate and adaptive immunity.  
However, the virus-host existence is severely altered when the host immune system is 
suppressed, for example following HIV infection or allogeneic HSCT. In these 
circumstances CMV disease -defined as viral dissemination with end-organ disease- has 
                                                                                                                                        Chapter 1 
  
  
 
   74 
a lethal potential and at the very least is a significant cause of morbidity. As the main 
reservoir for CMV is the leukocyte cell subset in blood, the use of leukocyte-depleted 
blood or blood products can diminish the risk of primary CMV infection upon HCST. 
However, viral replication and dissemination takes place in 60-70% of CMV-
seropositive transplant recipient, while the rate of primary infections for CMV-
seronegative recipients with CMV-seropositive donors is between 20 and 40% (Peggs, 
2009). Once viral replication occurs, if left untreated, it leads, in 40-50% of the total 
cases, to a symptomatic disease whose most common manifestations are interstitial 
pneumonitis (CMV-IP), hepatitis or gastrointestinal disease (Van Den Bosch et al., 
2006). Among all the clinically relevant symptoms, CMV-IP is the most important as it 
has an associated mortality of around 90%; antiviral drugs (ganciclovir, foscarnet) are 
available, but their limited efficacy once CMV-IP is established and the relevant 
morbidity associated with their use (renal toxicity and suppression of myelopoiesis) 
urgently call for alternative ways to control CMV infection. In this light, the 
reconstitution of pathogen-specific immune protection via immunotherapy is an 
attractive and promising strategy.  
 
1.6.5  IMMUNOTHERAPY FOR CMV IN HSCT SETTING: 
 
One of the main objectives in immunotherapy is to generate an effective cell-mediated 
immune response, particularly in the case of CMV infection where the virus persists in 
a latent state. In HSCT setting, CMV reactivation occurs rapidly after the 
immunosuppressive treatment is started. Moreover, it is possible that alloreactive 
immune responses play an important role in CMV reactivation, as the incidence of 
CMV-related morbidity is higher in allogeneic transplantation than in syngeneic setting 
(Soderberg-Naucler and Nelson, 1999).  
 
The transfer of antigen-specific T cells from the stem cell donor to the patient takes 
place several weeks after the HSCT has been performed and is a feasible and attractive 
option to restore effective antiviral immunity in patients. Kolb et al., 1990, produced the 
demonstration that this strategy was effective in clinic, when they performed donor 
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lymphocyte infusion (DLI) in patients to decrease the rate of relapse boosting the GvT 
effect. Some years later Gadner’s group demonstrated that cellular immunity could be 
transferred via DLI when they showed a CMV-specific response in a patient after 
leukocyte administration from a CMV-seropositive donor (Witt et al., 1998). These 
approaches, despite being promising, were not pursued further due to two main reasons; 
firstly, DLI is still associated with a significant GvHD rate and, most importantly, it was 
not intended to restore viral immunity in the first place, as it is a non-specific treatment 
(Van den Bosch et al., 2006). Indeed, the advent of DLI has revolutionised HSCT 
protocol but its main application remains the treatment of a malignant disease, rather 
than infections. However, the transfer of viral-specific cells holds more potential and 
considerably less drawbacks.  
 
In fact, the finding that CMV-specific CD8 T cells conferred protection against lethal 
CMV challenge in mice (Reddehase et al., 1985) encouraged the development of 
adoptive transfer protocols in humans. Greenberg’s group performed the first adoptive 
transfer of in vitro-expanded CMV-specific T cells lines and, upon reinfusion in the 
patients, CMV-specific cytotoxicity was shown (Riddell et al., 1992). Peggs et al., 
2001, introduced a modification in the in vitro protocol for CTL generation eliminating 
the need for live virus and using viral lysate instead (Peggs et al., 2001). Using this 
approach, half of the patients treated did not require antiviral drugs (Peggs et al., 2003). 
Of particular relevance in this study was the large in vivo expansion registered in the T 
cell compartment; tetramer-mediated analysis showed that the clonal expansion of T 
cells was in the order of 1 X 103-1 X 105 fold. Hebart’s group showed that CMV-
specific, polyclonal T cell lines containing both CD4 and CD8+ve cells were effective 
against viral reactivation even when the adoptive transfer was performed very late after 
HSCT (median 120 days, Einsele et al., 2002). The use of NLV peptide, rather than 
CMV lysate, to pulse the DCs used subsequently for T cell expansion, resulted in a 
skewing towards CD8 T cells with a high efficiency (62% NLV-specific T cells 
compared to 0.2-6.5% CMV specific CD8 T cells when using lysate) (Micklethwaite et 
al., 2007). A direct selection approach (i.e. effectors cells that are not expanded ex vivo) 
is also arriving in clinical settings; Cobbold et al., 2005, published their findings about a 
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cohort of nine HSCT patients receiving cells selected by HLA-peptide tetramers of 
various specificities. While total numbers of infused cells were low (between 1.2 and 33 
X 103 cells/kg) the purity was very high (median over 95%), making the absolute 
numbers of CMV-specific cells comparable to the ones published in Peggs et al., 2003 
(Cobbold et al., 2005). Multi-specific immunotherapy has also been employed; an 
approach using DCs transduced with pp65-encoding adenoviruses to expand CTLs, 
which are then infused prophylactically after transplantation, led to an increase in 
ELISPOT analyses in 7 out of 10 patients and in an increase in tetramer-specific cells in 
4 of the 7 patients above (Leen et al., 2006). Finally, a preclinical trial involving the 
preparation of CMV specific, TCR transgenic T cells showed promising results in an in 
vitro setting (Schub et al., 2009).  
 
1.7.0  SUMMARY OF THE PROJECT: 
 
This PhD project will describe the characterization of three engineered aAPC systems 
developed with the long-term objective of using them to generate antigen-specific 
CD8+ve T cells for immunotherapy. Two of the systems are cellular-based (DCs and γδ 
T cells of CB origin) while the third is liposome-based, completely artificial and 
prepared starting from data previously generated in the Anthony Nolan Research 
Institute and published in De La Peña et al., 2009. The main antigens used in this 
project are NLV (a CMV-derived peptide) as a model for immunotherapeutic treatment 
of HSCT-related viral infections and Melan A (a melanoma-derived peptide) as a proof-
of-concept for cancer-directed immunotherapy. Chapter 3 will describe the preparation 
and use of the liposome system in two in vitro models (a CMV human system and an 
ovalbumin murine one). Chapter 4 will describe the set up and characterization of the 
CB-derived DCs model and its use to generate CD8+ve T cells in an in vitro MelanA 
system. In Chapter 5 the data regarding the analysis of γδ T cells from CB and their 
APC potential will be presented and discussed. While in the case of γδ T cells from CB 
the generation of antigen-specific CD8+ve T cells was not accomplished, this 
experiment was set up in both the other two systems under examination (DCs and 
liposomes).  
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1.0  BIOCHEMISTRY: 
 
2.1.1  LIPOSOME PREPARATION: 
2.1.1.0  MATERIALS: 
 
Five different lipids (Avanti Polar Lipids, INC) were used for the lipid mix to prepare 
liposomes: phosphatydilcholine (PC), cholesterol (CHOL), 1,2-dystearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG), 1,2-
dystearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-
2000] (MAL), [1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (RHODA). The lipids were mixed together according to the 
following published ratio (Pagnan et al., 2000, Pastorino et al., 2000 and De La Peña et 
al., 2009):  
 
PC: CHOL: DSPE-PEG: MAL = 2: 1: 0.02: 0.08.  
 
RHODA, when used, was added at 1% of PC amount, resulting in a lipid mix/batch as 
follows: 
 
PC     76 mg 
CHOL    19.33 mg 
DSPE-PEG   4.20 mg 
MAL    11.76 mg 
RHODA   0.76 mg 
 
2.1.1.1  PREPARATION: 
 
The lipids were dissolved in a round-bottomed flask using chloroform as solvent. 
Following complete solubilisation, the chloroform was evaporated under a stream of 
liquid nitrogen using a rotor evaporator (many thanks to Dr Ramesh, Royal Free 
Hospital, for his technical assistance). The resulting dry lipid mix was hydrated using 
freshly made hydration buffer (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid or 
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HEPES (C8H18N2O4S) 25 mM + NaCl 140 mM, pH 7.4, filtered and degassed) to obtain 
multilayer “onion” vesicles. The preparation was then vortexed for one hour at room 
temperature (RT) prior to extrusion taking care not to overheat the mixture. The 
extrusion step required to cut the liposome at the desired dimension (100 nanometers 
(nm)) was accomplished using a manual mini extruder kit (Avanti Polar Lipids, INC): 
using two 1-ml syringes, the hydrated onion vesicles were then passed 10 times through 
a 100 nm pore filter. The liposomes were then kept at 4°C in the dark until use; they can 
be stored for a maximum of one week (as from indication of the lipid manufacturer) but 
were usually used the day after preparation, following loading and Fast Protein Liquid 
Chromatography (FPLC) purification. An overview of liposomes’ preparation is 
reported below in Figures 2.1 and 2.2. 
 
1. 
2. 
 Figure 2.1: scheme of liposome formation. The figure summarizes the steps leading to liposome formation starting from the swelling and detachment of the dry lipid sheet to form large, multilamellar 
vesicles (LMV). LMV’s size is then reduced via either mechanical energy (extrusion, as in figure 2) or 
sonication. Figure courtesy of http://www.pharmainfo.net/reviews/liposome-versatile-platform-targeted-
delivery-drugs. Figure 2.2: mini-extruder. It was used to reduce the LMV’s dimensions, as detailed by 
the manufacturer. Figure courtesy of Avanti Lipids.  
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2.1.1.2  CHROMATOGRAPHIC PURIFICATION: 
 
Following their coupling with MHC molecules (see paragraph 2.1.2.10) the liposomes 
underwent FPLC to remove all the unbound protein monomers from the preparation. 
The chromatography was performed also on “naked” liposomes (i.e. without any 
protein coupled) to provide a suitable control in downstream experiments. All FPLC 
experiments were performed on an AKTA purifier (Pharmacia Biotech) using sepharose 
CL-4B beads (40-165 µm diameter, Pharmacia) packed in XK column (16 mm 
diameter, 20 cm length) from Amersham Biosciences. The buffer used for the 
chromatography was the same HEPES buffer used for the hydration of the lipid film. 
Liposomes, both loaded and unloaded, usually fell around fraction 2-3 (see Figure 2.3B, 
below), while unbound protein was usually retrieved in fraction 6-7 (see Figure 2.3B, 
below), or, in any case, approximately 4-5 fractions after the liposomes. 
 
 
 
 
 
 
 
 
 
 
A 
Figure 2.3: chromatographic purification of liposomes. The chromatographic plots of purification of 
A, an unloaded liposome and B, an MHC-loaded liposome (the shoulder highlighted in the red circle 
represents the unbound MHC complexes) are shown. Fractions 7-10 and 3-5, for A and B respectively, 
were collected for liposome concentration and recovery. A chromatographic purification step was 
performed at every liposome preparation. mAU, milli absorbance unit. 
B 
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2.1.1.3  CONCENTRATION, FILTRATION AND STORAGE: 
 
Following chromatographic purification the liposomes (usually 1 or 2 fractions of 3 ml 
each) were concentrated to a final volume of approximately 3 ml using Vivaspin tubes 
(Vivascience) with a molecular cut-off of 10000 Dalton as molecular weight unit 
(MWDa), as the expected weight of the loaded liposomes was around 43000 MWDa. 
Centrifugation was performed at no more than 2200 revolutions per minute (rpm) or 
687.5g not to damage the liposomal membrane and for the shortest time possible. If 
they were to be used in vitro, they were then filtered using single-use filters with 0.20 
µm pores (Minisart) and stored aseptically.  
 
2.1.1.4  FLOW CYTOMETRY OF LIPOSOMES: 
 
Liposomes were blocked with 1/10 of final volume of human serum (BioWhittaker) for 
30 minutes at RT. The relevant antibodies (anti-HLA A2/fluorescein isothiocyanate 
(FITC); Abcam, anti-HLA class I (clone W6 32) FITC; Bioscience, and 
/allophycocianin (APC); Biolegend) were then added to the blocked liposomes and 
incubated for 30 minutes more at the same conditions prior to run the samples. 
Liposomes, when analyzed by flow cytometry on their own (i.e. when they were not 
added to cell cultures), were not washed (as in regular flow cytometry staining protocol) 
due to the poor tolerance of liposomes to centrifugation. 
 
2.1.2  MHC/PEPTIDE COMPLEXES SYNTHESIS: 
2.1.2.0  CLASS I HEAVY AND LIGHT CHAIN, PEPTIDES: 
 
Two MHC heavy chain were used in this project: HLA-A*0201 (exon 2, 3 and 4 only, 
corresponding to the exoplasmic portion of the protein) and H2-Kb (exoplasmic part 
only). Both heavy chains were refolded with the human β2m light chain. All the above 
molecules were already available in the laboratory before the start of this project as 
open reading frames (ORFs) inserted in the pET3D expression vector.  
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Two peptides were used for the human HLA-A*0201 heavy chain and one for the 
murine H2-Kb heavy chain. Their full sequence is presented in Table 2.1, below. The 
NLV peptide is a well-known immunodominant CMV epitope derived from the viral 
protein pp65 (Solache et al., 1999). The MelanA-Mart1 peptide (from now on called 
MelanA) is an HLA-A*0201 restricted melanoma-related antigen. Naïve MelanA-
specific CD8+ve T cells can be detected in up to 60% of the healthy, HLA-A*0201 
positive population (Pittet et al., 1999). The ovalbumin peptide was chosen as a model 
to be used in the OT-1 transgenic mouse strain (see Table 2.3, paragraph 2.2.1.5) kindly 
made available by Prof H. Stauss (Royal Free Hospital, London). All the peptides were 
bought from Alta Bioscience, Birmingham. 
 
Name Sequence Gene/protein of origin 
NLV NLVPMVATV pp65 (cytomegalovirus) 
OVA SIINFEKL Ovalbumin 
MelanA-Mart1 ELAGIGILTV MelanA gene 
 
 
All the peptides above were used to refold monomers, in combination with the relevant 
heavy chain. HLA-A*0201-NLV and HLA-A*0201-MelanA monomers only were also 
used for tetramerization, when required.  
 
2.1.2.1  INCLUSION BODIES PREPARATION: 
 
Glycerol stocks of the bacterial strains containing the protein of interest were plated on 
Luria-Bertani (LB) medium plates (Sigma) with 100 mg/ml of ampicillin, then 
incubated overnight at 37°C. A single colony was then used to inoculate 5 ml of 
ampicillin-supplemented LB medium, as above, and following an overnight incubation 
the whole culture was used to inoculate a litre of XYT medium (10 g of tryptone and 5 
g yeast extract, both Sigma, and 5 g NaCl, AnalaR BDH) supplemented with ampicillin 
as above. The cultures were incubated at 37°C with constant mixing until they reached 
an optical density (OD) of 0.4-0.6 at 550 nm. This usually required between 4 to 6 
hours. The expression of the protein was induced by adding to the cultures 1 mg of 
Table 2.1: list of the peptides used in this project. 
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isopropyl β-D-1-thiogalactopyranoside (IPTG, Alexis Biochemicals) and the culture was 
continued for 4 more hours to maximize protein expression. Aliquots of the culture 
were collected at hourly intervals to assess the induction efficiency. At the end of the 
incubation period, the bacteria were collected via centrifugation (30 minutes at 4000g, 
4°C). The resulting pellet was resuspended in the minimum amount possible of ice-cold 
PBS and frozen at -70°C overnight.  
 
2.1.2.2  PURIFICATION OF INCLUSION BODIES: 
 
The bacterial pellets were defrosted and sonicated 8 times for 45 seconds each time at 
maximum amplitude, taking particular care not to heat the mixture (sonication was 
performed with the tube containing the inclusion bodies always immersed in ice). The 
resulting solution was washed 3 times with freshly made Triton wash buffer (50 mM 
Tris HCl pH 8, 100 mM NaCl, 1 mM EDTA (C10H16N2O8) pH 8, 0.1% sodium azide 
(NaN3), 0.5% Triton X-100, 1 mM dithiotreitol (DTT, C4H10O2S2) added just before 
use) spinning at 15000 rpm (4700g), 4°C, between each wash and ensuring to break up 
the pellet thoroughly at each wash. A further wash step was performed using freshly 
made resuspension buffer (50 mM Tris HCl pH 8, 100 mM NaCl, 1 mM EDTA pH 8, 1 
mM DTT added just before use), prior to a final spin using the same condition as above. 
The resulting pellet was dissolved in the minimum volume possible of a urea-based 
buffer and left to dissolve at 4°C and rolling.  
 
The composition of the urea buffer for β2m chain was 8 M Urea (CH4N2O), 0.1 M 
NaH2PO4, 0.01 M Tris HCl pH 8, 0.1 mM EDTA pH 8, 0.1 M DTT, while the buffer 
for the heavy chains was 8 M urea, 50 mM 2-(N-Morpholino)ethanesulfonic acid (MES, 
C6H13NO4S) pH 6.5, 0.1 mM EDTA pH 8 and 0.1 M DTT. For both buffers, all the 
components except the DTT were added, then the solutions were deionized at 4°C using 
Amberlite beads (Merck). The solution was left stirring, adding more beads if 
necessary, until some of the beads retained their blue colour (while the majority turned 
yellow). The solutions were then filtered on filter paper to remove the beads. DTT was 
added immediately before use. After the overnight incubation any insoluble material 
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was removed with a centrifugation at 3300 rpm (1031g), 4°C, for 10 minutes. The 
concentration of the protein in the solution was then assessed, either via a BCA assay or 
using a Nanodrop spectrophotometer using appropriate settings.  
 
2.1.2.3  BCA ASSAY: 
 
The bicinchoninic acid (BCA) assay (Pierce) is a robust assay that allows the 
colorimetric detection and quantification of an unknown protein by spectrophotometer 
absorbance at 562 nm. Protein concentrations were determined comparing them to a 
standard curve prepared using bovine serum albumin (BSA) at known concentrations. A 
series of dilutions of albumin were prepared and assayed alongside the test protein. A 
titration curve was prepared aliquoting BSA from 0 to 8 µg in 500 µl of water. The test 
protein was instead aliquoted at 1, 2.5 and 5 µl in 500 µl of water. 500 µl of the A, B, C 
solution of the BCA kit (Pierce) mixed in a 1 : 0.96 : 0.04 (A:B:C) ratio were then 
added to all the experimental and standard curve samples. All the samples were mixed 
manually and incubated at 60°C for 1 hour to allow colorimetric development and then 
immediately read on a spectrophotometer at 562 nm. The protein concentration was 
assessed comparing the OD values against the ones of the standard curve. Figure 2.4 is 
an example of a BCA standard curve.  
 
 
 
 
Figure 2.4: BSA standard curve. The blue dots represent the actual spectrophotometric readings for 
each BSA sample while the black line is the approximate curve obtained via linear regression.  
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2.1.2.4  SDS-PAGE GEL: 
 
A denaturing protein gel was run using the samples collected during the induction with 
the two aims to assess the efficacy of the induction and the size of the proteins retrieved 
after purification. The SDS PAGE gel formula was as follows: 
 
• Running gel: 0.375 M Tris HCl pH 6.8, 0.1% sodium dodecyl sulphate (SDS, 
CH3(CH2)11OSO3Na), 30% acrylamide (C3H5NO), 0.03% ammonium 
persulphate (APS, (NH4)2S2O8), 0.15% tetramethylethylenediamine (TEMED, 
C6H16N2) (added in this order). 
• Stacking gel: 0.125 M Tris HCl pH 6.8, 0.1 % SDS, 5% acrylamide, 0.1% APS, 
0.1% TEMED (added in this order). 
 
10 µl of the samples preserved before and during the induction were loaded on the gel 
together with an equal volume of loading buffer (1 M Tris HCl pH 6.8, 10% SDS, 0.1% 
bromophenol blue, 10% glycerol, 1 M DTT). The samples+loading buffer were 
denatured for 3 minutes at 98°C and then loaded on a gel together with a molecular 
weight standard (Biorad Laboratories). The gel was run for 1 hour at 150V and 400 
milliAmpere (mA) in a running buffer composed of 25 mM Tris HCl, 250 mM glycine 
and 0.1% SDS. At the end of the run the gel was stained in Coomassie blue (0.1% 
Coomassie blue (BDH, catalogue number 44248) in 40% methanol (CH4O) and 10% 
acetic acid (C2H4O2)) for 30 minutes, de-stained overnight in methanol and acetic acid 
buffer (10% methanol, 7% acetic acid) and dried. Figure 2.5 shows an example of 
heavy chain induction on SDS gel.  
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2.1.2.5  MHC-PEPTIDE REFOLDING: 
 
In this project, the rapid dilution method for the refold of MHC-peptide complexes was 
selected among the various protocols available in literature. Working at 4°C, 4.8 mg of 
β2m, 6.2 mg of heavy chain and 2 mg of peptide (corresponding to a 2 µM: 1 µM: 10 
µM ratio) were added drop by drop, in this order, to 200 ml of refolding buffer (100 
mM Tris HCl, 400 mM arginine monohydrochloride (C6H14N4O2 · HCl, Sigma), 1 mM 
EDTA pH 8, 5 mM reduced glutathione, 0.5 mM oxidised glutathione, Sigma). The pH 
of the refolding solution was the single most important factor for the success of the 
refold and varied according to the peptide and heavy chain used: for HLA-A*0201-
NLV and HLA-A*0201-MelanA the optimal pH was 8.0, for H2-Kb-OVA was 8.5 
(optimization not shown). The solution was left stirring at 4°C for 48-60 hours and then 
spun at 4°C for 20 minutes at 3300 rpm (1031g) to remove any insoluble aggregate.  
 
The refolding protocol detailed above was followed for HLA-A*0201-NLV and H2-Kb-
OVA only. A slightly different protocol, as provided by Drs Mandruzzato and Della 
Santa (University of Padova, Italy), was chosen for HLA-A*0201-MelanA. The 
Figure 2.5: SDS gel run to assess the size and concentration of HLA-A*0201 molecules prepared 
via inclusion body purification. L, molecular weight ladder (BioRad Broad Range), 1-4, 10 µl aliquots 
of the HLA-A*0201 heavy chain collected at 1-4 hours post IPTG induction, PW, 1 µl aliquot of HLA-
A*0201 heavy chain post wash and solubilization, S, 1 µg of known HLA-A*0201 heavy chain 
preparation used as standard. The black arrow indicates the band of interest (45 KDa).  
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decision to use a modified refold protocol was taken as Drs Mandruzzato and Della 
Santa had already an optimized procedure for HLA-A*0201-MelanA refolding, while 
there was no previous experience in our laboratory; therefore, it was considered that a 
protocol already tried and tested, rather than a de novo optimization, would have 
guaranteed better chances of success. In this case the amount of the single components 
were the same, but peptide and β2m were added first in one aliquot, while the heavy 
chain was added in three aliquots over a total period of 36 hours. After this period the 
HLA-A*0201-MelanA refold was concentrated and treated as described below.  
 
The refold solution was then concentrated to 2 ml using sequentially the Amicon 
(Millipore) UltraFiltration Cell system and Vivaspin tubes, keeping it always at 4°C. 
The concentration process from 200 to 2 ml (the maximum amount that could be loaded 
for FPLC) usually required some hours. The concentrated solution was stored at 4°C 
until the moment of performing FPLC, usually immediately after the concentration step. 
Low salt buffer (10 mM Tris HCl, 5 mM NaCl, filtered and degassed) was used in the 
chromatography step and the fractions containing the correctly refolded peptide-MHC 
complexes were collected and stored at 4°C (see Figure 2.6 below).  
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The fractions of interest were then concentrated to 1 ml using Vivaspin tubes as above 
and the amount of protein was assessed via either BCA assay or Nanodrop 
spectrophotometer measurement. The refolded protein was then stored at 4°C for short-
term use (i.e. up to 2-3 days maximum) or aliquoted and stored at -70°C for long-term 
use.  
 
2.1.2.6  QUALITY MONOMER ASSESSMENT: DOT BLOT AND ELISA: 
 
Two different protocols (dot blot and Enzyme-Linked Immunosorbent Assay or ELISA) 
were used to assess the correctness of the MHC-peptide refolding following FPLC. As 
detection antibodies W6/32 (anti-HLA class I, recognizes the HLA monomer only if it 
is correctly refolded including the presented peptide) for HLA-A*0201 monomers and 
25.D1/16 (anti-H2-Kb-OVA) for the OVA-presenting H2-Kb monomer were used. The 
25.D1/16 antibody was a kind gift from Dr Reis E Sousa, Cancer Research UK, 
London. 
Figure 2.6: Chromatography plot of an HLA heavy chain-β 2m-peptide refold. 1: aggregate peak. 2: 
peak containing the refold of interest. 3: irrelevant shoulder. 4: peak of unrefolded β2m molecule. 5: 
peak containing arginine (from the refold solution) and unrefolded peptide. mAU, milli absorbance unit. 
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For the dot blot, a nitrocellulose membrane (Hybond ECL-Amersham) was “dotted” 
with the samples (either 1 µg of protein or 5 µl of water as negative control). The 
membrane was blocked by soaking it in blocking buffer (5% BSA in 0.05% Tween, 20 
mM Tris HCl, 150 mM NaCl, pH 7.5) for 30 minutes. The membrane was then 
incubated for one hour with the primary antibody (3 µg total) diluted in the same buffer 
as above but with 0.1% BSA instead of 5%. The membrane was then washed 3 times, 5 
minutes each time (same buffer as above, without BSA), and a secondary antibody –
anti-mouse peroxidase for W6/32, anti-goat peroxidase for 25.D1.16- was added to the 
membrane after dilution in phosphate buffered saline (PBS) solution (Lonza) and 
incubated for one hour. The sample was then washed 4 times (same conditions as 
above) and the detection was performed using the ECL detection kit (Amersham) 
according to the manufacturer’s instructions. The samples were detected as dark dots on 
Kodak films 18X24 cm. Figure 2.7, below, shows a representative dot blot performed 
using H2-Kb-OVA monomer. 
 
 
 
 
 
 
In figure 2.7, above, water only was used as –ve control. Other suitable -ve controls 
would have included either single heavy chain or β2m molecules and irrelevant human 
(or irrelevant murine) MHC molecules; these controls would also have provided a 
measure of the cross-reactivity of the primary antibody used. 
 
Figure 2.7: H2-Kb dot blot. Various aliquots of H2-Kb-OVA refold to be tested were dotted on a 
nitrocellulose membrane (1-4), alongside a 1 µg aliquot of a previously checked H2-Kb-OVA molecule 
as positive control (+ve) or water as negative control (-ve). Different exposure times were tested and 
only the best one (three minutes) is shown. 
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For the ELISA, an ELISA plate (Nunc-Immuno/MaxiSorp Surface, Gibco) was coated 
with a primary antibody (5 µg/ml W6/32 or 25.D1/16 antibody diluted in PBS or PBS 
only as negative control) and left for 2-3 hours at 37°C; the antibody was then flicked 
off. The plate was blotted on a tissue to drain and blocking buffer (1% BSA in PBS) 
was added to the wells and incubated overnight. Wells were then washed 6 times with 
PBS and a serial dilution of the protein to be tested was performed and incubated at RT 
for 1 hour. The plate was washed for 6 times with PBS and then a 1:5000 dilution of 
rabbit anti-human β2m (secondary antibody, Sigma) was added to the wells and 
incubated for 20 minutes at RT. The plate was then washed 6 times with PBS and a 
1:3300 dilution of horseradish peroxidase (HRP)-conjugated goat anti-rabbit Ig (Dako) 
was added to the wells and incubated for 20 minutes. The plate was then washed 6 
times with PBS and developed colorimetrically using the Substrate Reagent Pack 
(catalogue number DY999, R&D) for 20 minutes at RT in the dark. The reaction was 
stopped using Stop solution (catalogue number DY994, R&D) and the plate was 
immediately read on an ELISA plate reader (Biotek) at 450 nm. Figure 2.8 shows an 
ELISA result plot. 
 
 
 
 
 
In figure 2.8, above, PBS was used as –ve control. Other suitable -ve control would 
have included either single heavy chain or β2m and irrelevant human (or irrelevant 
murine) MHC molecules; these controls would have provided also a measure of the 
eventual cross-reactivity of the primary antibody used. 
Figure 2.8: ELISA results. The assay was performed to check 2 different aliquots of HLA-A*0201 
monomers (blue and red line, respectively tetramerized and monomeric molecules) compared to a known 
HLA-A*0201 refold used as standard (yellow line) and to PBS used as –ve control (green line).  
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2.1.2.7  MONOMER BIOTINYLATION: 
  
After testing for a correct refold, the monomers were conjugated with biotin for 
subsequent tetramerization, if required. The HLA-A*0201 expression vector carried the 
AviTag sequence for biotinylation mediated by the biotin ligase (BirA) enzyme 
(Avidity, Colorado), thus allowing the reaction to be performed in vitro.  
 
Briefly, the refolded protein was concentrated down to approximately 170 µl; a small 
unbiotinylated aliquot was taken and stored at –20°C to assess the efficiency of the 
reaction later on. 25 µl each of Biomix A and B were then added to the bulk of the 
refolded protein, followed by protease inhibitor and 0.5 µl of BirA enzyme (all from 
Avidity, Colorado). The reaction was incubated overnight at RT. The day after an FPLC 
step was performed to remove the excess of biotin in the reaction. This procedure was 
required, as biotin excess would have considerably hampered the efficiency of the 
successive tetramerization step. For biotin removal FPLC was performed using high salt 
buffer (150mM NaCl, 20 mM Tris HCl, filtered and degassed) and the fractions 
containing the biotinylated refold were promptly collected and concentrated as 
previously done. Figure 2.9, below, shows a chromatographic plot of the FPLC step to 
remove excess biotin.  
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Protein concentration was assessed either by BCA assay or by Nanodrop 
spectrophotometer reading using appropriate settings. A small aliquot was used for a 
native gel shift assay and the rest was either kept at 4°C for immediate tetramerization 
or aliquoted and stored at –70°C for long-term storage.  
 
2.1.2.8  NATIVE GEL SHIFT ASSAY: 
 
This assay is aimed to assess the efficiency of the biotinylation reaction. Pre-incubating 
biotinylated samples with extravidin (1 mg/ml stock, Sigma), biotin-conjugated HLA 
molecules will associate with the avidin molecule and will be heavier than unconjugated 
ones when run on a non-denaturing polyacrylamide gel. The difference in molecular 
weight results in a shift on the gel, as visible in Figure 2.10 below-confront lane 1 vs 2 
and 3 vs 4. 
 
Figure 2.9: chromatography plot of the biotinylated HLA-A*0201-NLV monomer. Peak 1, around 
fraction 19-20, represent the biotinylated monomer (confront with figure 2.6), while peak 2, from 
fraction 29 onwards, represents unbound biotin (which is always added in excess to the reaction to 
improve its kinetics).  mAU, milli absorbance unit. 
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Lanes 1 and 2 show the biotinylated preparation without and with extravidin, 
respectively. While both samples are quite blurred (this is possibly due to the non-
denaturing conditions of the gel; see as a comparison, for example, the clear bands 
showed in Figure 2.5), it is still possible to see a shift between extravidin-conjugated 
and unconjugated sample (as can be seen by a comparison of bands a and b). A similar 
shift can be observed between lanes 3 and 4, a commercial biotinylated sample without 
and with extravidin, respectively (compare bands labelled c and d). Between lanes 5, 6, 
7 and 8, no shift can be detected; as these were the unbiotinylated samples, extravidin 
could not associate with the protein and, therefore no change in molecular weight was 
observed. 
 
 In the example shown above molecular weight markers were not included. However, 
when run in parallel, it should be possible to confirm that the bands of interest contain 
proteins of the correct size. Note however that the migration properties of proteins in 
Figure 2.10: native gel shift assay. Lane 1: biotinylated monomer without extravidin. 2: biotinylated 
monomer after incubation with extravidin. 3: biotinylated commercial control without extravidin. 4: 
biotinylated commercial control after incubation with extravidin. 5 and 6: unbiotinylated monomer with 
(5) and without (6) extravidin. 7 and 8: unbiotinylated commercial control with (7) and without (8) 
extravidin. 9: extravidin loaded alone. 
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non-denaturing conditions can vary such that the relationship between size and 
molecular weight is not necessarily linear. 
 
All the monomers that showed a successful native gel shift were subsequently used for 
tetramer production; of those, only tetramers producing a definitive stain (as seen in 
example Figure 2.12A) were then used for experiments. 
 
This assay is performed in strictly non-denaturing conditions, with no SDS in the gel, 
loading or running buffer. The native gel was prepared as detailed in Table 2.2 below. 
  
Reagents Running gel Stacking gel 
30% acrylamide 
Distilled H2O 
1.5M Tris HCl pH 8.8 
1M Tris HCl pH 6.8 
APS 
TEMED 
8 ml 
14.5 ml 
7.5 ml 
- 
100 µl 
20 µl 
1.7 ml 
6.8 ml 
- 
1.25 ml 
100 µl 
10 µl 
 
 
Once cast, the gel was pre-run at 150V for at least 30 minutes to remove any excess salt 
that may influence separation in a running buffer made of 24.8 mM Tris base and 192 
mM glycine. Samples to be tested were incubated for 1 hour at RT with 3-6 µl of 
extravidin, then an equal amount of native loading buffer (50 mM Tris HCl pH 8.8, 
0.1% bromophenol blue, 10% glycerol) was added to the samples and they were then 
run at 150V until the blue dye reached the bottom of the gel. The gel was then stained 
with Coomassie blue, destained with methanol solution as detailed before and examined 
(see Figure 2.10 above). 
 
2.1.2.9  TETRAMERIZATION: 
 
Following biotinylation and the assessment of its efficiency, the monomer sample was 
concentrated down to approximately 100-200 µl depending on the starting amount. 
Tetramerization was routinely performed on small aliquots of monomers and only when 
tetramers were needed to avoid long-term storage of fluorescent tetramers. For 
Table 2.2: reagents required for a native gel. 
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tetramerization, a 4:1 molar ratio of monomers: fluorescent streptavidin is required (see 
Figure 2.11, below).  
 
 
 
 
 
Once the required amount of streptavidin was determined, it was added in 1/10th 
aliquots at 20 minutes intervals to the biotinylated monomer, which was maintained in 
gentle agitation at 4ºC at all times. After the last addition of streptavidin, 0.05% of 
NaN3 was added to each tetramer aliquot to prevent any bacterial growth. The tetramers 
were stored at 4ºC wrapped in foil. It was found that ready-to-use tetramers often 
degraded if stored long-term (i.e.>2 months) at 4ºC (data not shown); as such, it was 
preferred to store at -80ºC small aliquots of the biotinylated monomers, ready for 
tetramerization, and add the fluorescent streptavidin whenever required.  
Figure 2.12A, below, shows the tetramer titration performed on an HLA-A*0201, 
CMV+ve donor. The same donor was also stained using commercial HLA-A*0201, 
CMV specific pentamers (ProImmune) (Figure 2.12B). 
Figure 2.11: scheme of the tetramerization process. For this project both Pe- and APC-conjugated 
streptavidin was used. 
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It was found that the use of in-house tetramers was more effective compared to the 
commercial pentamers. Evidence of this is shown by the presence of a discrete CD8+ve 
tetramer+ve population with reduced unspecific labelling (CD8-ve tetramer+ve 
population) in Figure 2.12A. The staining with the commercial pentamers did not result 
in a discrete CD8+ve tetramer+ve population at any of the concentrations used and 
unspecific binding was more evident (see Figure 2.12B). Therefore, in-house tetramers 
were used in all the subsequent experiments.  
Below (Figure 2.13A) the tetramers were used on a HLA-A*0201+ve, CMV–ve adult 
donor to check for unspecific staining. HLA-A*0201-MelanA tetramers were also 
tested on a MelanA-specific cell line (see Table 2.3) to ensure that the binding was TCR 
specific (Figure 2.13B). 
 
 
 
 
Figure 2.12A: titration of HLA-A*0201-CMV tetramers. Fresh PBMCs from a CMV+ve, HLA-
A*0201+ve donor were stained with increasing amounts of tetramers (from left to right, 1, 2.5 and 5 µl 
respectively). The cells shown above were gated on lymphocytes.  
Figure 2.12B: titration of HLA-A*0201-CMV commercial pentamers (ProImmune). Fresh PBMCs 
from a CMV+ve, HLA-A*0201+ve donor were stained with increasing amounts of commercial 
pentamers (from left to right 2.5, 5 and 10 µl respectively). The cells shown above were gated on 
lymphocytes. 
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It was found that the use of HLA-A*0201-NLV in-house tetramers did not result in 
unspecific staining. The HLA-A*0201-MelanA tetramers were tested on the J-RT3 cell 
line, which provided a MelanA+ve control, and produced a good-quality staining (see 
above Figure 2.13B). 
 
2.1.2.10 MONOMER ACTIVATION FOR LOADING ON LIPOSOMES:  
 
The two monomers HLA-A*0201-NLV and H2-Kb-OVA were used in their native form 
for loading on the liposome surface. At the beginning of this project all the polypeptide 
chains to be loaded on the liposomes were treated with Traut’s reagent (2-Iminothiolane 
Hydrochloride-C3H7NS•HCl Pierce) to add more –SH groups and thus facilitate the 
binding on MAL-containing liposomes.  
The desired amount of protein (the highest amounts used in De La Peña et al., 2009, 
(7.98 and 10.64 µg) were used as references for this protocol) was dissolved in the same 
HEPES buffer used for hydrating the liposomes at a pH of 8.0. A stock solution 
prepared dissolving 8.5 mg of Traut’s reagent in 1.5 ml of HEPES buffer was used to 
add an approximate 10-fold molar excess of reagent to the protein (whose volume was 
typically a few µl). The protein-Traut’s solution was then taken to a final volume of 1 
ml using HEPES buffer as above and incubated at RT for 1 hour. At the end the excess 
Figure 2.13A: assessment of tetramer-related unspecific staining. HLA-A*0201-CMV in-house 
tetramers were used to stain fresh PBMCs from a CMV-ve, HLA-A*0201+ve adult donor. Any 
unspecific staining should appear as a population in the upper right quadrant. Cells were gated on 
lymphocytes.  
Figure 2.13B: assessment of HLA-A*0201-MelanA tetramers staining. An aliquot of J-RT3 cells 
(cell line transgenic for the HLA-A*0201-MelanA TCR) was stained with an aliquot of in-house 
tetramers. ()  unstained, () tetramer-stained (3 µl). 
A         B 
                                                                                                                                        Chapter 2 
  
  
 
   98 
Traut’s reagent was removed using PD-10 desalting columns (GE Healthcare) 
according to the manufacturer’s instruction. Cys-tagged monomers were treated in the 
same way omitting the Traut’s reagent. The activated protein was concentrated to a final 
volume of 200-300 µl using Vivaspin tubes and immediately aliquoted onto 1 ml of 
liposome in a 12-well plate. The liposome plus the activated protein were then left 
mixing overnight at RT to promote loading of the protein. At the end of the incubation 
period, the monomer-conjugated liposomes underwent a chromatographic purification 
step (see Figure 2.2).  
 
2.1.2.11 ELLMAN’S ASSAY: 
 
The degree of activation (here defined as the amount of SH groups newly introduced in 
the protein) was assessed using the Ellman’s reagent (5,5'-Dithio-bis-(2-nitrobenzoic 
acid)-DNTB, C14H8N2O8S2, Pierce), which is recommended by the Traut’s activation 
protocol as the best way to determine the free sulphydryl content in peptides and 
complex proteins. The Ellman’s assay was performed according to the manufacturer’s 
instructions: briefly, a buffer containing 1 mM EDTA, pH 8.0, and 0.1 M monobasic 
sodium phosphate (Na2HPO4•H20) was prepared and used to dilute fixed amount of 
both Ellman’s reagent and the sample to be tested (Traut’s treated and untreated 
monomer), which were then combined. All the samples were incubated at RT for 15 
minutes, then immediately read at 412 nm with a spectrophotomer. The amount of 
sulphydryls in each sample was then measured from the absorbance starting from the 
known DNTB extinction coefficient (14,150 M-1cm-1) and compared between Traut’s 
treated and untreated samples. The results for this experiment are presented in Figure 
2.14 below.  
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2.2  CELL BIOLOGY: 
 
2.2.1  CELL SOURCES AND GENERAL CELL CULTURE PROTOCOLS: 
2.2.1.0  BLOOD CELLS SOURCES: 
 
The adult volunteer donors required for experiments were chosen among the cohort of 
voluntary blood donors in the Anthony Nolan Research Institute. Their HLA typing and 
CMV serology, when appropriate, was assessed in the Anthony Nolan 
Histocompatibility Laboratories and each volunteer signed an informed consent to the 
use of his/her blood for research purposes. Buffy coat samples were obtained from the 
Sheffield NHS blood bank. 
 
Cord blood was used in the project either fresh as a whole cord blood sample (from the 
Anthony Nolan Cell Therapy Centre based in Nottingham, or from the Banc de Sang i 
Figure 2.14: Ellman’s assay on activated MHC monomers. Following the activation of MHC 
monomers with Traut’s reagent for Cys introduction they were then assessed for their new level of 
thiol groups, as examined by measurement of absorbance at 412 nm. N=1, column represent the 
mean results of triplicate wells. Error bars correspond to standard deviation. 
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Teixits, Barcelona, Spain) or as frozen cord blood aliquot after ficoll treatment (from 
the Anthony Nolan Cell Therapy Centre based in Nottingham). Frozen aliquots were 
always shipped as double bags, one of 5 ml one of 20 ml, which could be processed 
independently (see Figure 2.15 below).  
 
 
 
 
Whenever possible, fresh samples were used within 24 hours from collection as it was 
found that time significantly affected monocyte viability (data not shown and Drs 
Richard Duggleby and Francesc Borras, personal communication). Whole fresh cord 
blood samples were shipped at 4ºC and as such, upon receiving, they were always 
diluted in the same volume of fridge-cold transport medium (RPMI supplemented with 
5 mM β-mercaptoethanol (C2H6OS) and 3.3% sodium citrate (Na3C6H5O7), dissolved in 
deionized water and filtered) and left to equilibrate at RT. This process usually required 
1-2 hours. Fresh cord blood samples were always processed on the day of arrival to use 
cells as viable as possible. 
 
2.2.1.1  PBMCs PURIFICATION FROM ADULT BLOOD: 
 
A small amount of heparin (200-300 µl for up to 50 ml starting blood) was added to 
fresh blood immediately after collection to prevent clotting. The heparinized blood 
could be maintained at RT for up to 24 hours without any adverse effect, if necessary, 
but it was always aimed to use it immediately after collection. The blood was layered 
over an equal amount of Lympholite (Cedarlane Laboratories Limited) and centrifuged 
Figure 2.15: segmented bag used for cord blood cryopreservation. Image courtesy of 
www.cordlife.com/images/cryobag2. 
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at 2200 rpm (687g) for 20 minutes at RT. The brake was not applied during the slowing 
down of the centrifuge to avoid any disturbance in the phase separation. The interphase 
containing the leukocytes was collected in a fresh tube and washed twice with RPMI 
1640 medium (BioWhittaker) supplemented with 1% of penicillin/streptomycin solution 
(pen/strep), BioWhittaker (from now on called wash medium), or 1X PBS. The first 
wash was at 1800 rpm (562.5g) for 10 minutes, the second at 1800 rpm (562.5g) for 5 
minutes. The brake was applied in both washes. The supernatant was then poured off, 
pellet was re-suspended by flicking and viable cells were counted. Cells were then 
maintained in wash medium until re-suspension and plating out as soon as possible after 
purification. The same procedure was applied to Buffy coat samples.  
 
2.2.1.2  CBMCs PURIFICATION FROM CORD BLOOD: 
 
Cord blood (mixed with the same amount of transport medium) was layered over Ficoll-
Paque Premium (GE Healthcare) in a 50-ml Falcon tube using the following ratio: 15ml 
Ficoll-Paque: 35ml blood + transport medium. Cells were centrifuged at 2000 rpm 
(625g) for 30 minutes at RT. Brakes were not applied during the slowing down of the 
centrifuge not to disturb the phase separation. The pellet was re-suspended in two steps; 
firstly, the pellet was re-suspended in a few drops of media and then the suspension was 
diluted in x25 wash buffer and washed twice, as with adult cells (see 2.2.1.1). 
 
If cell clumps occurred upon resuspension or during washing –a sign of early cell lysis- 
a DNAse treatment was performed. Briefly, a suitable amount of DNase I (CalBiochem, 
1 X 106 U/ml, resuspended in PBS 1X) –the quantity varied for each sample according 
to total cell number and pellet size- was added to the resuspended cells and the solution 
was then incubated in a water bath at 37ºC with constant mixing until complete clumps 
disappearance or for up to three minutes maximum. Following a DNase treatment, cells 
were washed with 50 ml of warm wash medium and centrifuged for 5 minutes at 1700 
rpm (531g) in addition to the two washes performed during the Ficoll-Paque treatment. 
Cells were then counted with Trypan Blue and/or Turk’s stain. Following Ficoll-Paque 
                                                                                                                                        Chapter 2 
  
  
 
   102 
treatment cells were then re-suspended in wash medium until use, if they were to be 
used in the same day. If not, they were cryopreserved. 
 
2.2.1.3  CELL COUNTING:  
 
Cells were counted using two different methods in function of the red blood cell 
percentage of the sample. Trypan Blue (Sigma) 0.4%, a vital stain, seeps inside the cells 
(hence making them blue) when the cell membrane is damaged i.e. when cells are dead 
or apoptotic. Viable cells are not coloured by Trypan Blue appearing bright pink. 
Trypan was used in a 1:1 volume ratio to cells to assess the number of total viable cells. 
Trypan Blue cannot however discriminate between nucleated and anucleated cells. To 
accomplish this, Turk’s staining was used (acetic acid 1% V: V in water and 
bromophenol blue) in a ratio 9 Turk’s solution: 1 cell volume/volume. Turk’s solution 
stains only nucleated cells, hereby allowing the removal of erythrocytes from the count 
of the total white cells as retrieved by Ficoll-Paque protocol. Turk’s solution was used 
primarily for cord blood samples due to the higher number of red blood cells present. 
Nucleated cells appear as very bright and compact spots using Turk’s staining. 
 
2.2.1.4  CRYOPRESERVATION AND THAWING: 
 
If cord blood or adult PBMCs were not used on the day of collection they were 
cryopreserved for long-term storage. Briefly, cells were pelleted by centrifugation at 
1700 rpm (531g) for 5 minutes, resuspended in a solution made of 90% heat-inactivated 
fetal calf serum (FCS) and 10% dymethylsulphoxide (DMSO, C2H6OS) and transferred 
into cryovials (Nunc). No more than 10 X 106 cells/ml and/or 1.5 ml of cells/freezing 
mix were added to a single cryovial. They were immediately transferred on ice and 
stored at -80°C in a polystyrene box (for a gradual lowering of the temperature) for up 
to 3 days. The cryovials were then transferred into liquid nitrogen tanks for long-term 
storage.  
To thaw adult PBMCs, the cryovials were warmed in a water bath at 37°C until no ice 
clumps were seen. The cell suspension was then quickly transferred to a 15-ml Falcon 
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tube containing 10 ml of warm RPMI medium and centrifuged at 1700 rpm (531g) for 5 
minutes. The supernatant was poured off and the cell pellet was resuspended in RPMI 
medium for cell counting. 
 
Frozen cord blood samples were thawed using a different protocol to minimize the 
temperature shock, as firstly described by Querol et al., 2000. Briefly, the bags 
containing cord blood were warmed in a water bath at 37°C as seen above. Immediately 
upon complete thawing, the cell suspension was collected and added to an equal volume 
of chilled dextran buffer (dextran/gentran 40, Baxter, 5% heat-inactivated FCS, 0.63% 
sodium citrate, 5 mM MgCl2, 1000 IU/ml DNase-I). This mixture was left at 4°C for 5 
minutes. At this point more dextran was added (1 ficolled frozen cord blood: 4 dextran, 
or 1 unprocessed frozen cord blood: 6 dextran in volume) and the cells were spun for 20 
minutes, 450g, at 10°C. The pellet was resuspended in RPMI medium and at this point a 
DNAse treatment was performed if cell clumps appeared. Otherwise, cells were counted 
and used.  
 
2.2.1.5  CELL LINES AND GENERAL CULTURE CONDITIONS: 
 
In addition to the primary cells (PBMCs from adult donor and CBMCs from cord 
blood), various cells lines were also used in this project. They are listed in Table 2.3 
below. 
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Name: Growth conditions: Source/Owner: Propriety: 
RF 33.70 RPMI+10%FCS, 1% PS 
1% l-glutamine, 1% 
NEAA (non-essential 
amino acids), 1% Hepes  
Prof K. Rock, 
Umed, 
Massachussets 
T cell hybridoma; it secretes 
IL-2 in the supernatant if its 
TCR is specifically engaged 
with an H2-Kb-OVA 
molecule. 
J-RT3 RPMI+ 10% FCS Prof P. 
Romero, 
Lausanne, 
Switzerland 
T cell line (Jurkat-derived)-
TCR-ve on its own, it has 
been transfected with an 
HLA-A*0201 MelanA-
specific TCR. 
K562 RPMI+ 10% FCS Lab collection Lymphoblast cell line of 
bone marrow origin; it is 
MHC class I-ve. 
OT-1 RPMI+ 10% FCS Prof H. Stauss, 
Royal Free 
Hospital  
CD8+ve T cell line; it 
expresses only H2-Kb and 
derives from a transfected 
RAG-/- mouse. 
RMA RPMI + 10% FCS Prof H. Stauss 
Royal Free 
Hospital 
Murine T cell tumour line; 
it is an H2-Kb-expressing 
cell line and was used as an 
H2-Kb cDNA source 
 
 
 
2.2.2  FLOW CYTOMETRY: 
2.2.2.1  ANTIBODIES: 
 
The commercial antibodies used in this project for flow cytometry, their optimal 
staining dilution, their clone and company are listed in Table 2.4 below. 
 
 
 
 
 
 
 
Table 2.3: cell lines used in this project, their source and the main characteristic for which 
they have been chosen. 
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Antibody 
specificity: Clone Dilutions Company Cat no: Isotype 
CD8 FITC SK1 1/10  BD 345772 IgG1  
CD8 PerCp SK1 1/10  BD 345774 IgG1 
CD3 Pe HIT3a 1/17  Pharmingen 555340 IgG2a k 
CD3 PerCp SK7 1/17  BD 345766 IgG1 
CD3 FITC HIT3a 1/10  Pharmingen 555339 IgG2a k 
CD45 APC HI30 1/16  Pharmingen 555485 IgG1, k 
CD 45 FITC HI30 1/10  Pharmingen 555482 IgG1, k 
HLA-DR FITC  HL-39 1/12.5  Immunotools 21279993 IgG3, k 
CD 80 PE L307.4 1/5  BD 340294 IgG1, k 
CD11c APC B-ly6 1/25  BD 559877 IgG1, k 
CD83 PE HB15e 1/5  Pharmingen 556855 IgG1, k 
CD14 FITC MEM-15 1/5  Immunotools 21279143 IgG1 
CD86 PerCP Bu63 1/20  Abcam ab77131 IgG1 
CD40 FITC 5C3 1/5  BD 555588 IgG1, k 
FITC isotype 
IgG3 MG3-35  Biolegend 401305 IgG3 
HLA-A2 FITC BB7.2 1/5  Abcam ab27728 IgG2b 
HLA-A, B, C 
APC W6-32 1/100  Biolegend 311401 IgG2a, k 
  
 
 
2.2.2.2  SURFACE STAINING: 
 
Whole PBMCs/CBMCs, selected populations and/or cell lines were stained as follows: 
200 µl of cells (up to 1 million cells/staining) were aliquoted into a flow cytometry tube 
(fluorescence-activated cell sorting (FACS) tubes BD, catalogue number 352052) and 
spun at 1800 rpm (562.5g) for 3 minutes at 4ºC. If a pellet was visualized the 
supernatant was poured off and the cells were resuspended in 50 µl PBS 1X + 0.5% of 
heat-inactivated FCS (from now on FACS buffer) already containing the relevant 
antibody and/or tetramer and the tube was incubated in the dark for 10 minutes at 4°C. 
Following the incubation, tubes were spun as before and washed twice using 200 µl of 
FACS buffer. Samples were washed three times if tetramers were used to minimize the 
unspecific binding due to free fluorescent streptavidin. The sample was then 
resuspended in 100 µl of FACS buffer, or PBS, for immediate analysis. If the sample 
was to be stored before analysis (for up to 4 days) it was resuspended in PBS+4% 
Table 2.4: monoclonal antibodies and isotype controls used in this project, with the unique 
clone, company and catalogue number. 
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paraformaldehyde (PFA) for 30 minutes at 40C; the cells were then pelleted via 
centrifugation, the PFA solution was removed and the sample was resuspended in PBS 
until analysis. For DCs the same protocol was followed but the staining was performed 
in PBS 1X+10% mouse serum to achieve a better blocking, given the very high number 
of Fc receptor present on the surface of DCs.  
 
2.2.2.3  ANTIBODY TITRATION AND ISOTYPE CONTROLS: 
 
Most of the recommended dilution in table 2.4, above, were obtained titrating the 
relevant antibody against a suitable cell population. Moreover, most of the monoclonal 
antibodies used to stain DCs were compared to the staining of the corresponding isotype 
control prior experimental use to be certain to keep the unspecific binding to a 
minimum. Figure 2.16A shows the antibody titration for CD86 while Figure 2.16B 
shows an example of titration of CD83 with isotype control.  
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The amount of CD86 antibody chosen for a 50 µl-staining volume was 2.5 µl; initially, 
an MFI analysis was not performed during titration and a slightly suboptimal amount 
was chosen, as 2.5 µl is on the edge of the plateau and therefore more vulnerable to 
dilution errors. The amount of CD83 antibody chosen for a 50 µl staining was 10 µl (the 
maximum amount tested). The amount of antibody in the total volume of the staining, 
rather than the more precise concentration, was used in this case as neither supplier 
provided a working concentration for its product (only indications of dilutions were 
given). 
Figure 2.16A: saturation curve of the titration of the anti-CD86 antibody. The DCs cells were gated 
and the median fluorescent analysis (MFI) for each staining was plotted on the Y-axis against the 
corresponding amount of antibody (on the X-axis) used each time.  
Figure 2.16B: saturation curve of the titration of the anti-CD83 antibody. The DCs cells were gated 
and the median fluorescent analysis (MFI) was plotted on the Y-axis against the corresponding amount 
of antibody (on the X-axis) used each time. In this case an isotype control was used as well; its MFI 
value was plotted in the curve as second value (highlighted by a circle in the plot). In both cases, a final 
volume of 50 µl per staining was used. 
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2.2.2.4  IFN-γ INTRACELLULAR STAINING: 
 
Intracellular staining, when required, was performed using the Cytofix/Cytoperm 
Fixation/Permeabilization kit (BD Biosciences) following the manufacturer’s 
instructions. Briefly, the samples to be stained intracellularly were firstly incubated with 
5 µg/ml Brefeldin A for 4-5 hours prior staining. Brefeldin A interferes with the protein 
transport from the endoplasmic reticulum (ER) to the Golgi and its use results in protein 
accumulation inside the ER. Following Brefeldin A incubation, the samples were 
surface-stained in FACS tubes and then washed twice using intracellular staining wash 
buffer (PBS 1X, 1% heat-inactivated FBS, 0.09% NaN3). After the second wash, 
samples were incubated for 20 minutes at 4°C with 250 µl of Fixation/Permeabilization 
solution, then washed twice using 1 ml of 1X Perm/Wash buffer (all provided in the 
kit). This step caused cell membrane permeabilization; from this point on, the cells were 
maintained in permeabilization buffer to the end of the protocol. After the 
permeabilization step cells were incubated with the IFN-γ antibody (1 µl/staining) at 
4°C for 30 minutes in the dark. Following the incubation with the antibody, cells were 
then washed 3 times using 1 ml of 1X Perm/Wash buffer each time, centrifuging at 
1800 rpm (687.5g) for 5 minutes at every wash. The longer and harsher centrifugation 
condition, compared to a standard surface staining, were required as due to the 
permeabilization cells are swollen and much looser than their intact counterparts and as 
such harder to pellet. Following the last wash, cells were resuspended in 200 µl of 1X 
Perm/wash buffer for FACS analysis.  
 
2.2.3  CELL LINES GENERATION AND CELL-BASED ASSAY: 
2.2.3.0  PREPARATION OF DCs: 
 
Monocytes were purified from PBMCs via CD14+ve selection kit (Miltenyi) according 
to the indications of the manufacturer. The purified monocytes (and the –ve fraction) 
were then routinely stained as follows to check purification efficiency and viability: 
 
• Monocytes (CD14+ve fraction): CD14, 7-AAD 
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• Flowthrough (CD14-ve fraction): CD45, 7-AAD 
 
The CD14–ve fraction (flowthrough) was frozen down for future use when required. 
The CD14+ve fraction (monocytes) was incubated at 0.5 X 106 cells/ml/1 well of a 24-
well plate in RPMI medium supplemented with 1% AB serum (FCS was not used to 
avoid aspecific DC maturation) supplemented with 70 ng/ml of GM-CSF (it stimulates 
growth and differentiation of monocytes) and 35 ng/ml of IL-4 (it stops macrophage 
growth) at 37°C. On day 2 and 4, half of the medium was changed adding full amount 
of cytokines. On day 5, monocytes were pulsed with the relevant peptide (if necessary) 
for 3 hours and matured overnight. Cells were matured either with 10 µg/ml of 
polyinosinic: polycytidylic acid (poly I:C) or 1 µg/ml of lipopolysaccharide (LPS, from 
E. coli, serotype 055:B5, Sigma). Poly I:C is a toll-like receptor (TLR)-3 stimulant and 
can be considered a synthetic analogue of a double stranded RNA, a common viral 
feature, while LPS is a bacterial constituent derived from the outer membrane of Gram-
negative bacteria and it interacts with the CD14/TLR4/MD2 receptor. Both mature and 
immature DCs were used the day after the incubation with the maturing stimulus. One 
aliquot of differentiated monocytes was always left immature to provide a suitable 
control for flow cytometry and further experiments.  
 
2.2.3.1  DCs-RESPONDER STIMULATION ASSAY: 
 
Two different protocols for the DCs-responder stimulation assay were used according to 
the source of the cells employed (CB or adult samples). The conditions that follow 
apply to HLA-A*0201+ve, HLA-B*0702-ve, CMV+ve PBMCs derived from healthy 
adult donors. When used for tetramer-specific expansion one well of the DCs prepared 
as above was washed twice with 1X PBS, to remove both dead cells and any LPS/poly 
I:C residues, then 1.5 X 106 autologous responders (from the CD14-ve fraction of the 
monocyte purification), resuspended in 1 ml RPMI+10% AB serum, were added to the 
DCs. The culture was incubated at 37°C for 1 week and then stained with the relevant 
antibodies and tetramers. 
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When cord blood-derived DCs and responders were used, a protocol using stronger 
stimulation conditions was followed due to the higher naivety and hyporesponsiveness 
of cord responders. The cord blood optimized protocol was based on previously 
published evidence (Salio et al., 2003). In this case, DCs were pulsed for 3 hours and 
responders were added as above. However, recombinant IL-2 was added from day 4 to 
7 at 10 U/ml and cells were then expanded with 500 U/IL-2 until analysis (at days 10-
15) via surface and intracellular staining and tetramer staining.  
 
2.2.3.2  APCs STIMULATION CONDITION: 
 
In addition to DCs-mediated expansion, adult PBMCs were also expanded using the 
liposomal aAPCs described in chapter 3 in a HLA-A*0201+ve, HLA-B*0702-ve, 
CMV+ve system. Briefly, 100,000 PBMCs resuspended in 100 µl RPMI+10% AB 
serum were aliquoted in a round-bottomed 96-well plate and 60 µl of liposomes 
(corresponding to the best ratio as optimized in De La Peña et al., 2009) were added to 
the wells, together with +ve controls (NLV peptide or HLA-A*0201-NLV monomer) 
and –ve controls (cells left without stimulus). 20 ng/ml IL-7 was added to the culture at 
day 0 (to promote CD8 memory cell expansion), 50 ng/ml IL-2 was added at day 1 (and 
not at day 0 to prevent aspecific CD8 expansion). Cells were incubated at 37°C for 7-10 
days or longer (up to 21 days maximum) and examined with the relevant antibodies and 
tetramers.  
 
2.2.3.3  MLR STIMULATION ASSAY: 
 
A stimulation assay was employed to establish the alloreactivity of CB-derived APCs 
(immature (iDCs) and mature DCs (mDCs)) and compare them to adult APCs obtained 
using the same protocol. Briefly, 5,000-10,000 APCs (stimulators) were irradiated (30 
grays for 7 minutes) to stop proliferation and aliquoted in 100 µl RPMI+10% AB serum 
in a round-bottomed 96-well plate. For CB-derived DCs it was found that an irradiation 
step was not necessary as the level of proliferation (as assessed by thymidine uptake) 
was negligible and comparable with the one of irradiated cells. Varying amount of 
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allogeneic PBMCs or CD14-ve fraction-derived cells (termed “responders”, 10,000, 
25,000, 50,000 cells/well) were resuspended in 100 µl of RPMI+10% AB serum and 
added to the stimulators. As positive controls responders were incubated with 
Dynabeads (Dynal Biotech anti-CD3 anti-CD28 microbeads, 0.15 µl/100 µl cells), 
while all the cell types co-cultured in the MLR were also added alone and used as 
negative control. No cytokines were added and the culture was incubated at 37°C and 
5% CO2 for 5 days. At day 5 H3-thymidine was added to each well (0.074 Mbq/well) 
and the plate was incubated for a further 16 hours at 37°C. Cells were then harvested 
using an Harvester 96 Mach III M (Tomtec) and transferred on a paper filter (Printed 
Filtermat, Wallac), scintillant was added to the filter (Betaplate Scint, Wallac) and the 
H3-thymidine was counted using a 1450 Liquid Scintillation Counter Microbeta Plus 
(Wallac). 
 
2.2.3.4  γδ T CELLS PROTOCOLS: 
 
For all experiments involving gamma-delta (γδ) T cells an expansion protocol was 
devised in order to overcome their very low number in both adult and cord blood. 
Briefly, whole PBMCs or CBMCs were plated in 24-well plates at 1 X 106 cells/well/ml 
of RPMI+10% human AB serum and supplemented with 60 ng/ml of IL-2. The cells 
were checked daily and half of the medium was changed twice weekly, together with 
IL-2. If cells were too dense (i.e. reaching over 2-2.5 X 106 cells/well) they were 
collected by gentle scraping and re-seeded at the conditions above. The rate of γδ T 
cells enrichment in the preparation was measured by weekly staining with an 
appropriate antibody. γδ T cells expansion was performed for 2 to 3 weeks, then all 
cells were collected and if appropriate positively selected using the Anti-TCR γδ 
Microbead kit (Miltenyi) according to the manufacturer’s instructions.  
 
For some of the experiments described, positively selected γδ T cells were incubated for 
three days with different stimuli to boost their HLA-DR expression level. In addition to 
Dynabeads (anti-CD3 anti-CD28 microbeads, as seen in section 2.2.3.3), used at the 
same concentration employed for MLR, irradiated K562 cells (in a 1:1 ratio to γδ T 
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cells) and isopentenyl pyrophosphate (IPP, Sigma), alone, or in combination, were used. 
IPP is a classic γδ TCR ligand and was added to the cells at 50 µM, the concentration 
most commonly used in literature (Brandes et al., 2005, Brandes et al., 2009 and 
Campos Alberto et al., 2009). 
 
2.2.3.5  RF 33.70 CELL LINE STIMULATION FOR ELISA-MEDIATED IL-2 
DETECTION: 
 
The T cell hybridoma, RF 33.70, was used to investigate whether the H2-Kb-loaded 
liposomes were able to present the OVA peptide effectively. Briefly, 50,000 RF 33.70 
cells/well were resuspended in RPMI+10% FCS and added to a 96-well plate (effectors) 
and liposomes (either loaded with H2-Kb molecules or left unloaded, as a –ve control) 
were added to the effectors. As a +ve control for the reaction, OT-1 splenocytes -
resuspended in the same medium, pulsed overnight with the OVA peptide, then 
irradiated and washed prior adding them to the effectors- were used as stimulators. RF 
33.70 cells alone, and OT-1 splenocytes unpulsed, were used as –ve control. The plate 
was incubated overnight at 37°C and the day after 50 µl of supernatant/well were 
collected and either used immediately for an ELISA or stored at –20°C for later use. 
The Mouse IL-2 DuoSet ELISA kit (R&D systems, DY402) was then used according to 
the manufacturer’s instructions. Briefly, the capture antibody (rat anti-mouse IL-2) was 
aliquoted onto an ELISA plate and incubated overnight at RT. The plate was then 
washed three times, blocked with 1% BSA in PBS 1X for a minimum of 1 hour, then 
the experimental sample (and the standard provided in the kit) was added to the plate 
and incubated for 2 hours. Following three washes, the detection antibody (biotinylated 
goat anti-mouse) was added to the plate and incubated for a further 2 hours. After 
extensive washing, the horseradish-peroxidase (HRP)-conjugated streptavidin was 
added to the plate for 20 minutes and then the plate was colorimetrically developed 
using the Substrate Solution (R&D systems, DY999) at RT in the dark for 10-15 
minutes until a pale blue colour appeared in the wells. The reaction was then stopped 
using 50 µl/well of Stop Solution (R&D systems, DY994) and the plate was 
immediately read at 540 nm on a BioTek EL-X 800 reader.  
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2.3  DNA AND MOLECULAR BIOLOGY WORK: 
2.3.0  IN-HOUSE HLA-TYPING: 
 
As the MelanA antigen is an HLA-A*0201-restricted epitope, only HLA-A*0201+ve 
cords could be employed. To this purpose, cord blood-derived DNA was extracted and 
typed in-house. Briefly, 200 µl of whole CB were used for DNA extraction using the 
QIAamp DNA Blood mini kit (QIAGEN, 51104), according to the manufacturer’s 
instructions. DNA yields of 100 ng/µl or more, as assessed via Nanodrop 
spectrophotometer measurement, were routinely obtained and the DNA was stored at 
4°C for immediate use or at –20°C for long-term storage. Typing was performed using 
the SSP HLA-A low resolution-bulk kit (Olerup, Sweden) according to the 
manufacturer’s instructions. Briefly, 23 primer-specific reactions and one –ve control 
were set up using the primer set and master mix provided in the kit. The reactions were 
then run on a thermal cycler (MJ Research, PTC 200 Peltier Thermal Cycler) using the 
following PCR cycling parameters: 
 
1. 1 cycle:  94°C for 2 minutes Denaturation 
2. 10 cycles:  94°C for 10 seconds Denaturation 
    65°C for 60 seconds Annealing and extension 
3. 20 cycles:  94°C for 10 seconds Denaturation 
    61°C for 50 seconds Annealing  
    72°C for 30 seconds Extension 
 
The PCR reaction were then loaded on a 2% agarose (Invitrogen) gel, after addition of 2 
µl/sample of DNA loading buffer (10% glycerol + 0.1% bromophenol blue) and run in 
1X TBE buffer (Lonza) at 150V until the dye reached the bottom of the gel. The typing 
outcomes were analyzed with the help of Mr Tavarozzi and his team (Anthony Nolan 
Histocompatibility Laboratories). Out of 10 samples analyzed 6 were HLA-A*02+ve 
and 3 were HLA-A*02-ve; one sample showed maternal blood contamination and was 
discarded. 
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2.3.1  IN-HOUSE SEQUENCING AND OUTPUT ANALYSIS: 
 
All the sequencing required for the re-cloning of HLA-A*0201 and H2-Kb heavy chains 
sequences was performed and analysed in-house. Briefly, the DNA of interest was 
extracted from the bacterial strains used for cloning or expression using the QIAprep 
Spin Miniprep kit (QIAGEN) according to the manufacturer’s instructions. Yields up to 
1 µg/µl of DNA were routinely obtained and, if not used immediately, the DNA was 
stored at –20°C until use. At the moment of sequencing, DNA was thawed, diluted up to 
0.5 µg/µl if necessary, and the sequencing reaction was prepared. For each sample to be 
analysed, 1 µl of ready reaction mix (BigDye Terminator v3.1 Cycle Sequencing RR-
100, Applied Biosystems), 2 µl of 5X buffer (supplied with the reaction mix, Applied 
Biosystems), 1 µl of the relevant primer (1.6 mM), 0.5 µg of DNA and, if necessary, 
deionized water up to 10 µl final volume, were added in a well of a 96-wells sequencing 
plate. The plate was then sealed and the cycling protocol was performed on a Perkin 
Elmer Cetus 9600 thermocycler as follows: 
 
1. 1 cycle:   96°C for 1 minute Denaturation 
2. 25 cycles:   96°C for 10 seconds Denaturation 
     50°C for 5 seconds Annealing  
     60°C for 4 minutes Extension 
 
At the end, reactions were either immediately precipitated or stored at 4°C for up to 48 
hours. For the precipitation protocol, 2.5 µl of 125 mM EDTA were added to each well 
and the plate was quickly spun. Then 30 µl of 100% ethanol were added to each well 
and the plate was vortexed thoroughly, incubated at RT for 15 minutes and then spun at 
3200 rpm (1000g) at RT for 30 minutes. The plate was quickly inverted to remove the 
supernatant, 30 µl of 70% ethanol were added to each well and the plate was spun again 
at 3200 rpm (1000g), RT, for 10 minutes. The plate was then inverted as above, spun in 
an inverted position briefly to remove all the supernatant and air-dried for 5 minutes. 
The samples were then resuspended in 10 µl of HiDi Formamide (Applied Biosystems) 
-10 µl of water were also added to any empty well- and either sequenced immediately 
or stored at -20°C until loading on the sequencing machine (3730 DNA Analyzer, 
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Applied Biosystems). The sequencing output was collected using Sequencing Analysis 
5.2 software and analyzed. An example of sequencing outcome is reported in Figure 
2.17.  
 
 
  
 
The sequencing results were analysed using the 4Peaks software, to assess the quality of 
the sequencing, and the Seaview software to perform alignment and highlight any point 
mutation occurring in the sample. 
 
2.3.2  DNA CLONING AND VECTOR-RELATED WORK-GENERAL: 
 
During this project, it was required to re-clone the heavy chains of both the HLA-
A*0201 molecule (exoplasmic part only) and the H2-Kb molecule (exoplasmic part 
only), to add a Cys in the 3’ end position. For a starting source of HLA-A*0201 cDNA, 
the corresponding expression vector was used. However, the same could not be done for 
H2-Kb and as such a suitable H2-Kb-expressing cDNA had to be produced. Various H2-
Kb-expressing cell lines were tested and the process of RNA extraction and reverse 
transcriptase are described in paragraph 2.3.4. The primers used in this project are listed 
in Table 2.5, below. 
Figure 2.17: an example of sequencing output.  
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2.3.3.0 GENERAL PCR CONDITIONS, OPTIMIZATION AND 
MATERIALS: 
2.3.3.1  HLA-A*0201 CLONING: PRIMER OPTIMIZATION: 
 
The Cys-cloning for the HLA-A*0201 molecule was performed using the HLA-
A*0201-pET3D vector for monomer expression already available in the laboratory and 
specific primers. Upon arrival the primers were optimized for best PCR conditions 
using a temperature and Mg2+ gradient. This optimization step is used when receiving 
previously untested primers (or primers that yet have to be tested on a new template 
source) and was performed for all primer pairs used in this project (data not shown). 
The two factors tested in any optimization protocol were Tm (temperature of annealing 
of the primers to the template) and amount of Mg2+ in the reaction. Tm affects primer 
binding to the template (the higher Tm is, the more specific the binding 
primers/template is), while the Mg2+ form complexes with the dNTPs, and those 
complexes (rather than the dNTPs alone) are the actual substrate for the DNA 
polymerase. Each reaction was set up as follows: 
 
DNA (up to 100 ng/µl)     1 µl 
Taq polymerase (Bioline)     0.2 µl 
Mg2+ (Bioline, 50 mM)     1 to 3 µl /reaction 
DNTPs (Promega, 1mM)     1 µl 
10X buffer (Promega)      3 µl 
FW primer (10 mM)      1 µl 
RW primer (10 mM)      1 µl 
Primer name: Sequence: 
Actin FW 5’-GCTCCGGCATGTGCAA-3’ 
Actin RW 5’-AGGATCTTCATCAGGTAGT-3’ 
Oligo-dT 5’-TTTTTTTTTTTTTTTTTT-3’- 
A2 FW cloning out 5’-ATGGCTCTCACTCCATGAGG-3’ 
A2 RW cloning out 5’-TTAACACCCATCTCAGGGTC-3’ 
H2-Kb FW cloning out 5’-GGATCCATCGGCCCACACTCGCTG-3’ 
H2-Kb RW cloning out 5’-GGATCCTTAACAAGGCTCCCATCTCAGGGT-3’ 
Table 2.5: the main primers used in this project, with their sequence and the name that has 
been used in the text. All the primers used were ordered at ThermoElectron (Ulm, Germany).  
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H20        up to 30 µl 
 
The PCR protocol used is detailed below:  
 
1. 1 cycle:  95°C for 5 minute  Denaturation 
2. 35 cycles:  95°C for 30 seconds  Denaturation 
    45°C to 50° for 1 minute  Annealing  
    72°C for 1 minutes  Extension 
 
3. 1 cycle:  72°C for 10 minutes  Final extension 
 
An example of primers optimization is shown in Figure 2.18 below.  
 
 
 
 
 
 
 
2.3.3.2  INSERT PRODUCTION: 
 
After primer optimization, a large-scale PCR reaction was set up (final reaction volume 
50 µl) in order to have enough material to perform a gel-extraction and retrieve the band 
of interest. Briefly, after performing the PCR, the whole reaction product was loaded on 
an ethidium-bromide-free gel in 2 aliquots: 2-3 µl were loaded immediately alongside 
the molecular weight marker, while the remaining product was loaded in the adjacent 
well. When the dye reached the bottom of the gel, the run was stopped and the gel 
portion containing the molecular weight marker and the small aliquot of PCR product 
cut out, placed in a 50 ml Falcon tube filled with TBE buffer and 10 µl of ethidium 
Figure 2.18: primer optimization. From left to right: L: molecular weight ladder (Hyperladder 4, 
Bioline). Lanes 1-6: optimization of primer A2 FW cloning out and A2 RW cloning out, using a gradient 
temperature (45° to 50°) and 1 µl of Mg2+. Lanes 7-11: optimization of primer A2 FW cloning out and 
A2 RW cloning out, using a gradient temperature (45° to 49°) and 2 µl of Mg2+. In this case all 
temperatures and Mg2+ concentrations tested allowed amplification of the desired band (expected weight 
840 bp). 
840 bp 
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bromide (10 mg/ml), and incubated for 10 minutes. At the end the gel cut-out was 
examined on UV transilluminator (UVP, Inc) and the height of the band was localized 
and used to cut out the bulk of the PCR product from the ethidium-bromide-free portion 
of gel. This procedure was employed for every gel extraction where the product was to 
be used in a ligation, to minimize the impact of DNA mutagenic agents, and therefore 
the chance of mutations, in the sequence of interest. Once cut out of the gel, the band 
was agarose-extracted using the QIAquick Gel Extraction Kit (QIAGEN) according to 
the manufacturer’s indications, its concentration was estimated via Nanodrop reading 
and, if not used immediately, the DNA was stored at –20°C until use.  
 
2.3.3.3  TRANSFORMATION IN CLONING VECTOR AND SCREENING: 
 
The PCR product was then cloned in a cloning vector; for this project the pDRIVE 
Cloning Kit ligation (QIAGEN) was used (the map of the vector is reported in the 
Appendix section). Briefly, the pDRIVE cloning vector is a linear vector with a Uracil 
overhang at each 3’ end. This allows its efficient hybridisation with PCR products 
containing an Adenine overhang, such as those generated by Taq or other non-
proofreading DNA polymerases. The cloning of the HLA-A*0201 insert was performed 
in two steps; firstly the insert was amplified from a suitable template (as seen in 
sections 2.3.2, 2.3.3.2 and 2.3.4) and ligated into pDRIVE via A-U hybridisation. The 
ligation was then used to transform E.coli competent cells and the transformation 
products analysed for orientation/points mutations of the inserted sequence; once a 
clone carrying the desired sequence was detected, the insert was transferred into an 
expression vector via restriction enzyme digestion (as detailed in section 2.3.3.4). 
 
When choosing the insert-to-vector ratio it was decided to always use the maximum 
amount of insert allowed by the reaction, up to 10:1 molar excess, as it was observed 
that this promoted a more efficient reaction (data not shown). A ligation reaction was 
set up as follows: 
 
pDRIVE Cloning Vector (50 ng/µl)     1 µl 
PCR purified product       4 µl 
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Ligation Master Mix 2X      5 µl 
 
The reaction was mixed by reflux pipetting then incubated for 30 minutes at 10°C in a 
thermocycler. The reaction was then immediately used to transform an aliquot of 
chemically competent cells (TOP10, Invitrogen) according to the indications of the 
manufacturer. Briefly, for each transformation an aliquot of TOP10 cells was thawed on 
ice, paying attention not to overheat the bacteria, then 5 µl of the ligation mixture were 
added to the cells and the tube was gently flicked to ensure mixing. The cells were 
incubated on ice for 30 minutes, then placed at 42°C in a pre-heated thermoblock for 
exactly 30 seconds and placed on ice again briefly. 250 µl of pre-heated SOC medium 
(Invitrogen) was added to each transformation and the vial was placed in a 37°C-heated 
shaking incubator (225 rpm) for 1 hour prior to plating out on antibiotic-supplemented 
LB plates and incubating overnight. The following day, plates were observed for the 
presence of colonies and, if they were present, they were immediately screened for the 
presence of the insert. The PCR protocol was the same described above (see paragraph 
2.3.3.1, using an annealing temperature of 50ºC and 1 µl of Mg2+/reaction) with the 
only difference that the source of DNA in this case was a small part of a single colony, 
collected with a tip and dipped in the PCR reaction tube (where all the other 
components were already added) prior to be transplanted on a fresh LB plate for 
storage.  
 
2.3.3.4  FURTHER CLONING STEPS: 
 
Wherever a positive insert was amplified via PCR, the relevant bacterial culture was 
inoculated for small-scale DNA extraction and sequencing to confirm the presence and 
orientation of the insert. When a positive clone was identified via sequencing it was 
then inoculated for large-scale DNA extraction, restriction digestion and ligation in the 
expression vector. The restriction digestion was performed incubating the DNA in a 
final volume of 50 µl as follows: 
 
DNA (variable volume, up to 10 µg)    X µl 
Restriction enzyme      1 µl each 
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10X buffer        5 µl 
H20        up to 50 µl 
 
The reaction was incubated for up to 4 hours at 37°C and then the whole of the 
digestion was loaded on an ethidium bromide-free agarose gel.  
 
In parallel, the expression vector pET3d was prepared for ligation as well. pET3d is a 
commercially available expression vector derived from the pBR322 plasmid (the map is 
shown in the Appendix). It carries an N-terminal T7 tag and it had been used previously 
in this laboratory to express various MHC class I molecules. It was, therefore, a natural 
choice for the Cys-recloning of HLA-A*0201 and H2-Kb. The restriction enzymes used 
for cloning were BamHI and NcoI for HLA-A*0201 and BamHI and XbaI for H2-Kb.  
 
Following a large-scale DNA extraction (performed using the QIAfilter Plasmid Maxi 
kit according to the manufacturer’s instructions) the vector was digested with the same 
set of restriction enzymes used for the insert, then dephosphorylated prior ligation. The 
dephosphorylation step, while not being fundamental for a successful ligation, is often 
performed to avoid re-circularisation of the vector on itself. This is prevented via the 
enzyme-mediated removal of the 5’ phosphate group, which is a required substrate by 
all DNA ligases, from the linearized vector DNA. Dephosphorylation was performed 
post gel extraction using the Antarctic Phosphatase (NEB). Briefly, to 1 µg of DNA 
1/10 of the final reaction volume (depending on the DNA volume) of 10X reaction 
buffer and 1 µl of phosphatase were added, then the reaction was incubated for 15 
minutes at 37°C. The enzyme was inactivated by incubating the reaction at 65°C 
minutes for 5 minutes, and then the dephosphorylated vector was used for ligation. In 
this case, as well, an insert-to-vector ratio of 10:1 or more was used in each case and the 
reaction was performed overnight at 10°C in a thermocycler using T4 DNA ligase 
(1U/µl, Invitrogen). The ligation was then used the day after for transformation into 
TOP10 competent cells and screened as seen above. Once a positive clone was 
identified, the DNA was extracted and transformed into a suitable expression competent 
strain; BL21 competent cells (laboratory collection, kindly provided by Ms Forde), an 
E. coli strain optimized for protein expression, and AVB 101 (Avidity) cells were both 
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used. Both these strains are chemically competent and the transformation protocol was 
the same as seen for TOP10 competent cells. An overview of the full cloning process 
for the HLA-A*0201 is presented below in Figure 2.19. 
 
 
 
 
 
 
 
As seen above, the HLA-A*0201 heavy chain was first PCR-amplified and then cloned 
in a cloning vector. Following PCR screening to detect the presence of the insert 
(Figure 2.19A), 10 colonies showing the presence of a band at the right height were 
Figure 2.19: overview of HLA-A*0201-Cys cloning and heavy chain production. A, colonies 
transformed with a pDRIVE-HLA-A*0201-3’-Cys heavy chain (exoplasmic region only) were PCR-
screened for the presence of the insert. The expected band was 840bp (MW, DNA ladder, 1-23, 
colonies). B, sequencing output of one of the colonies showing the insert. Orientation, 3’-Cys presence 
and eventual point mutations were checked; the initial ATG and the Cys insertion are shown in the red 
rectangles. C, chromatographic plot of the 3’-Cys refolded monomer (the red arrow highlighting the peak 
containing the correctly-refolded molecule).  
840 bp 
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then sequenced using primers annealing to the middle of the amplified fragment (Figure 
2.19B). It was decided to sequence a reasonably large number of samples in order to 
have more than one perfect (i.e. right orientation, no point mutations at all and 3’ Cys 
presence) clone to be stored and used in further cloning steps if necessary. One positive 
clone was then cut out of the cloning plasmid and into the expression vector, re-checked 
by PCR and expressed for heavy chain purification. The purified heavy chain was then 
used for a MHC refold (Figure 2.19C) whose correctness was subsequently checked by 
ELISA using a conformation-specific antibody. 
 
2.3.4  H2-Kb RT-PCR: 
 
Total RNA was extracted from 3-5 X 106 H2-Kb expressing cells (RF 33.70 or RMA 
cells) using the RNAeasy mini kit (QIAGEN) according to the manufacturer’s 
instructions. Yields of 3-5 µg/µl total RNA were routinely obtained, as assessed via 
Nanodrop spectrophotometer reading. If not used immediately, RNA was stored at -
20°C. Given the fragility of RNA and the ubiquitous presence of RNAses, particular 
care was taken to maintain an RNAse-free environment when working with RNA (in 
addition to good laboratory practice, dedicated filter tips and RNAse-free plastic-ware 
were used and surfaces and equipment were wiped with RNAse Zap, QIAGEN, prior to 
use). Total RNA was then retro-transcribed using the M-MuLV Reverse Transcriptase 
(New England Biolabs-NEB) according to the manufacturer’s instructions. Briefly, 2 µg 
of RNA solution, 2 µl of oligo-dT (40 mM, see Table 2.5), 4 µl of dNTPs mix (2.5 mM 
each diluted in deionized water) and nuclease-free water up to a final volume of 16 µl 
were added in a PCR tube. The tube was heated for 5 minutes at 70°C in a Grant BT1 
Block Thermostat, then spun briefly and placed on ice. 2 µl of 10X RT buffer (supplied 
with the M-MuLV Reverse Transcriptase), 1 µl of Rnase inhibitor (NEB) and 1 µl of 
M-MuLV Reverse Transcriptase were added to the tube and the reaction was incubated 
at 42°C for one hour. The enzyme was inactivated by incubating the reaction at 90°C 
for 10 minutes; if not used immediately, the cDNA was stored at -20°C until use. In 
addition to the H2-Kb amplification, an actin band was also amplified in a separate PCR 
reaction to ensure the retrotranscribed cDNA had been produced correctly. Figure 2.20 
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below, shows an example of PCR performed using H2-Kb primers (experimental 
reaction) and actin primers (control reaction).  
 
 
 
 
 
 
After retrieving a good quality H2-Kb cDNA, the Cys-recloning of this molecule was 
performed with the same protocol and steps seen above for HLA-A*0201. The main 
passages of this process are summarized in Figure 2.21 below. 
 
Figure 2.20: H2-Kb RT-PCR. This reaction was performed using cDNA (extracted from RMA cell line, 
lanes 1 and 3, or from BL/6 splenocytes, lanes 2 and 4) as template. Lanes 1 and 2 show the 
amplification of an actin band (control reaction, expected height: 542 bp); while in lanes 3 and 4 the 
experimental samples (H2-Kb exoplasmic region, expected height 840 bp) were loaded. Next to the 
molecular weight ladder (Hyperladder 4, Bioline) the size of the relevant bands has been highlighted. 
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Figure 2.21: overview of H2-Kb-Cys cloning and heavy chain production. A, colonies transformed 
with a pDRIVE-H2-Kb-3’-Cys heavy chain (exoplasmic region only) were PCR-screened for the 
presence of the insert. The expected band was 840bp (MW, DNA ladder, 1-23, colonies). B, sequencing 
output of one of the colonies showing the insert. Orientation, 3’-Cys presence and eventual point 
mutations were checked, the initial ATG and the Cys insertion are shown in the red rectangles. C, SDS 
gel showing the H2-Kb-Cys heavy chain pre-induction (lane 1), post induction (lane 2), post induction 
and inclusion body purification and wash (lane 3), as compared to a standard (Std) and to a molecular 
weight ladder (L). D, picture of the chromatographic plot of the 3’-Cys refolded monomer (the red circle 
highlighting the shoulder containing the correctly-refolded molecule). mAU, milli absorbance unit. 
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2.4.0  CONFOCAL MICROSCOPY: 
 
For confocal microscopy only freshly prepared PBMCs were used. It was found that the 
use of frozen PBMCs, or Buffy coats, had a negative effect on the sample preparation 
and as a result the quality of the images that could be acquired decreased markedly (data 
not shown). Cells were cultured in PBS+1% heat-inactivated FCS instead of complete 
medium. This was due to the high level of autofluorescence imparted by the RPMI 
medium (data not shown) and required cells to be prepared just before the setting up of 
the liposome-cells co-cultures, to reduce the time in minimal culture conditions. Cells 
were plated at 300,000 cells/100 µl volume in a 48-well plate, then fluorescent, 
unloaded liposomes were added at different time points (0, 2, 4 and 8 hours and 
overnight) in a 500 µl final volume. The –ve control was provided by the same cells 
plated without liposomes. The cells+liposomes co-cultures and the –ve control were 
then pelleted at 1700 rpm (531g) for 5 minutes at RT and the pellet was resuspended in 
4% PFA for 20 minutes in the fridge. The cells were then pelleted again and the PFA 
was replaced with PBS, then the preparation was stored at 4°C overnight. The day after 
the cells were mounted on glass slides and fixed. Briefly, 100 µl of cells were loaded on 
a glass slide using a cytospin (speed 030, 6 minutes-the equipment was generously 
made available by Dr Steele and Mr Reed, Royal Free Hospital). Once all the slides 
were prepared they were left to dry for 20 minutes at RT. Cells were then rehydrated by 
adding a drop of PBS and leaving it for 5 minutes, then the PBS was washed off and a 
drop of 4% PFA was added on each sample. The PFA was left for 20 minutes and then 
the slides were washed twice in PBS. After removing as much PBS as possible, the 
slides were left to dry for 20 minutes (or until no more liquid could be seen on the glass) 
then 10 µl of Prolong Gold fixative (Invitrogen) was dotted on each sample to help 
maintain the fluorescence. A cover slide was then mounted on the samples and the 
slides were stored at RT in the dark until use. Images were acquired with an Olympus 
FV-1000 and FluoView v2.0 software microscope using an Olympus Plan super 
Apochromat 60X/1.35 NA oil objective (many thanks to Dr Garcon, Babraham 
Institute, Cambridge, for technical help and assistance with image acquisition) and the 
results were analysed using ImageJ software for preparation of stacked pictures.  
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2.5  STATISTICAL ANALYSIS: 
 
All the statistical analyses showed in this work were performed using the GraphPad 
software. A student t-test was performed in every case; whenever possible, a paired t-
test was performed (i.e. when the samples to be assessed were perfectly paired, for 
example being the same samples assessed at different time points), otherwise an 
unpaired t-test was used. P values were considered significant when they were less than 
0.05; P values at 0.001 or less were usually reported in the text. 
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CHAPTER 3: 
DEVELOPMENT AND CHARACTERIZATION OF LIPOSOME-BASED aAPCs 
FOR IMMUNOTHERAPY: 
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3.1.0  INTRODUCTION: 
 
A number of immunosuppressive treatments are performed in preparation to HSCT; 
however, these leave patients susceptible to the reactivation of latent viruses such as 
CMV and this is one of the main causes of morbidity and mortality in HSCT (Van Den 
Bosch et al., 2009), during the post-transplant period. While antiviral agents, such as 
ganciclovir, are available and effective, their side effects can be substantial; therefore, 
the development of immunotherapy-based protocols, where the patient’s immune 
system is manipulated to restore CMV cellular immunity, is an attractive option (Van 
Den Bosch et al., 2009). Whilst a T cell-mediated response would be very effective 
against CMV reactivation, this would require CMV-specific CD8+ve T cells. The 
generation of these cells presents more than one challenge, as they would have to be 
HLA-specific and there may be a requirement for a suitable CMV-pulsed APC to 
expand the autologous lymphocytes. DCs are the most efficient physiological APCs and 
as such they would be the best choice as APCs for CD8+ve T cells production but their 
generation ex vivo is long and labour-intensive. Other cell populations, such as 
macrophages and B cells, display APC properties both in vitro and in vivo, but not as 
effectively as DCs and, as with DCs, would be required to be generated from the patient 
or donor. A different way to tackle this issue would be developing an off-the-shelf 
artificial antigen presenting cell (aAPC) which would be ready whenever required and 
would not involve extensive manipulation and expansion prior to use. Whilst such an 
aAPC could be cellular or acellular an acellular-based option would offer the greatest 
flexibility and ease of use. It would also, arguably, provide fewer obstacles for clinical 
approval than any engineered cell line. MHC-coated liposomes would fit well the aAPC 
identikit described so far and their production, characterisation and testing, in both 
human and murine models, is the topic of this chapter.  
 
Liposomes have been used for many years in clinical and biological practice for a wide 
range of applications. In therapy, they are mainly used for gene delivery, transfection 
and drug delivery, especially in cancer settings (see Park, 2002 and Mamot et al., 2003, 
for a review on the subject).  
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When used as “transporter” liposomes, there is generally not a requirement for proteins 
or peptides to be loaded onto their surface. However, there are a number of exceptions 
such as when targeting the liposomes to a specific subset of cells, such as tumour cells. 
As such, various approaches to add proteins to the surface of liposomes, and maintain 
their orientation whilst doing so, are reported in literature (Koning et al., 2006, Hussain 
et al., 2007 and Baum et al., 2007 among others).  
 
The loading of antibodies, for example, has been achieved by adding thiol groups to the 
protein and coupling it with liposomes enriched with maleimide or thiol groups (Hansen 
et al., 1995). Generally speaking, the binding of the protein on the liposome surface is 
achieved via chemical cross-linking between reactive groups on the protein and a 
suitable reactive molecule incorporated into the lipids that constitute the liposome 
(Altin and Parish, 2006). Other possibilities include a biotin-avidin-mediated 
interaction, or, in the case of Fab binding, a hydrazone-mediated binding following Fc 
oxidization (Hansen et al., 1995), a detergent-mediated preparation (Prakken et al., 
2000) and the insertion of a metal chelator into the liposomes, for the binding of His-
tagged proteins (Altin and Parish, 2006).  
 
There are two examples in the literature that might support the concept of liposomes as 
aAPC. The first was published by Prakken et al. (Prakken et al., 2000); in this work, 
liposomes were loaded with MHC class II in order to study the immunological synapse. 
The second involves the exosome model proposed by the groups of Amigorena (Thery 
et al., 2002b) and Zitvogel (Mignot et al., 2006). In this model small lipid vesicles, 
loaded with MHC class I and co-stimulatory molecules, are shed by various cell types, 
including cancerous cells, and elicit an immunological response. This model might be 
considered to be describing a naturally occurring example of what is being attempted 
with liposomes. 
 
The aim of this PhD project is the generation and characterisation of aAPCs to be used 
in immunotherapy. This research line has been an important object of investigation at 
the Anthony Nolan Research Institute in the last years; this PhD started from the data 
obtained previously in the laboratory and published by De La Peña et al. in 2009. De La 
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Peña et al. described the construction of a nanotechnology-engineered aAPC in the 
form of an MHC-loaded liposome, or artificial exosome, and its use as an 
immunotherapeutic tool in a human memory/recall response (De La Peña et al., 2009). 
Both in the paper and in the work described in this chapter, CMV was chosen as antigen 
due to its importance in transplantation. Moreover a new, murine-based system was 
introduced in this project, to substantiate the findings obtained in the CMV context and 
as a preliminary set up for future in vivo experiments.  
 
3.1.1  STRUCTURE OF THE LIPOSOME-BASED aAPC: 
 
Figure 3.1, below, describes the liposome-based aAPC used in this project. The 
represented model is a modification of a previously published system (Pastorino et al., 
2003 and De La Peña et al., 2009) and is essentially a polyethylenglycole (PEG)-
modified liposome with MHC monomers covalently linked to its surface.  
 
 
 
 
 
 
 
 
Figure 3.1: model of the liposome-based APC. A lipid bilayer formed by cholesterol and 
phosphatidylcholine encloses an aqueous centre (— in the figure above). In the lipid bilayer are 
interspersed rhodamine-conjugated, fluorescent (red triangles) and PEG-conjugated (grey triangles) 
lipids. Maleimide-conjugated lipids (blue triangles) are used to couple MHC proteins (yellow double 
rectangles) on the liposome’ surface.  
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The main structure of the liposome is composed of cholesterol and phosphatidylcholine 
(PC and CHOL, depicted as a turquoise ring in the picture above). Three other lipids 
(DSPE-PEG, RHODA and MAL) are interspersed in the main structure, each one of 
which has a distinct function. DSPE-PEG prevents the liposomes’ clearance from the 
monocytic cell system by reducing the liposomes’ interaction with opsonizing proteins 
(Allen, 1994), thus prolonging its in vivo persistence from minutes to up to 5-10 hours 
(Klibanov et al., 1990). RHODA renders the whole liposome fluorescent, allowing it to 
be tracked in vivo and in vitro via flow cytometry analysis and/or fluorescent 
microscopy. MAL is a maleimide-conjugated lipid that allows covalent binding of 
proteins to the liposome surface, wherever a reactive thiol group on the protein is free to 
form a disulphide bond with the corresponding thiol group on the liposome surface.  
 
3.2.0  EXPERIMENTAL AIMS: 
 
The aims of the work performed in this chapter are the preparation, characterisation and 
assessment of the antigen presenting potential of MHC-loaded liposomes using both 
human (HLA-A*0201-NLV)- and murine (H2-Kb-OVA)-based models. Two different 
loading strategies and the various techniques used to assess the liposome loading will be 
described. 
 
3.3.0  RESULTS: 
 
In the data presented in this chapter, two different approaches were followed to load 
each of the proteins of interest (see Table 3.1, below) onto the liposomes’ surface. The 
first method involved random introduction of SH groups into the MHC molecules -
thereafter called “activation”- performing a thiol-exchanging reaction (using Traut’s 
reagent) as published by De la Peña et al., 2009. It was then decided to engineer a thiol 
group into the 3’-end of the heavy chain of both MHC molecules to be bound on the 
liposome, as was done by the Schwendener group (Marty et al., 2001). This second step 
had two main objectives: firstly, to improve efficiency of loading by ensuring that a 
high percentage of the MHC molecules were presented on the liposome surface in an 
orientation favourable for interaction with the TCR and secondly, if possible, to reduce 
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the amount of monomers required for each loading. The range of MHC class I 
monomers (mouse H-2 and human HLA) bound on the liposomes’ surface was also 
broadened compared to De la Peña et al., 2009, and Table 3.1, below, lists the systems 
used and the main characteristics for each.  
 
MHC model: Cell type Response type Readout Chosen because: 
HLA-A*0201-NLV PBMCs from adult donors Memory Tetramers 
Previous results 
were published in 
this model and we 
sought to reinforce 
them+strong 
expertise and 
materials available 
H2-Kb-OVA 
RF 33.70 
hybridoma (cell 
line) 
Recall (only TCR 
engagement is 
required) 
ELISA 
Cleaner readout 
(one cell population 
compared to mixed 
cultures in 
PBMCs), more 
robust than primary 
cells+used as a 
pilot model for in 
vivo upgrade.  
 
 
The liposome system employed in this thesis possesses two modifications from the one 
described by De La Peña et al., 2009. While performing the first flow cytometry 
experiments using fluorescent liposomes prepared as published in De La Peña et al., 
2009, it became apparent that the extreme intensity of the rhodamine dye used in the 
lipid mix made instrument compensation very difficult. Moreover, it limited the choice 
of antibodies that could be used in conjunction with liposomes. It was therefore decided 
to modify the published protocol and RHODA was excluded when liposomes were to 
be examined by flow cytometry or ELISA in co-cultures with cells. Instead, RHODA 
was used when liposomes were detected by fluorescent microscopy or when they were 
examined by flow cytometry without being added to cells. Secondly, it was decided to 
focus experiments in setting up the liposome model per se, using systems that did not 
require further co-stimulation in addition to TCR engagement. Therefore, no Fab 
molecules were added to the liposomes in conjunction with MHC molecules at any 
point of the protocol.  
Table 3.1: the MHC class I models used and their main characteristics.  
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3.3.1  MHC ACTIVATION AND LOADING ON LIPOSOMES: 
 
All the proteins of interest need to bind the exposed SH groups on the MAL lipid with a 
free SH lateral chain in order to be loaded onto the liposome surface. The only amino 
acid with a sulphydryl group at the end is cysteine (Cys), unfortunately MHC molecules 
contain only 6 Cys groups, all of which are occupied forming intra-molecular bonds. 
Consequently, to allow binding to the liposome surface, the MHC molecules are 
required to be activated by addition of SH groups to surface exposed residues. The first 
liposome preparations were designed, therefore, to assess the efficacy of activation of 
the MHC monomers. Following activation, the presence of SH groups in the treated 
protein was evaluated by performing an Ellman’s assay. The assay was successful and 
its results are shown in Materials and Methods, Figure 2.14; however, it was performed 
only once as the amount of monomers required for each experiment was extremely high 
(around 1/3 of the total stocks available for each protein) and a relevant noise was 
registered.  
 
Following the Ellman’s assay, the next experimental question was to assess whether the 
activated monomer was being loaded on the liposome surface and, more importantly, if 
a sufficient amount retained an orientation conducive to antigen presentation. To 
achieve this result, the best technique was to use MHC class I-specific conformational 
antibodies (such as W6/32 for HLA-A*0201) and a suitable system of secondary 
detection on the loaded liposomes. Therefore, the assessment of the efficiency of 
monomer loading on the liposome surface was initially performed via dot blot. To this 
aim, different amounts of liposomes were aliquoted onto a nitrocellulose membrane, 
incubated with W6/32 and detected using a secondary antibody (see Figure 3.2). Dot 
blots were performed either on the same day of liposome preparation (i.e. after 
chromatographic purification following MHC coupling) or the day after (see Materials 
and Methods paragraph 2.1.1.1). 
 
                                                                                                                                         Chapter 3 
  
  
 
   134 
 
 
 
 
In Figure 3.2, above, the positive control is shown in blue and the negative control in 
yellow. In red, a series of positive dots marked the position where the loaded liposomes 
were added on the membrane, thus confirming the presence of a detectable amount of 
MHC molecules on the liposome’ surface. This experiment showed that at least a 
fraction of the activated monomers was being loaded on the liposomes. However, the 
relatively faint signal and most importantly, the lack of consistency between different 
liposome batches while performing the dot blot suggested the need to look into new, 
more adequate and sensitive ways to assess the efficiency of liposome loading.  
 
3.3.2  FLOW CYTOMETRY OF MHC-LOADED LIPOSOMES: 
 
Following the dot blot evidence and the reproducibility issues encountered while 
performing it, it was decided to use flow cytometry to detect loaded liposomes. It was 
speculated that flow cytometry would provide both sensitivity and increased 
reproducibility. The first such attempt was performed on liposomes alone (see Figure 
3.3A and 3.3B, below).  
 
Figure 3.2: Dot blot. MHC loaded (red rectangle) or unloaded (yellow rectangle) liposomes were dotted 
in triplicate on a nitrocellulose membrane, subsequently incubated with W6/32 antibody. MHC 
monomers alone were used as +ve control (blue rectangle). N=1. 
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The aim of this experiment was to elucidate the FSC-SSC appearance of liposomes; in 
this case, they were prepared with the addition of RHODA as the rhodamine 
fluorochrome was meant to be the only channel of detection. As expected given the 
small diameter of the liposomes (100 nm after extrusion) their dimension was very 
small, as assessed by the low forward side scatter (FSC) value. Two different 
populations (one with high SSC the other with low SSC, see Figure 3.3A and 3.3B) 
were detected when examining the liposomes by flow cytometry. While it was not 
possible to ascribe this finding to a specific feature, one hypothesis is that the liposomes 
in suspension, when left untouched, tend to clump into different-sized micelles that 
have varying SSC properties when analysed via flow cytometry. The higher density of 
events in the population with high SSC (as represented by the brighter colour in the 
plot) could indicate that in this case the density of the liposomes is higher, possibly as a 
result of clumping. This theory was in some part substantiated by fluorescence 
microscopy of the liposomes in the absence of cells; on two independent occasions 
fluorescent spots of very different dimensions were detected when liposomes alone 
were observed (data not shown). Once it had been established that liposomes could be 
detected by flow cytometry a loaded batch was prepared and stained with W6/32 
antibody. The W6/32 labelling was then detected with a fluorescent conjugated 
secondary antibody. Unloaded liposomes treated in the same way provided the required 
negative control. Figure 3.3C shows a small but detectable shift between loaded and 
unloaded liposomes, suggesting the presence of MHC class I on the surface of the 
examined liposomes and reinforcing the evidence obtained with the dot blot (Figure 
3.2).  
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3.3.3 FLOW CYTOMETRY OF LIPOSOMES-CELLS CO-CULTURES: 
 
One of the issues that emerged during the experiments of flow cytometry performed on 
liposomes alone was the difficulty encountered during the staining protocol that resulted 
from the inability to centrifuge the liposomes. The usual washes to remove unbound 
antibody could not be performed and, therefore, high degree of unspecific binding was 
common. In an attempt to circumvent this problem HLA-A*0201–ve cells were 
cultured with HLA-A*0201-NLV monomers. Liposomes that have been successfully 
loaded with the HLA-A*0201-NLV monomer should be taken up by the HLA-A*0201-
ve cells. This should then be theoretically be detected using an HLA-A*0201-specific 
antibody. Any HLA-A*0201 labelling detected in the cell culture would be liposome-
derived.  
 
For the first cellular-based experiment, the first cell type selected to co-culture with 
liposomes was HLA-A*0201-ve DCs. Professional APCs were selected as it was 
considered that their marked phagocytic capacity might enhance the uptake and 
Figure 3.3: analysis of liposomes by flow cytometry. A, Liposomes by themselves were examined via 
flow cytometry, resulting in two discrete population having high and low SSC (representative of 4 
experiments). B, When fluorescent liposomes were examined, both subpopulations were clearly positive 
for rhodamine (—) compared to unfluorescent population (—). C, liposomes were loaded with MHC 
class I molecules and the level of W6/32 was examined in the loaded (—) and unloaded (—) population. 
B and C, representative of 2 experiments, each time performed in duplicate. 
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presentation of liposome-loaded HLA-A*0201 monomers on the cell membrane. Figure 
3.4 shows the results of this experiment. 
 
 
 
 
 
 
As seen in Figure 3.4, above, a small shift in HLA-A*0201 labelling was observed in 
the liposomes-DCs co-culture after 7 hours (Figure 3.4A), but not after an overnight 
incubation (Figure 3.4B). Two possible conclusions could be drawn from these data; 
either that the absorption of liposomal MHC molecules by cells reached a saturation 
point in a few hours or that the half-life of liposomes in culture with cells was limited to 
a short period. In any case, the outcome of this experiment suggested that the incubation 
time (in particular overnight or longer cultures) was an important variable in the system 
used and that prolonged incubation times might have affected liposome detection.  
Performing intracellular staining for HLA-A*0201 might have served to localize the 
MHC molecules from the liposomes after uptake. However, it is also possible that 
uptake of the MHC molecules would then lead to degradation/digestion. Therefore, 
such labelling might not quantify functional or intact HLA-A*0201. 
 
3.3.4  IMPROVING THE LOADING VIA CYSTEINE CLONING: 
 
Whilst all the data up until this point suggested that monomer had indeed been loaded 
onto the liposomes, the results were subtle with no clear indication of success. One 
Figure 3.4: flow cytometry analysis of DCs-liposomes co-cultures. DCs from an HLA-A*0201-ve 
donor were prepared, incubated with nonfluorescent liposomes A, for 7 hours, or B, overnight, and the 
HLA-A2 expression (—) was then measured by flow cytometry for each sample within the DC gate and 
compared to a liposome-free DC preparation (—). N=1. 
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possibility is that the activation of the monomers was too stochastic and led to a high 
degree of variability in the extent of SH group introduction into the molecules.  
 
To reduce this variability it was planned to re-clone the existing heavy chain molecules 
adding a 3’-Cys residue and re-express the newly Cys-modified heavy chains to use 
them for monomer refolding. This Cys residue would eliminate the need for random 
activation prior to loading on the liposomes’ surface, as MHC molecules would already 
have a Cys-based anchor for the liposomes in the best possible position for correct 
loading. The whole process is summarized in Figure 3.5, below.  
 
 
 
 
 
The re-cloning of both heavy chains (HLA-A*0201 and H2-Kb) was then undertaken 
according to the procedure detailed in Materials and Methods and shown in Figure 2.19 
(for HLA-A*0201) and Figure 2.21 (for H2-Kb). Both molecules were successfully 
cloned in an expression vector, expressed in a prokaryotic system and used for refolding 
together with the appropriate peptides.  
Figure 3.5: new mechanism of monomer loading. A, monomers are at the moment loaded randomly on 
the liposomes’ surface. The introduction of a Cys at 3’ in the monomer, B, should promote a better 
orientation of the monomers on the liposomes’ surface, C.  
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3.3.5  LIPOSOME-MEDIATED CMV EXPANSION: 
 
Once the Cys-modified HLA-A*0201 monomer was produced, it was decided to test 
the potential of HLA-A*0201-NLV-loaded liposomes as aAPC. This was performed by 
setting up a liposome-PBMC co-culture, as previously published (De La Peña et al., 
2009). To this end, both versions of the monomer (with and without added 3’-end Cys) 
were loaded on different aliquots of the same batch of liposomes. The effectiveness of 
these liposomes in expanding an HLA-A*0201-NLV tetramer-specific population was 
assessed using freshly purified, unselected PBMCs from an HLA-A*0201+ve, CMV 
positive donor. 
 
Firstly it was decided to test the liposome-mediated expansion and compare it to as 
many positive controls as possible (NLV peptide and HLA-A*0201-NLV monomer). 
Whilst peptide-mediated expansion is the commonest choice in literature, monomers 
have also been used. By using monomers as a control the influence of loading the 
monomers onto liposomes could be assessed. Two negative controls, cells incubated 
without any stimulus and cells incubated with unloaded liposomes, were also used. The 
ratio of liposomes-to-cells and the cell culture conditions previously optimized in De La 
Peña et al., 2009, were used throughout the whole series of liposome-mediated 
expansions. Figure 3.6A, below, shows a representative result from one of the 
liposome-mediated expansion performed, while Figure 3.6B summarizes as a column 
graph the results obtained in all the expansions performed. 
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Figure 3.6A: flow cytometry analysis of PBMCs-HLA-A*0201-NLV loaded liposomes co-cultures. 
PBMCs from an HLA-A*0201+ve healthy donor were incubated with HLA-A*0201-NLV loaded, 
nonfluorescent liposomes for 7-10 days and analysed for their HLA-A*0201-NLV tetramer specific 
expansion. NLV peptide and HLA-A*0201-NLV monomer were used as +ve controls, cells incubated 
without antigenic stimulus were used as -ve control. In all cases lymphocytes were gated and the CD8+ve 
tetramer+ve population was shown. Results shown are representative of 5 independent experiments on 2 
different donors. 
Figure 3.6B: graph summarizing the results from all the liposome-mediated PBMCs expansion 
performed. Data are expressed as columns representing the mean of the CD8+ve HLA-A*0201-NLV-
tetramer+ve population for each condition tested, while the error bars represent the standard deviation. 
Mean values ± standard deviation are also quoted in the text. Data were analysed using the student paired 
t-test; N=5, P*<0.05.  
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A small but clear tetramer+ve population was detected in all cases in the unstimulated 
aliquot, thus providing a starting point for the assessment of HLA-A*0201-NLV 
tetramer-specific expansion. The positive controls used promoted relevant tetramer 
expansion in the donors tested (see figure 3.6A above, upper row, for a representative 
example). No comparable or consistent expansion was detected when using HLA-
A*0201-NLV-loaded liposomes in any of the conditions tested (see Figure 3.6A bottom 
row and 3.6B last two columns on the right). In the representative case shown above in 
Figure 3.6A there is a slight expansion between the loaded- and unloaded-liposome 
cultures (1.49% vs 1.13% of CD8+ve HLA-A*0201-NLV tetramer+ve cells, as shown 
in the lower row of figure 3.6). In contrast, the level of CD8+ve HLA-A*0201-NLV 
tetramer+ve cells in the Cys-loaded liposomes is 0.8%, which is below the 
correspondent amount of cells in the negative control (unstimulated cells- Figure 3.6A, 
upper row, left quadrant). Loading the monomers through a Cys anchor did not appear 
to improve the aAPC potential of the liposomes. 
 
A plot summarising all the liposome-mediated expansion experiments is presented in 
figure 3.6B. A significant difference in the percentage of CD8+ve HLA-A*0201-NLV 
tetramer+ve cells was detected when comparing unstimulated cells versus peptide-
stimulated cells (0.76±0.1% versus 6.4±1%, respectively; P=0.004). There was a trend 
of expansion with the monomers over unstimulated cells but this expansion was too 
inconsistent to be significant with this sample size. No significant difference was 
observed between the unstimulated control (Figure 3.6B; -ve control) and PBMCs 
stimulated with unloaded and loaded liposomes, regardless of the loading protocol used 
(Figure 3.6B first and last three columns).  
 
The results presented above may suggest that liposomes inhibited responses rather than 
expanding tetramer-specific cells. The results in Figure 3.6 were obtained in five 
independent experiments using two different donors and did not change with different 
batches of monomer-loaded liposomes, different batches of monomers as stimulators 
and different culture times (the longest one attempted was 21 days). 
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This series of experiments suggested firstly that the cell culture conditions by 
themselves were compatible with PBMCs’ survival and growth, as a tetramer-specific 
expansion was detected in all of the positive controls. Even if not statistically 
significant, the use of HLA-A*0201-NLV monomers as stimulus resulted in a tetramer-
specific expansion, thus ruling out any MHC-related role in the absence of expansion 
observed with monomer-loaded liposomes. However, the lack of expansion and 
possible liposome-mediated inhibition observed in the cell/liposome co-cultures 
prompted further investigation into the effect of liposomes (loaded and unloaded) on 
cells.  
 
3.3.6  QUALITY CONTROL AND LIPOSOME-MEDIATED EFFECT ON 
PBMCs CULTURES: 
 
Up to this point the experimental evidence suggested that liposomes were not promoting 
tetramer-specific cell expansion when incubated with primary cells, in contrast with 
previously published data. The priority now was to understand the action of liposomes 
on PBMCs. Firstly it was determined whether the presence of unloaded liposome could 
affect expansion in the peptide and monomer driven positive controls and secondly the 
effect of liposome alone on the amount of tetramer+ve cells was assessed in the absence 
of stimuli. The effect of empty liposome on peptide and monomer driven expansion is 
shown below in Figure 3.7.  
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As before, stimulating cells with positive controls produced a convincing expansion of 
the tetramer-positive population (2.41% tetramer+ve cells from 0.18% in the 
unstimulated control) whilst cells co-incubated with liposomes see the same population 
drop below the level of the negative control (0.07%). The presence of liposomes in the 
peptide and monomer cultures resulted in a much smaller expansion (0.59% 
tetramer+ve cells), than that registered in the sample stimulated in the absence of 
liposomes. This pattern of reduced tetramer-specific expansion when cells are co-
incubated with liposomes was, therefore, observed in two independent series of 
experiments.  
 
The effect that liposomes, both loaded and unloaded, had on PBMCs cultures without 
any other exogenous antigen was then examined. In this case, different amounts of 
liposomes were added to PBMCs and the percentage of tetramer+ve cells was assessed 
and compared to cultures without liposomes (-ve control). Results for this experiment 
are shown in Figure 3.8. 
 
Figure 3.7: the effect of empty liposomes on peptide- and monomer-driven HLA-A*0201-NLV 
PBMCs expansion. PBMCs from an HLA-A*0201+ve healthy donor were incubated with unloaded, 
nonfluorescent liposomes and either NLV peptide or HLA-A*0201-NLV monomer as stimulus. HLA-
A*0201-NLV tetramer specific expansion was analysed at day 7. Bars show the CD8+ve HLA-A*0201-
NLV tetramer+ve population. Results shown are representative of 3 independent experiments on 2 
different donors.  
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Figure 3.8, above, compares the percentage of tetramer+ve cells in PBMCs incubated 
with various amount of liposomes with the same cells without liposomes. Results 
suggested that large amounts of liposomes, from 30 microliters upwards, corresponding 
to the condition used in Figure 3.6, have an inhibitory/toxic effect on culture, as 
demonstrated by the drop in number of tetramer+ve cells (less than 0.8% of tetramer+ve 
cells). Conversely, small or very small volumes of liposomes, up to 15 microliters, have 
no effect on the percentage of tetramer+ve cells and presumably on cell viability, as 
tetramer+ve cells remained above 1.4%. Unfortunately, such limited amounts of 
liposomes may be ineffective in promoting a cellular response.  
 
The effect of unloaded liposomes on viability was also tested on Buffy coat samples, 
which were stained for 7-AAD following incubation with increasing amounts of 
liposomes and the buffer used for liposome preparation (HEPES buffer). The results are 
shown below in Figure 3.9. 
 
Figure 3.8: the effect of liposomes on HLA-A*0201-NLV tetramer+ve cells. PBMCs from an HLA-
A*0201+ve healthy donor were incubated with different amounts of loaded and unloaded, nonfluorescent 
liposomes for 7 days, then analysed for their HLA-A*0201-NLV tetramer specific population. Bars show 
the CD8+ve tetramer+ve population; the black line across the graphs marks the level of tetramer+ve cells 
in the -ve control (PBMCs incubated without either liposome). Results shown are representative of 2 
independent experiments on 1 adult donor and 1 Buffy coat sample. 
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The first conclusion from the results is that the co-culture of unloaded liposomes with 
Buffy coat cells results in an increase in the percentage of CD3+ve 7-AAD+ve cells 
(marked for Buffy coat 1, more moderate in the case of Buffy coat 2). The decrease in 
viability was observed with every liposome amount; however, it does not seem to be 
dose dependant for liposomes. An increase in the CD3+ve 7-AAD+ve population is also 
seen with the buffer used to prepare the liposome, suggesting it is not compatible with 
Buffy coat viability in the conditions and system used. Buffy coat 1 and 2 had different 
background non-viable lymphocyte populations (CD3+7-AAD+) as shown by the 
percentage of dead cells in the empty cells condition. However, the trend of increase in 
the CD3+ve 7-AAD+ve population when in the presence of liposomes or HEPES buffer 
is similar in both samples.  
 
3.3.7 PBMCs/LIPOSOME CO-CULTURES, PRELIMINARY CONCLUSIONS:  
 
All the evidence presented so far suggested that liposomes were being prepared and 
loaded correctly. However, their prolonged (i.e. >overnight) co-incubation with PBMCs 
Figure 3.9: the effect of liposomes on Buffy coat cells’ viability. PBMCs from 2 Buffy coat samples 
were incubated with different amounts of unloaded, nonfluorescent liposomes and with the buffer used to 
resuspend them (HEPES only) for 7 days. The cultures were then analysed for their CD3+ve 7-AAD+ve 
population for a general assessment of the effect that liposomes and buffer had on the viability of T cells. 
Empty cells (PBMCs without any liposomes or buffer) provided the negative control. Bars show the 
CD3+ve 7-AAD+ve population. In this case large wells, and consequently larger amounts of liposomes, 
were used due to the availability of a large number of cells from the Buffy coats. N=1. 
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resulted in a lack of expansion of tetramer-specific cells, in contrast with previously 
published data, suggesting that there were intrinsic issues with the liposome system. 
The data suggested the liposomes were apparently exerting an inhibitory/toxic effect 
when incubated with cells. However, it was important for the project to assess the 
general feasibility of using liposomes in the in vitro PBMCs system employed in this 
work, assuming the toxicity issues could be resolved. In particular, it needed to be 
clarified whether liposomes retained their integrity in co-culture with PBMCs long 
enough to exert an antigen presenting effect. Among the explanations proposed for the 
data in Figure 3.4 was that liposomes are taken up by the cells at very early time points; 
if this were the case, it would affect the capability of these MHC-loaded liposomes to 
act as aAPC (being sequestered inside cells). Therefore, it was decided to assess the 
PBMCs-liposomes interaction via fluorescent and confocal microscopy, to determine if 
all the liposomes were internalized. 
 
3.3.8  FLUORESCENT MICROSCOPY OF LIPOSOMES-CELLS CO-
CULTURES:  
 
Fluorescent microscopy and a PBMC-fluorescent (rhodamine) liposome co-culture was 
used to determine the extent of liposome uptake by cells at early time points (Figure 
3.10). To rule out any membrane localization of the liposomes, confocal images were 
taken for some of the most relevant time points to have a stack of images for any given 
slide section examined (Figure 3.11). The results for these experiments are shown 
below. 
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Figure 3.10: Fluorescent microscopy analysis of liposome-PBMCs co-culture. Unloaded, fluorescent 
liposomes were added to fresh PBMCs and the rhodamine-derived fluorescence was examined at various 
time points, as indicated in each figure. For each time point: PBMCs alone were examined for 
autofluorescence, A, and in bright field, B, and PBMCs-liposomes co-culture were examined for 
rhodamine fluorescence, C, and in bright field, D. Results shown are representative of 2 independent 
experiments.  
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As seen in Figure 3.10, above, rhodamine fluorescence can be detected in all samples; it 
is brightest at 0, 2, and 4 hours and a fainter fluorescence can be detected at 8 hours and 
overnight too. At 0 and 4 hours the liposome-mediated fluorescence appears 
concentrated on the edges of some cells, whilst at 2 hours the brightest spot in the focal 
slide examined belongs to a single cell, even if edge fluorescence is still detectable 
around the brightest point. All samples (with the exception of hour 8) show that the 
respective –ve controls are autofluorescence-free so the signal observed in the 
rhodamine-fluorescence channel can be genuinely attributed to the liposomes. While it 
is not possible to detect a gradient of pigmentation in the samples between 0 and 4 
hours it appears that, in the system in use, liposomes are present on the cell surface and 
are possibly internalized at early time points, as better shown in the next figure. Figure 
3.11, below, shows stacked images for some of the same time points photographed in 
one-plane in figure 3.10. 
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In the case of confocal microscopy it was decided to focus on 0 and 8 hours time points 
as examples for very early and late uptake, respectively. As it can be observed in Figure 
3.11A, the rhodamine fluorescence is clearly detectable in all the focal slides of the 
single cell examined at t = 0. This suggests that at least a fraction of the liposome 
preparation is entering into the cells immediately after establishment of the co-culture. 
The low level of autofluorescence detected in the negative control (cells alone in Figure 
3.11B) is most likely due to fixing procedure. The fluorescence signal is more intense in 
Figure 3.11: Confocal microscopy analysis of liposome-PBMCs co-culture. Unloaded, fluorescent 
liposomes were added to fresh PBMCs and the rhodamine-derived fluorescence in stacked slides of the 
same image was examined at 0 (A, B) and 8 hours (C, D). A and C, PBMCs+liposomes, B and D, 
PBMCs alone (as a control for autofluorescence). For each image a representative series of stacked slides 
was reported, except for D where all the available slides were shown.  
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the 8-hour samples (Figure 3.11C-D), which show a high level of rhodamine 
fluorescence inside many cells in the majority of the focal slides examined, and little or 
no autofluorescence in the control. Taken together, the confocal microscopy results 
shown in Figure 3.10 and 3.11 strongly suggest that liposomes are taken up early by 
PBMCs when co-cultured. This finding might affect their employment as aAPC; uptake 
by cells could affect the ability of the liposome to form an immunological synapse, to 
present the MHC monomer to the TCR on the T cells and/or have an impact on TCR 
signalling. Moreover, high levels of liposome inside the cytosol might have a cytotoxic 
effect by themselves by affecting intracellular osmolarity. However, it has to be pointed 
out that such effects might be cell-dependent, with different cell types uptaking the 
liposomes at different rates. Ideally, liposome uptake should be assessed independently 
in each cell system used.  
 
3.3.9  SETTING UP THE RF 33.70 READOUT: 
 
In parallel to the liposomes-PBMCs experiments, the ability of the liposomes to 
function as aAPCs was also tested using a murine model. This involved using the OVA 
restricted RF 33.70 non-lytic CD8 T cell hybridoma (see Materials and Methods section 
2.2.1.5) as responding cells; murine H2-Kb-OVA monomers (see Table 3.1) were 
employed as stimulus. As was done with HLA-A*0201-NLV, a re-cloning step was 
undertaken to add 3’- end Cys residues.  
 
H2-Kb-OVA-specific RF 33.70 cells release IL-2 upon successful TCR engagement, 
consequently the readout for this system was IL-2 in the culture supernatant, measured 
by ELISA. The first experiment performed was an ELISA test on the RF 33.70 cells 
incubated with OVA peptide alone, to ensure that no cross-presentation of peptide was 
occurring in the absence of exogenous monomer or antigen presenting cells. No 
detectable IL-2 secretion was recorded and the background from unstimulated cells was 
very low (data not shown). This confirmed that the system in use was “clean”-i.e., 
peptide alone could not exert an effect. Consequently even if peptide were to become 
detached from the liposomes’ surface, this would not interfere with a genuine liposome-
mediated antigen presentation.  
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A suitable positive control was then established using H2-Kb-expressing splenocytes 
from OT-1 mouse, pulsed overnight with various concentrations of OVA peptide and 
irradiated. They were then co-incubated with two different amounts of RF 33.70 cells to 
evaluate which was the combination promoting the best IL-2 secretion. Results for this 
experiment are shown in Figure 3.12, below. 
 
 
 
 
 
 
 
Figure 3.12 shows marked secretion of IL-2 only when the responder RF 33.70 cells 
were incubated with pulsed OT-1 splenocytes. Neither type of cells alone, nor RF 33.70 
incubated with unpulsed OT-1 splenocytes, resulted in significant amounts of IL-2 
being released in the supernatant. However, all the concentrations of peptide tested 
resulted in consistent IL-2 secretion with both amounts of RF 33.70 cells used. There 
was no correlation between increasing amount of peptide and increased secretion of IL-
2. Instead, a relatively low peptide dose (0.5 µg) gave one of the best responses, while 
the next increment -1 µg- gave the poorest response registered. It was decided that 0.5 
µg of peptide gave the most consistent response from the RF 33.70 cells. However, it is 
possible that a more optimal peptide concentration existed at a lower dose. If the 
Figure 3.12: RF.33.70 cell line ELISA optimization. 2 different amounts of RF 33.70 cells (H2-Kb-
OVA specific hybridoma) were incubated overnight with a fixed number of unpulsed OT-1 splenocytes 
(third from left) or splenocytes pulsed with increasing amount of OVA-peptide (fourth to seventh from 
left). Both cells types alone (first and second from left, respectively) were used as -ve controls. IL-2 in 
the supernatant was then detected by ELISA and plotted as a column (each column is the mean result of 
values from triplicate wells; standard deviation is plotted as error bars). Results shown are 
representative of 2 independent experiments.  
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optimal dose had been needed, a dose response curve from dose of 0.5 µg and lower 
would have been required to elucidate it. 
 
3.3.10  LIPOSOME MEDIATED IL-2 SECRETION IN THE RF.33.70 
SYSTEM: 
 
After setting up all the controls (see Figure 3.12) the antigen presenting potential of H2-
Kb-OVA-loaded liposomes was tested in the RF 33.70 system. To this end, a batch of 
H2-Kb-OVA-loaded liposomes was prepared and incubated with RF 33.70 cells, 
together with OVA-pulsed OT-1 splenocytes as controls. Liposome doses that had been 
shown to be optimal by De La Peña et al., 2009, were used. A RF 33.30-liposome 
specific titration was not performed, as the amount of liposome required to form an 
increasing dose titration was impractical (approximately half the culture volume was 
required to be liposomes to achieve the De La Peña et al. doses used in this 
experiment).  
 
 
  
 
 
 
 
In this case the IL-2 secretion for the +ve control (Figure 3.13, third column from left) 
was not as marked as shown in Figure 3.11, however it was still enough to produce a 
Figure 3.13: RF.33.70-liposomes ELISA. 2 independent cultures of RF 33.70 cells were incubated 
overnight with unloaded liposome (empty lip), with liposome loaded with an irrelevant human monomer 
(irrelevant lip) or with two different H2-Kb-OVA loaded liposomes (H2-Kb-OVA lip 1 and 2). As -ve 
controls, RF 33.70 cell alone or RF 33.70 cells incubated with unpulsed splenocytes (RF 33.70 + OT-1 
no pept) were used, while as +ve control RF 33.70 cells incubated with pulsed splenocytes (RF 
33.70+OT-1+pept) were employed. Results shown are representative of 2 independent experiments using 
both H2-Kb-OVA- and Cys- H2-Kb-OVA-loaded liposomes. Columns represent the mean values from 
triplicate wells, while the standard deviation is plotted as error bar.  
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clear positive result. None of the negative controls (RF 33.70 cells on their own and 
incubated with unpulsed splenocytes) showed any IL-2 secretion. However, neither did 
any of the liposome-stimulated samples. In addition to two independent batches of H2-
Kb-OVA-loaded liposomes, an unloaded liposome and a liposome loaded with an 
irrelevant human monomer (HLA-B*0702) were used and in no case was a significant 
amount of IL-2 was detected. Similar results were obtained when using Cys-H2-Kb-
OVA-loaded liposomes (data not shown). These findings suggested that the H2-Kb-
OVA-loaded liposomes were not exerting an antigen-presentation effect in this system, 
or were not being correctly recognized by the cells.  
 
3.4.0  DISCUSSION: 
 
The initial aim of the work described in this chapter was to produce a liposome-based 
aAPC to be used for immunotherapeutic applications, following the results obtained 
previously in the laboratory and published in De La Peña et al., 2009, during the course 
of this PhD project. In this work, it was decided to focus on T cell systems involving 
memory responses only. This should have reduced the need for co-stimulatory 
molecules on the liposomal surface; signal 1, i.e. TCR-MHC/peptide engagement, 
should have been the only requirement for an immune response. During the project, 
however, unforeseen and persisting standardization issues were encountered during the 
preparation and MHC loading of the liposomes. Moreover, results that were not 
consistent with the previous reports emerged in the more functional, cellular-based 
experiments. In the next sections some possible explanations for these results will be 
discussed and various hypotheses to explain the discrepancies between the published 
data and these findings will be presented.  
 
3.4.1  MONOMER ACTIVATION: 
  
The first objective to be accomplished in this project was the correct loading of each 
type of monomers on the liposomal surface. Due to the requirement for a Traut’s 
reagent-mediated activation step, it seemed natural to employ the Ellman’s assay to 
assess whether the introduction of novel SH groups had been successful or not. It was 
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discovered, however, that it was not possible to quantify exactly how many new thiol 
groups were introduced; Ellman’s assay would have provided only an overall 
quantitative assessment of the increase in SH groups in the activated protein. The first 
attempt was successful but it was performed only once as the method was very 
inefficient. A single experiment required 1/3 of the total refolded monomer stocks 
available for each protein and a high experimental noise was registered. To continue 
with the Traut’s reagent protocol would likely require the titration of different amounts 
of the reagent to the monomers and the evaluation of activation via Ellman’s assay. 
Optimization would have to have been performed independently for each of the 
substrate used in the project-i.e. the HLA-A*0201-NLV and H2-Kb-OVA molecules. 
However, this approach was abandoned on the basis of both the very high amounts of 
monomers required for each Ellman’s assay and the difficulties in detecting correctly 
loaded monomers on the liposome surface using only biochemical methods. In fact, 
these preliminary results and considerations prompted the question whether a 
biochemical assay was the best choice to evaluate liposome quality, or if there were 
other possible options available.  
 
3.4.2  MONOMER LOADING AND DETECTION: 
3.4.2.1  BIOCHEMISTRY METHODS: 
 
Some technical issues were also encountered during the next step in liposome 
preparation, the evaluation of loading efficiency. Initially this was assessed via 
biochemical methods, as previously published by De La Peña et al., 2009, but very poor 
consistency between different assays and batches of liposome was experienced. The 
reported sensitivity of a dot blot i.e., the minimum amount of protein that can be 
detected, is around 1 µg. As each batch of liposome was loaded with a maximum of 10 
µg protein, pre-chromatography, the maximum amount of MHC-loaded liposome that 
could be added to a blot membrane was likely to contain approximately 0.9 µg of 
protein. Whilst this should have been in the range of detection it would have been at the 
lower end. However, more sensitive biochemistry-based assays such as silver staining 
of polyacrylamide gel (which can detect nanogram amounts of protein), Western Blots, 
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or ELISA, were not viable options. For silver stains and Western Blots, the difficulty 
was loading a sufficient amount of whole liposomes on a gel (data not shown) without a 
denaturation step that would have most likely affected the loaded monomer. In the case 
of the ELISA, the liposome cannot be adhered to the plate, making washing to remove 
detection antibody difficult to impossible.  
 
3.4.2.2  FLOW CYTOMETRY METHODS: 
 
Taking into account all these considerations it was decided to use flow cytometry-based 
techniques to further elucidate the efficacy of loading, as it was considered that flow 
cytometry detection would provide a good balance between practicality and sensitivity. 
Initially, flow cytometry experiments performed on liposomes alone showed positive 
results. However, it was discovered that the staining of liposomes led to very high non-
specific binding, amplified or possibly caused by the inability to wash the preparation. 
The flow cytometry analysis was complicated further by the very high level of 
fluorescence imparted to the liposome preparation by the rhodamine-fluorescent lipid. 
This was an unavoidable requisite when liposomes were examined alone. To 
circumvent both these problems, it was decided to examine liposome-cell co-cultures. 
In this case, liposomes did not need to be fluorescent and staining and washing could be 
performed as normal, resulting in an improved clarity on whether monomer loading was 
successful or not. Regardless of its detection level, however, it could well be possible 
that the scarce amount detected as correctly loaded on the liposomes’ surface is more 
than enough to exert a cellular action. As such, a poor detection did not necessarily 
imply a poor liposome-mediated expansion in the PBMCs system.  
 
3.4.3  MONOMER LOADING OPTIMIZATION: 
 
Even after having ascertained that monomer molecules were present on the liposome 
surface and could be detected, albeit at a low level, the orientation issue still remained. 
It was perfectly possible that the amount of randomly-activated monomers loaded on 
the liposome surface was enough to elicit a response from cells. However, the 
orientation of single proteins on the liposome surface was impossible to control as there 
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was no way to add cysteines preferentially on one part of the molecule rather than the 
other. To improve monomer loading and decrease the intrinsic variability of the process, 
it was decided to insert one Cys at the 3’-end of each heavy chain molecule (HLA-
A*0201 and H2-Kb). The addition of a single amino acid, rather than a string as has 
been described in the literature (Marty et al., 2001 and Marty et al., 2002), was chosen 
to avoid self-annealing of SH reactive group from contiguous cysteine amino acids. 
Moreover, it was speculated that the addition of a single amino acid, rather than a string, 
was less likely to affect the tertiary structure of the refolded protein. In fact, the addition 
of a single Cys at the 3’-end position did not impact on the refold of the monomer, as 
assessed by conformation-specific ELISA in both HLA-A*0201-NLV and H2-Kb-OVA 
monomers (data not shown). Finally, it was considered that, in the case of HLA-A*0201 
at least, the addition of a single Cys could have had a significant impact on loading. As 
there are only other 6 cysteines in the entire protein, all used for inter-protein binding, 
(Bjorkman et al., 1987), it was predicted that one more Cys at the 3’-end of the 
molecule would provide a good anchor for liposome attachment without affecting the 
structure of the protein.  
 
Another reason to optimize the monomer loading was the possibility to reduce the 
amount of protein that resulted unused during the attachment to the membrane. With the 
activation protocol it was very likely that a relevant amount of the monomer used for 
loading ended up in an unfavourable orientation. However, there was no way to recover 
and reuse such misloaded molecules. Therefore, after the appropriate optimization, a 
more rational procedure of monomer attachment would have reduced the amount of 
protein required for each loading, improving greatly the efficiency of the protocol. The 
overall amount of monomers available was in fact one of the limiting factors of the 
system. Indeed, the preparation and optimization of a monomer-producing cell line, 
starting from a tricistronic vector transfected in a eukaryotic expression system, was 
considered at the beginning of the project but abandoned due to time considerations. 
However, a larger amount of monomer available from the start would have been 
beneficial for the aAPC-liposome system, as it would have allowed the testing of a 
larger number of conditions. 
 
                                                                                                                                         Chapter 3 
  
  
 
   158 
3.4.4  TOXICITY AND EXPANSION: 
 
Following liposome preparation and characterisation, it was decided to test the antigen 
presenting potential of HLA-A*0201-NLV loaded liposomes in an in vitro system. 
PBMCs from CMV+ve, HLA-A*0201+ve healthy adult donor and optimized conditions 
described in De La Peña et al., 2009, were used in the experiment.  
The controls for this system, both positive and negative, worked consistently well; 
indeed, in some experiments a better tetramer-specific expansion was seen when using 
HLA-A*0201-NLV monomer rather than NLV peptide as +ve control (data not shown). 
This was explained with the fact that, while the peptide was prepared and used 
aseptically across the whole procedure, this was not the case for the monomers. In fact, 
heavy and light chain were obtained by bacteria inclusion bodies and, despite lengthy 
washes and chromatography, the resulting preparation could not be completely sterile-
i.e., completely free of bacteria-derived components. Therefore, it is likely that some 
PAMPs or other immunogenic bacterial byproducts survived in the monomer 
preparation. This could have promoted general T cell activation, resulting in an 
increased percentage of tetramer-specific cells if compared to the peptide-stimulated 
PBMCs.  
 
In the experimental samples, however, it was not possible to detect the same level of 
HLA-A*0201-NLV liposome-mediated expansion described in the published data. 
Instead, a small but noticeable decrease of tetramer+ve cells often occurred when the 
PBMCs were co-incubated with the liposomes. In the first experiments this effect was 
detected when using Cys-modified MHC-loaded liposomes. If this trend had been 
observed in all the expansions performed a possible conclusion would have been that 
only the Cys-modified loaded liposomes were, for some reason, ineffective and possibly 
promoting cytotoxicity. In further experiments, however, whenever liposomes 
(unloaded or loaded with either protocol) were used, the percentage of CD8+ve HLA-
A*0201-NLV tetramer+ve cells in the corresponding co-cultures tended to either 
remain at the same level of the unstimulated culture or to diminish slightly. These 
results were observed in more than one donor and with different incubation times 
(including longer time points than those described in De La Peña et al., 2009). This 
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finding lead to an interruption in further PBMCs-liposome expansion experiments, as it 
was necessary to assess the effect of liposomes on cells in the system used in this 
project. Judging from the experimental evidence, it was speculated that liposomes might 
be taken up by cells at early time points in the co-culture and such an uptake might have 
resulted in the inhibition/mild toxic effect observed.  
 
The effect of unloaded liposomes was also assessed using Buffy coat cultures; a 
decrease in cell viability upon co-incubation with liposomes (as evaluated via direct 7-
AAD staining) was observed. Some possible mechanisms of action were hypothesised 
as explanation for this finding. Firstly, the formulation of the liposomes’ suspension is 
not at a physiological concentration. More accurately, the concentration of NaCl in the 
buffer used for re-suspension and chromatography is 140 mM, whilst the physiological 
solution used in medical practice is 154 mM. Whilst the osmotic difference is slight, it 
may have a damaging effect on PBMCs, leading to potential loss of viability. The 
HEPES buffer might have also have had an adverse effect, as the Buffy coat samples 
had a slight increase in overall mortality when incubated only with the re-suspension 
buffer. Secondly, without access to GMP facilities, it was not possible to maintain 
complete sterility during liposome preparation. Liposomes were filtered just before use 
and subsequently maintained aseptically but there is still the possibility they will not be 
suitable for prolonged in vitro use. Even in the absence of obvious contamination (such 
as bacterial or fungal growth during cell culture) the possibility of contamination 
remains which may negatively impact on cell viability.  
 
3.4.4.1  THE TIME INCUBATION EFFECT: 
 
The most relevant determination of toxicity is likely to be a combination of primary cell 
use with relevant amounts of liposomes (i.e.>30% of total culture volume) and 
prolonged incubation. Analysing the studies reported in the literature reveals few details 
of the exact amounts of liposomes added to a specific number of cells (one of the few 
examples is reported by Marty and Schwendener, 2005). The liposomes-cell incubation 
times vary greatly, ranging from 30 minutes (Marty and Schwendener, 2005) to 1 
(Koning et al., 2006, Huth et al., 2006 and Baum et al., 2007), 2 (Copland et al., 2003) 
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and 6 hours (Mercadal et al., 1999). The longest incubation described was up to 48 
hours (Ignatius et al., 2000). Albani’s group (Prakken et al., 2000) used liposome-based 
aAPCs as a stimulus for the measurement of IL-2 production in a setting similar to that 
presented in this work, and described a cell-liposome co-incubation time of 8 hours.  
Exosomes are a physiological analogue of the liposome system presented in this project. 
Amigorena’s team (Thery et al., 2002a) employed exosomes in a 4 day thymidine-based 
assay while the Zitvogel group (Andre et al., 2004) used them in a 2-hours co-
incubation with either DCs or peripheral blood lymphocytes. Finally Admyre et al., 
2006, added them as stimulators of CD8+ve T cells for 48 hours for a subsequent 
ELIspot assay. With the exception of De La Peña et al., 2009, there are no studies 
published involving incubations greater than one week. 
 
In addition to the much shorter incubation times, all the liposome papers quoted above 
described experiments performed with immortalized cell lines. In most cases, tumour-
derived cell lines and not primary human cells (such as the PBMCs used in the present 
work) were employed. Ultimately, it was speculated that the combination of primary 
cells combined with long incubation periods with large volumes of liposomes resulted 
in overall “extreme” culture conditions. This could have lead to the lack of PBMCs 
expansion observed in the tetramer-specific expansion and PBMCs/liposome co-
incubations and the possible liposome-mediated decrease in viability observed in the 
Buffy coat experiments. 
 
3.4.4.2  LIPOSOME UPTAKE BY CELLS: 
 
In addition to an inhibitory liposome-mediated effect on tetramer+ve specific 
expansion, evidence for early uptake was also detected. The first indication of its 
occurrence in PBMCs-liposome co-cultures was suggested by the DCs-liposome 
experiment. Here, liposome associated HLA-A*0201+ve fluorescence was detected 
after 7 hours, but not after an overnight incubation, suggesting the possibility of DC 
uptake since DCs are characterized by high phagocytosis. However, this feature is not 
extensively shared by other cell populations within the PBMC fraction. Therefore, 
phagocytosis and liposome uptake is likely to have been more relevant for DCs than for 
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PBMCs. The experiment above was performed only once, and as such, no stand-alone 
conclusions can be derived. However, its results were further substantiated by time 
courses performed on HLA-class I negative cell lines. These also showed liposome 
absorption (as measured by HLA-A*0201+ve cells) at very early time points (data not 
shown).  
 
Stronger evidence of liposome absorption and uptake by PBMCs was indicated by the 
microscopy results. All the slides required fixation; this, in addition to the slide 
preparation protocol, possibly resulted in the limited degree of autofluorescence 
observed in some samples. However, the strong rhodamine fluorescence that was 
detected in all samples (albeit fainter at 8 hours or overnight) was considered to be 
genuine. Single-plane fluorescence microscopy does not provide information on 
whether the fluorescence is on the membrane or inside the cells. Consequently, stacked 
images were also taken at some of the time points considered. The stacked images at 
t=0 showed rhodamine fluorescence in all the slides of the single cell in the field, 
strongly suggesting that liposomes are internalized in the cytosol rather than merely 
being absorbed on the cell membrane. This was confirmed by the same result obtained 
after 8 hours of co-incubation, further demonstrating that part of the liposome is 
internalized by PBMCs shortly after setting up the culture.  
 
The results obtained in the microscopy experiments supported the evidence for early 
liposome uptake presented in the chapter. In the microscopy case, it is not known which 
particular cell type mediated the phagocytosis, as a mixed cell population was used. 
However, considering that DCs and other highly phagocytic populations are usually a 
minority within PBMCs, it could be inferred that liposome uptake is a feature shared by 
all cells in PBMCs.  
While the requirements for T cell activation and immune synapse formation are under 
active investigation, it is known that DC-T cell interactions leading to activation are 
stable and may last several hours (Bousso, 2008). Also, T cells may demonstrate 
immunological synapses lasting 90-minutes and are characterised by continuous 
recycling within this time (Dustin, 2008). Considering the long and stable contact 
between APC and T cells required for T cell activation, and the important liposome 
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internalization observed, it is possible that the loaded liposomes do not remain in 
solution long enough, or are stable enough, to effectively present antigen.  
 
Other liposome preparations reported have been formulated with the specific aim to 
study the immunological synapse. These studies all utilized some mechanism to cluster 
the antigen on the liposome surface (Giannoni et al., 2005 and Zappasodi et al., 2008). 
This is a factor that might have had a strong impact, as it is known that the antigen 
density on the aAPCs surface is crucial for a good T cell stimulation (Zappasodi et al., 
2008). However, it would have been impossible to determine the exact amount of 
monomers on the surface of our liposomes when using the activation method (i.e. 
random introduction of SH molecules). In fact, antigen clustering was achieved in these 
previously reported studies using quite complicated systems of neutravidin/streptavidin 
rafts and/or cholera/tetanus binding sites (Giannoni et al., 2005 and Zappasodi et al., 
2008). These methods are not neither physiological nor compatible with an in vivo 
model.  
 
3.4.5  THE MURINE MODEL: 
 
All the results presented and discussed so far were obtained in a human model using 
primary cells. However, a murine, in vitro model was also employed. This system had 
fewer variables to be accounted for; a single cell population and an easier readout 
technique (ELISA vs tetramer-specific expansion) were used. It was expected that the 
use of the RF 33.70 cell line would not pose any toxicity issue. Moreover, any results 
obtained with the hybridoma cell line would have been easier to interpret as a purified 
population was being employed. Another main advantage of the RF 33.70 hybridoma 
was the sensitivity of its readout. According to the manufacturer, the ELISA kit in use 
would have reliably detected concentrations of IL-2 of less than 20 pg/ml. This would 
allow for even minimal liposome-mediated TCR engagement to be detected. However, 
these advantages were somewhat counterbalanced by the increased difficulties in 
obtaining the murine protein. The H2-Kb-OVA heavy chain production and refolding 
required extensive optimization, with the maintenance of a correct pH throughout being 
critical. Also the complete monomer had much lower stability than the HLA-A*0201-
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NLV monomer. Consequently, the overall yield of H2-Kb-OVA monomer available for 
liposome loading was consistently less than that for HLA-A*0201-NLV (data not 
shown). Moreover, flow cytometry analysis could not be performed on this monomer as 
the conformational specific antibody 25.D1/16 was not fluorescently conjugated and 
using a secondary antibody prevented by the high non-specific binding shown by 
liposomes. When testing the antigen presenting potential of H2-Kb-OVA-loaded 
liposomes, results were similar to those encountered in the human model ie. no 
liposome-mediated antigen presentation could be detected. In this case as well the 
presence or absence of a 3’-end Cys on the monomer was irrelevant in terms of antigen 
presentation efficacy. 
 
3.4.6  CONCLUSIONS: 
 
Considering the issues described so far in terms of liposome preparation, 
standardization and loading, if the research work had continued on this topic the focus 
of this project would have had to shift radically from an immunological focus to a 
biochemical one. At this point, in fact, the only way to cast some light into the poor 
standardization/lack of expansion issues seemed to be the step-by-step assessment of 
the liposome preparation protocol using all techniques available and an assessment of 
the effect each component had on the PBMCs (and, as a control, more robust cell lines).  
It still remains an open question as to why it was not possible to reproduce the 
previously published results; all aspects of the liposome preparation and loading were 
verified by the first author of De La Peña et al., 2009. All stimulation and cell culture 
conditions were as previously optimized (as published in De La Peña et al., 2009). 
There was, however, one important condition that was not reproducible; the access to 
the same CMV+ve donors. Therefore, previously untested donors had to be used. All 
the newly selected donors were checked for the resting HLA-A*0201-NLV-tetramer-
specific population and all of them were tested for both peptide and monomer-driven 
expansion (as shown in Figure 3.6). In some cases, they were also tested for NLV-
pulsed, DCs-mediated expansion (data not shown) as a further control to ensure the 
CMV response was maintained. In all cases a marked tetramer-specific expansion was 
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obtained, effectively ruling out a general hypo-response to CMV stimulation as cause 
for a lack of liposome-mediated tetramer expansion.  
 
To conclude, the issues of standardization and reproducibility encountered using the 
models presented in this chapter would suggest a stop against their further use as 
immunotherapeutic tool until all the questions related to loading, cytotoxicity and 
degree of response have been addressed. To maintain an immunological focus in the 
PhD project, other forms of antigen presentation were subsequently explored. 
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CHAPTER 4: 
PREPARATION AND CHARACTERISATION OF CD-DERIVED DCs FOR 
IMMUNOTHERAPY 
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4.1.0  INTRODUCTION: 
 
In addition to the liposome-based aAPC, various possible cellular-based APCs and the 
source of these cells were also evaluated in this project. Of these sources cord blood 
(CB) was the primary focus due to its increasing importance in all aspects of HSCT. Of 
the cells types available, CB-derived DCs were likely to be the most potent APCs, as 
they are professional APCs, able to stimulate naïve and resting T cells more effectively 
than monocytes, macrophages or B cells (Steinman, 1991).  
 
4.1.1  DCs FROM CB: 
 
Several studies have assessed the properties of DCs either present in CB or 
differentiated from CB-derived stem cells/or monocytes. These studies could be divided 
in two distinct groups involving either a phenotypical characterization, often in 
comparison with adult-derived DCs, or establishment of DCs-cytotoxic T cell (CTL) 
models using various antigens.  
 
Takahashi’s group compared DCs generated from fresh and frozen CB-derived 
CD34+ve cells, and reported that both cell types expressed markers relating to antigen 
presentation, had DCs-like morphology, and were more effective than peripheral blood 
mononucleated cells in promoting MLR (Sato et al., 1998). In contrast Lau’s group 
reported reduced expression of HLA-DR, but not of CD86 and CD11c, on monocyte-
derived DCs from CB compared to their adult counterparts. Importantly, they also 
showed reduced alloreactivity by T cells stimulated with CB-derived DCs as compared 
with adult-derived DCs (Liu et al., 2001). These results were confirmed and expanded 
upon by the Cairo lab showing that monocyte-derived DCs from CB were less effective 
than their adult counterparts in an allogeneic MLR, despite being phenotypically similar 
(Bracho et al., 2003). It was also recently published that CB-derived DCs, either 
differentiated from monocytes or freshly purified, induced less IFN-γ secretion but 
induced more IL-4 production when compared to adult peripheral blood DCs and 
suggested that CB-derived DCs were more prone to Th2 rather than Th1 T cell priming 
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(Naderi et al., 2009), confirming similar results published earlier (Langrish et al., 2002). 
It would therefore seem, on this basis, that whilst stem cell derived DCs from cord 
blood are fully functional, that isolated or monocyte-derived DCs have reduced antigen-
presenting activity. 
 
Whilst there is evidence of reduced antigen presenting activity by CB monocyte-derived 
DCs there is also evidence that they can support naïve T cell responses. In 2003 
Cerundolo’s group showed that priming of CB-derived T cells by autologous DCs could 
be achieved in a MelanA-specific system (Salio et al., 2003). Using the same antigen 
model, it has been recently shown that MelanA-specific CD8 T cells of CB origin could 
be expanded also with peptide expansion/polyclonal stimulation, and that these cells 
displayed an effector phenotype (Merindol et al., 2010). In 2004, Her2/neu-specific 
CTLs were generated using a CB-derived DC autologous system and repeated 
administration of peptide (Wang et al., 2004). Szabolcs’s group showed the successful 
production of CB-derived, CMV-specific T cells following priming with autologous 
DCs pulsed with CMV lysate. These T cells were able to lyse CMV-pulsed autologous 
targets and secreted IFN-γ and TNF-α (Park et al., 2006). Recently, Bollard’s team 
reported they were able to generate virus-specific T cells starting from non-adherent 
cells as responders and viral-transduced DCs and EBV-transformed B cell lines as 
APCs (Hanley et al., 2009). They focused on CMV, adenovirus, and EBV-specific T 
cells due to the importance of these viruses in HSCT. Importantly, they used only frozen 
CB samples throughout their entire protocol, the only source of CB actually available 
for clinical transplantation.  
Taken together, the evidence in the literature supported the choice to explore the APC 
potential of monocyte-derived DCs from CB and their use for the generation of a DC-
CD8+ve T cells autologous system using a model peptide. Since there was also 
evidence of alloreactivity and, in some cases, reduced DCs-markers expression but 
effectiveness in CTL generation the CB derived DCs would be thoroughly assessed for 
both phenotype and alloreactivity prior to development of an antigen-specific CD8 T 
cell response system. 
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4.2  EXPERIMENTAL AIMS: 
 
The work described in this chapter aimed to generate a CB-derived, peptide-specific 
DC-CD8 T cell system, using a MelanA peptide as a model antigen and conditions as 
shown in Salio et al., 2003; success would be measured by both IFN-γ intracellular 
staining and evidence of tetramer-specific expansion. To achieve this, DCs were 
generated from CB CD14+ve cells, characterized and compared to adult monocyte-
derived DCs. The cells were assessed for the expression of DC-specific markers and to 
highlight any eventual difference between the two subsets. Cultured DCs from CB and 
adults were then assayed using an MLR to evaluate their overall antigen presentation 
potential. Finally, a peptide-specific expansion system was set up.  
 
4.3  RESULTS:  
 
DCs (from CB and, as a control, from adults) were differentiated from CD14+ve 
precursors. DCs of either origin were then characterized for relevant markers (the most 
important were HLA-DR, CD11c, CD80, CD86) and their potential to elicit an allo-
reaction was measured in an MLR. When using cells from HLA-A*0201+ve, HLA-
B*0702-ve, CMV+ve adult individuals it was only necessary to demonstrate that the 
DCs could mediate an NLV tetramer+ve expansion to indicate APC functionality. 
MelanA expansion was then assessed in adult and CB samples.  
 
4.3.1  DCs GENERATION: 
 
4.3.1.1  ADULT-DERIVED DCs: 
4.3.1.1.1 PHENOTYPE: 
 
The first step in the protocol was the preparation and characterization of DCs of both 
adult and CB origin. It was decided to set up the adult system first to have a solid 
control base for any CB-derived results. Summarized in Figure 4.1 is a representative 
example of adult-derived DCs preparation and characterization. 
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Figure 4.1 shows the outcome of the CD14+ve selection from freshly prepared adult 
PBMCs (Figure 4.1A, circled population) and their change in morphology (indicated by 
their increase in FSC-SSC) following differentiation into DCs after the 5 days of culture 
with GM-CSF and IL-4 (Figure 4.1B, gated population). Adult DCs were then matured 
with LPS and the relevant markers were analysed and compared between immature 
DCs, as control, and the mature DCs population (in the histograms in Figure 4.1C). 
All gated cells were CD11c+ (the αX subunit of integrin CR4), both matured (shown 
here) and immature (not shown), indicating that the cells are myeloid or conventional 
DCs. A subset of the DCs (<50% of gated cells) showed an increase of HLA-DR and 
CD80 expression upon maturation. The proportion of CD86 expressing cells remained 
similar but a total population shift was observed with CD83 expression. This indicates 
that a signification proportion of the DCs had a mature DC phenotype. The results 
Figure 4.1: flow cytometry analysis of DCs generated from adult monocytes. A, monocytes were 
isolated (via CD14 selection) from healthy adults PBMCs and analyzed by flow cytometry. They were 
cultured for 5 days with GM-CSF and IL-4, then pulsed with the relevant peptide if necessary and 
matured with LPS. On day 6, mature and immature DCs were analysed by flow cytometry. B, DCs were 
selected on the basis of FSC and SSC and C, the relevant markers were analyzed within the DC-gated 
population ((——) immature DC (——) mature DCs, with the only exception of CD11c where (——) is 
mature unstained and (——) mature stained DCs). Representative of 8 independent experiments. 
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shown above suggested that the system in use generated DC-like cells in terms of 
morphology and phenotype starting from a CD14+ve population. 
 
4.3.1.1.2 TETRAMER-SPECIFIC EXPANSION: 
 
Since CB T cells are naïve they will, therefore, require professional APCs to elicit a 
response to antigens. Consequently, before using them to generate CD8 T cell lines it 
was important to demonstrate that the DCs, in additional to having an APC-like 
phenotype, were functional. Therefore, to assess whether adult-derived DCs were also 
effective APCs, it was determined if they could support the expansion of an NLV-
tetramer+ve population. This system, used as positive control, was chosen to check the 
general conditions of culture and assess the degree of tetramer-specific expansion in a 
well-known model (as done in De La Peña et al., 2009). Shown in Figure 4.2, below is a 
representative, NLV-specific, expansion from an adult donor.  
 
 
 
 
 
 
 
As shown above, a high percentage of HLA-A*0201-NLV-tetramer+ve cells (>40%) 
was obtained when PBMCs were incubated with NLV-pulsed DCs as compared to the 
control (<1%), thus confirming the effectiveness of our protocol in generating DCs 
capable of promoting peptide-specific T cell expansion in an adult system.  
4.2. Flow cytometry analysis of DCs-mediated tetramer expansion. Following generation of DCs as 
shown in Figure 1, autologous responders (frozen CD14-ve fraction) were added to the DCs culture and 
the mixed culture was incubated for a further week to promote peptide-specific CD8 T cell expansion. In 
the figure above, the lymphocyte population was selected and the CD8+ve HLA-A*0201-tetramer+ve 
double +ve population within the lymphocyte gate was shown above. On the left, -ve control (responders 
incubated without DCs), on the right responders incubated with pulsed DCs. Representative of 2 
experiments.  
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4.3.1.2  CB-DERIVED DCs: 
4.3.1.2.1 PHENOTYPE: 
 
Having set up the DC generation and CD8 cell expansion system in adults the work we 
then progressed to CB samples beginning with the differentiation of DCs from CB 
CD14+ cells (Figure 4.3). 
 
 
 
 
 
 
 
Figure 4.3: flow cytometry analysis of DCs generated from CB monocytes. A, monocytes were 
isolated (via CD14 selection) from CBMCs and analyzed by flow cytometry. They were cultured for 5 
days with GM-CSF and IL-4, then pulsed with the relevant peptide if necessary and matured with LPS. 
On day 6, mature and immature DCs were analyzed via flow cytometry. B, DCs were selected on the 
basis of FSC and SSC and C, the relevant markers were analyzed within the DC-gated population ((——
) immature DCs, (——) mature DC, with the only exception of CD11c where (——) is unstained and (—
—) stained DCs). Representative of 8 experiments. 
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Figure 4.3 shows the outcome of the CD14+ve selection from whole fresh CBMCs 
(Figure 4.3A, circled population) and their change in FSC-SSC appearance following 
their differentiation into DCs after the 5 days culture with cytokines (Figure 4.3B, gated 
population), as seen for their adult counterparts. CB-derived DCs were then matured 
with LPS and compared with immature DCs for surface marker expression (in the 
histograms in Figure 4.3C). As seen in the adult culture all cells were CD11c+ve 
(myeloid DCs) and showed an increase in CD83. However, unlike the expression that 
was observed in the adult cultured DCs, HLA-DR, CD80 and CD86 expression was 
seen to increase for the whole population, rather than a subset.  
To summarise the results presented in Figures 4.1 and 4.3, an analysis of the median 
fluorescent intensity (MFI) for each label is reported below as a column plot (Figure 
4.4). 
 
 
 
Figure 4.4: column plot of the median fluorescent intensity (MFI) of HLA-DR, CD80, CD86, 
CD83 in the adult and CB samples subsets. The MFI for each marker/sample was calculated and the 
columns represent the average of all MFI values; the error bars represent the standard deviation. N=6. 
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All the results shown above were analysed using the student t-test, to detect significant 
differences in the MFI of each marker between immature and mature samples of the 
same origin (paired t-test) or to compare the expression of the same marker between 
adult and CB samples (unpaired t-test). While no significant differences were detected, 
Figure 4.4 shows that in both the CB and adult subsets there is a trend of increase in the 
expression of each marker between immature and mature DCs. MFI values for HLA-
DR and CD80 are higher in CB than in adult samples, while the opposite is seen for 
CD86 and C83. Moreover, MFI values were on average higher for HLA-DR and CD86 
than for CD80 and CD83, regardless of the subset examined. Following these findings, 
it was concluded that both adult and CB-derived DCs were successfully generated and 
that there were not any significant differences in the expression of the markers 
examined. It was also concluded that CB-derived DCs exhibited a mature phenotype 
that should be compatible with effective antigen presentation. 
 
4.3.1.2.2 FUNCTIONALITY OF CB-DERIVED DCs:  
 
Following CB-derived DC generation and phenotypical characterization, the next 
objective was the assessment of their functionality. It was chosen not to set up a 
peptide-specific response system as a control for the CB system functionality (as done 
for adults in the HLA-A*0201-NLV-tetramer expansion). The CB sample used would 
need to be HLA-A*0201+ve, however typing of a cord sample before receipt was not 
practical. As an alternative option, it was decided to assess their alloreactivity potential 
compared to adult-derived DCs. With a relative short incubation time (compared to a 
lengthy expansion and re-stimulation for peptide specific expansion) this would provide 
a quick and clear readout. Finally, as literature results were quite discordant on the 
antigen presentation potential of CB-derived DCs (describing either a delayed 
alloreactivity for CB-derived DCs or effective antigen presentation and successful CD8 
T cells generation in different publications) it was important to evaluate the behaviour 
of the CB DCs in this system.  
 
A successful CB-DC-mediated MLR was considered a preliminary step for all 
subsequent experiments and a general proof of principle that CB-DCs could act as 
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antigen presenting cells and promote cell proliferation. To this end, an MLR assay 
comparing immature and mature DC from both adults and CB was set up and results are 
presented below in Figure 4.5.  
 
 
 
 
 
 
 
In figure 4.5 A and C adult and CB derived iDCs and mDCs (5000 or 10,000) were 
used to stimulate adult PBMCs. All DCs used, irrelevant of their origin or amount 
employed in the assay, elicited proliferation. Overall, the levels of proliferation induced 
by iDCs of three different CB and adult iDCS appeared to be similar; only one CB, at 
10,000 cells, showed a significant difference with the same number of adult iDCs 
(Figure 4.5C 10k iDCs, P*0.01). With mDCs significant differences were detected 
between responses to adult and CB DCs in two out of three CB samples used (Figure 
4.5A, 10k mDCs CB2, P*0.011 and Figure 4.5C, 5k mDCs CB, P*0.047). Overall, 
Figure 4.5: comparison of alloreactivity between CB and adult-derived iDC and mDC-mixed 
lymphocyte reaction. CB- and adult-derived iDC and mDC were assessed for their alloreactive 
potential against responder cells (unselected adult PBMCs). A, C experimental samples; B, controls for 
samples shown in A and D, controls for samples shown in C. DCs and responders by themselves as -ve 
controls and responders incubated with Dynabeads (anti-CD3CD28 beads) as +ve controls were used. 
P*<0.05 (t-test in all cases), N=3 independent experiments using different CB samples and adults. 
Results are expressed as the mean of triplicate wells (columns), while the error bars represent the 
standard deviation.  
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when mDCs were used as stimulators, a trend of lower proliferation compared to that 
elicited by adult was detected (although this was not statically significant in all cases). 
 
All the different cell types employed in the MLR as stimulators and the responders were 
also incubated alone, as a negative control, and showed no significant proliferation 
(Figure 4.5B and D). As a positive control, responders were co-incubated with anti-
CD3CD28 Dynabeads and a robust proliferation was observed (Figure 4.5B and D, last 
column on the right).  
 
From the data presented in Figure 4.5 it seems that, overall, the CB-derived mDCs 
examined here were not as effective as adult-derived cells in eliciting an allogeneic 
response; this difference was not observed in the iDC subset, where CB-derived iDCs 
appeared as effective as or, in one case, more effective than their adult counterparts. 
Regardless, the results of this experiment confirmed that CB-derived DCs were able to 
stimulate a robust proliferation in an MLR assay. Therefore, it was concluded that CB-
derived DCs could demonstrate reasonable APC activity and that as such it was 
appropriate to test them for peptide-specific expansion in further experiments.  
 
4.3.2.1 MELAN-A TETRAMER-SPECIFIC EXPANSION IN ADULT 
DONORS: 
 
Following the generation and characterization of monocytes-derived DCs in both adults 
and CB, the next step was to generate CD8 T cell lines from a responder population 
stimulated with autologous DCs. The peptide model selected for the CB-derived CD8 T 
cells generation was MelanA, using a protocol published by Salio et al., 2003. As a 
preliminary step to the expansion in CB, the level of MelanA-specific CD8 cells in 
resting healthy adult humans and the expansion of this subset that could be obtained 
was assessed. Unfortunately we had no access to melanoma patients and therefore could 
not compare the response with a MelanA positive control (MelanA is a tumour antigen).  
As the MelanA antigen is HLA-A*0201-specific, only healthy adults carrying the HLA-
A*0201 allele were chosen for assessment and peptide expansion. The results from this 
experiment are shown below in Figure 4.6.  
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All the available donors were tested for presence and amount of CD8 HLA-A*0201-
MelanA tetramer+ve cells. In all cases a very small percentage of tetramer+ve cells was 
detected (0.16±0.09, see Figure 4.6A for three representative stainings), comparable to 
the 0.07±0.06 % reported by Pittet et al., 1999. Having detected a putative tetramer+ve 
population in resting PBMCs, an expansion protocol was then performed to have a 
comparison model for the planned generation of CB-derived CD8 T cells and to assess 
whether it was possible to obtain a more defined tetramer+ve population after 
expansion. PBMCs were incubated with the MelanA peptide and the tetramer+ve 
population was assessed after 1 week (Figure 4.6B) to check for expansion. 
Tetramer+ve staining was also performed after 2 weeks of culture but no expansion was 
registered (data not shown). 
In only one of the donors used a moderate expansion in the CD8+vet tetramer+ve subset 
was detected after 1 week (donor 3, see Figure 4.6B right panel and compare with the 
same sample in the row above), registering an increase of 0.12% in the tetramer+ve 
Figure 4.6: MelanA expression in adult samples. PBMCs from HLA-A*0201+ve donors were 
analyzed by flow cytometry for their expression of Melan-A specific CD8 T cells with (B) or without 
(A) peptide-specific expansion. A, lymphocytes were stained at day 0 (donor 1 and 2) or after one week 
culture in the absence of antigenic stimulus, to provide a time-matched control for the tetramer-specific 
population (donor 3). The results are representative of 7 experiments on 4/5 different donors. B, 
lymphocytes were stained after 1 week of peptide-specific expansion. Results are representative of 3 
independent experiments. 
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population. This expansion, however, was accompanied by an increase in the proportion 
of CD8-ve, tetramer+ve labelling. It is, therefore, debatable whether it was a genuine, 
tetramer-specific expansion. One of the most important conclusions from this 
experiment was that not every stimulated adult sample resulted in a clear, MelanA-
specific population. If this also occurs in the CB samples, it is possible that we will be 
unable to detect a tetramer specific expansion in the CB cohort. 
 
4.3.2.2  MELAN-A TETRAMER-SPECIFIC EXPANSION IN CB SAMPLES: 
 
Following the results obtained in adults, a MelanA specific expansion protocol was set 
up in CB samples. As with adults, the CB needed to be HLA-A*0201+ve to present 
MelanA peptide.  
 
Each cord unit has a 20ml and a 5ml section; the 5-ml section from frozen CB samples 
was used for typing (see Materials and Methods paragraph 2.2.1.0). When a HLA-
A*0201+ve CB sample was encountered, CD14+ve cells were selected, from the 20ml 
section, DCs were prepared as described in Figure 4.3 and the CD14-ve fraction 
obtained after selection was frozen for future use. When DCs reached the maturation 
point, they were pulsed overnight with the MelanA peptide, the responders were added 
the morning after and the culture was incubated until the tetramer+ve expansion was 
assessed (day 10-12). In addition to the tetramer+ve expansion, IFN-γ intracellular 
staining was also performed as a general assessment of T cells activation. Figure 4.7, 
below, shows the results for this experiment.  
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The figure above reports the results of a CB-derived expansion performed following the 
protocol published by Salio et al., 2003. No significant difference could be detected 
between the control (responders incubated with unpulsed DCs) and the experimental 
samples (Figure 4.7A). Figure 4.7B shows the IFN-γ intracellular staining performed on 
the MelanA expanded samples and on the control. In this case, a moderate increase in 
IFN-γ producing cells was detected in the experimental sample compared to the control 
(0.14% over 0.049%); however, an increase was registered in both the CD8+ve and 
CD8-ve subsets of the experimental sample so it appears unlikely to be peptide-specific.  
 
Overall, these results suggested that a moderate degree of activation was taking place in 
the MelanA expanded sample, as measured by IFN-γ intracellular staining, but a 
relevant tetramer+ve specific expansion in the CB samples examined could not be 
recorded, even if a background population of HLA-A*0201-MelanA+ve cells was 
detected. Following these results, an optimization of the expansion protocol (checking 
Figure 4.7: analysis of MelanA expression in CB samples. DCs from CB samples were prepared and 
pulsed with the MelanA peptide (as in Figure 4.3) and at day 6 autologous responders were added. Co-
cultures were then incubated and analysed by flow cytometry at day 9-10 for A, tetramer expansion and 
B, IFN-γ expression as a general activation marker. Results are representative of 2 independent 
experiments. 
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all culture conditions, starting with the dose of peptide used to pulse the DCs and its 
repeated administration during DCs-responders incubation) was planned. However, 
while setting up the CB system described in Figure 4.6, issues concerning its overall 
viability were detected.  
 
4.3.3  VIABILITY: 
4.3.3.1  RESPONDERS (CD14-VE FRACTION): 
 
When frozen CB samples began to be routinely used as a cell source, as required by the 
need of typing for HLA-A*0201 positivity, issues concerning cell numbers and/or 
viability in the cell populations of interest (the CD14+ve fraction, to be isolated 
immediately upon thawing, and the CD14-ve or responders fraction, which was 
collected after CD14+ve selection and frozen again prior its final use) were registered. 
Figure 4.8, below, provides an overview on the total amount, viability and general 
phenotype by flow cytometry of the responder fraction upon collection after CD14+ve 
selection.  
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Figure 4.8A, above, shows the percentage of CD45+ve cells (used in this context as an 
approximate indication of the total numbers of responders available) in the CB used for 
CD8 T cells generation. A significant difference between fresh and frozen unselected 
cells (68.6±3.9 vs 35.8±5.4 respectively, P*0.0003) was detected. A statistically 
significant difference was also found in fresh CB between selected and unselected 
samples (68.6±3.9 vs 32.4±4.7, respectively, P*<0.0001). This difference is still 
present, albeit not significant, in frozen CB (32.3±4.7 for unselected vs 20.3±9 for 
selected samples, respectively). This evidence seems to suggest a damaging effect of the 
selection process on the percentage of CD45+ve cells retrieved in the negative fraction, 
regardless whether the sample had been freeze-thawed. Another important result was 
the extremely low percentages of CD45+ve cells obtained in these samples (regardless 
fresh or frozen) after selection; retrieving around 20% from whole frozen-thawed CB 
after selection meant that often only a few millions cells were available for use. Finally, 
a relevant point to be considered is that all the data presented in Figure 4.8 refer to the 
Figure 4.8: analysis of the fresh vs frozen CB samples-responders fraction. CB samples, both fresh 
and frozen, were examined immediately after thawing to assess numbers and overall quality as 
responders. A, graph showing the percentages of CD45+ve cells in various CB populations and B, 
representative example of FSC-SSC appearance of fresh vs frozen CB sample. Representative of 5 
frozen and 7 fresh CB samples. Student t-test was performed (paired between the same CB samples, 
unpaired between fresh and frozen), P*<0.05 was considered significant. 
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first thawing only –i.e., when the whole frozen CB sample is thawed for the CD14 
selection and DCs differentiation. The CD14-ve fraction then needs to be re-frozen until 
the DCs are ready to be pulsed, when they are thawed again and finally used. Figure 
4.8B shows a representative example of flow cytometry analysis for the CD14-ve 
samples from fresh and frozen samples, respectively. While in the fresh sample a clear 
lymphocyte population can be outlined, this is not the case in the frozen one-in fact, 
cells in this case have an unusual appearance where no lymphocytes, granulocytes or 
other blood populations can be discerned.  
 
4.3.3.2  MONOCYTES (CD14+VE FRACTION): 
 
While overall low numbers and the effect repeated freeze-thawing procedures were 
having on the CD14-ve fraction were the main concerns regarding the responders, a 
viability issue emerged when working with the CD14+ve fraction. Figure 4.9, below, 
shows the main results obtained when CD14+ve cells were selected from fresh and 
frozen CB samples.  
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Figure 4.9A shows the purity of CD14+ve selection between fresh and frozen CB 
samples; no significant difference was detected. It was observed that a purity around or 
above 90% was obtained most often in fresh rather than frozen CB, however this 
finding might be explained with the relatively small size of both set of samples and in 
any case even a purity below 80%, as was most often retrieved from frozen samples, did 
not adversely affect the DCs preparation. Figure 4.9B and 4.9C show the flow 
cytometry analysis of a differentiating monocyte culture (at day 4 after plating out the 
monocytes, so one day before DC maturation), showing that in the DCs gate the 
percentage of 7-AAD+ve cells was around 30%. While this experiment was performed 
on one CB sample only, at least 2 more DCs cultures showed a similar suboptimal 
viability (data not shown).  
Figure 4.9: analysis of the fresh vs frozen CB samples-CD14+ve fraction. CB samples were selected 
for CD14 using microbeads. A, The CD14+ve fraction was further analyzed to assess purity of selection 
(frozen CB N=5, fresh CB N=8). CD14+ve cells from frozen CB, plated out for DCs maturation, were 
stained with 7-AAD at day 4 to assess their overall viability. B, cells were firstly gated on maturing DCs 
according to FSC and SSC and C, the 7-AAD+ve cells were quantified within this gate (N=1). D, graph 
plotting the sum of annexinV+ve 7-AAD-ve (apoptotic) and annexinV+ve 7AAD+ve positive (necrotic) 
monocytes before and after thawing in a cohort of CB samples from the Anthony Nolan Cell Therapy 
Centre (courtesy of CB Bank and Dr RC Duggleby). Paired student t-test, P*<0.01; the values are 
expressed in the text as average ± standard deviation. 
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Figure 4.9D (data kindly provided by Dr RC Duggleby and the Anthony Nolan Cell 
Therapy Centre, Nottingham) shows the percentage of both necrotic and apoptotic 
monocytes (by CD45high SSChigh phenotype) in a small cohort of CB samples 
examined fresh and upon thawing. While usually apoptotic (annexinV+ve) and necrotic 
(7-AAD+ve) cells are kept separate during results evaluation, as they constitute 
different subsets with different properties, it was decided to group them in a single 
analysis here as both fractions affect the final percentage of viable monocytes in the 
culture. While the percentages of necrotic and apoptotic monocytes in fresh CB is quite 
variable but the average value is still below 50% (46.3±20.3), the same subsets in the 
same samples after freezing and thawing record an average of 90.3±7.1 of necrotic and 
apoptotic monocytes, resulting in an overall viability (for the monocytes subset) of 
around 10%. Of note, the variability range for the thawed samples was much reduced 
compared to the fresh one, being consistently over 79% vs 28-83% in frozen vs fresh 
respectively, and the difference in the overall percentage of necrotic and apoptotic cells 
in fresh and frozen samples was significant (P* was 0.0045). The results presented in 
Figure 4.9D suggested that, despite viability in monocytes selected from fresh CB being 
variable but still high enough to support productive DCs generation, the same parameter 
in frozen-thawed monocytes was not, resulting in possible problems with the use of 
frozen monocytes for DCs generation.  
 
4.3.3.3  DCs-RESPONDERS CO-CULTURES: 
 
The results shown in Figure 4.8 and 4.9 raised questions about the overall feasibility of 
a DCs-responder co-culture set up using frozen CB samples as starting material. An 
annexin staining was performed on the DC-responders co-culture in expansion and 
Figure 4.10, below, shows the results for this experiment. 
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As shown above, the percentage of apoptotic (annexin+ve) and necrotic (7-AAD+ve 
annexinV+ve) cells exceeded 90% in the culture. This experiment was performed only 
once as it was decided not to establish more DC-CD8 T cells cultures after experiencing 
the technical issues described above (poor monocyte-DCs viability, low responder 
numbers and overall appearance upon second thawing, or both). The results described 
from Figure 4.8 onwards suggested a thorough reassessment of the feasibility of CD8 T 
cells generation in the system described so far.  
 
4.4  DISCUSSION: 
 
This chapter describes the preparation and characterization of DCs from CB and their 
use in generating peptide-specific CD8+ve T cells in an autologous system. While the 
controls and setting up in adults worked as expected and gave consistent positive 
results, various problems were experienced in the DCs-CD8+ve T cells system in CB, 
particularly regarding monocytes viability and responder numbers. These issues, 
together with a comparison of the results obtained in this project with the current 
literature, will be discussed below. 
 
Figure 4.10: viability of a frozen CB-derived DCs-responder culture. Frozen CB-derived, DCs-
responder co-culture was stained with annexin V and 7-AAD at day 7 to assess viability. CD45+ve cells 
were gated and the viability was assessed within this gate (N=1).  
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4.4.1  DCs FROM CB AND THEIR PHENOTYPE: 
 
The choice of CB as source material for this project was logical due to its increasing 
importance in HSCT. As the immunosuppression required prior each transplant leaves 
the patient severely immunocompromised and exposed to opportunistic infections, a 
DLI is often performed. This is even truer in the case of CB transplants, which are 
characterized by later engraftment compared to adult donors, but in which a DLI is not 
possible as the whole of the CB is used in transplantation. Adoptive immunotherapy in 
the form of CD8+ve cells infusion would then constitute a suitable alternative to DLI. 
 
To assess the potential of CB-derived APC and their use for development of an 
autologous APC-CD8 T cell system, the first step was to select which APC was to be 
employed. DCs were then chosen, partly because they are the professional APCs and 
the only cell type capable to elicit a full CD4 and CD8-mediated response, from naïve 
cells. It was decided from the start of the project not to focus on the DCs already 
differentiated in CB. This was due to their low number, the finding that their viability 
starts decreasing after CB collection (data not shown) and the difficulty in selecting 
simultaneously all the subtypes of DCs. The focus was instead on the ones that could be 
differentiated from precursor populations.  
 
In the literature two approaches for the generation of DCs from precursor populations 
were reported, one starting from CD34+ve cells (Sato et al., 1998, Kobari et al., 2006 
and Balan et al., 2009) and one starting from CD14+ve cells or mononuclear cells 
selected by plastic adherence (Liu et al., 2001, Bracho et al., 2003 and Hanley et al., 
2009). The second approach was selected for two reasons; not only CD14+ve cells are 
more abundant than CD34+ve in CB blood, but most importantly it is possible to select 
large numbers of CD14+ve cells from adults without previous treatment, while the 
CD34+ve cells circulating in healthy adults are negligible. Moreover, the use of 
CD34+ve cells would have had most likely required an expansion step, thus 
complicating the whole protocol, while working with CD14 cells was much more 
straightforward. Initially a plastic adherence step was performed, but as a microbeads 
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CD14+ve selection resulted in much more consistent and high yield results (data not 
shown), this option was preferred in all the experiments described in this chapter.  
 
Once DC generation from CB was successfully accomplished, as seen from their DC-
like phenotype, their APC potential was assessed. As discussed previously, the state-of-
the-art literature on CB-derived DCs seemed quite discordant on this point. Some 
papers suggested CB-derived DCs were less functional than their adult counterparts, 
especially in terms of alloreactivity and Th1-skewing/polarizing (Liu et al., 2001, 
Langrish et al., 2002, Bracho et al., 2003 and Naderi et al., 2009). However, other 
publications (Salio et al., 2003, Park et al., 2006, and Hanley et al., 2009) reported that 
CB-derived DCs were able to elicit a Th1-skewed response and CD8 expansion, thus 
suggesting that DCs of CB origin did not show any functional difference from their 
adult counterparts and could be as effective as adult DCs.  
 
The results presented in this chapter seemed to be halfway between these two options: 
on one hand no relevant difference in DC-related marker expression was seen between 
CB- and adult-derived DCs, however some significant differences in alloreactive 
proliferation were detected when using DCs of CB origin rather than adult.  
In terms of DCs-related markers, it was speculated that the similar level of expression 
between adult and CB-derived DCs (and especially the expression of CD83, a marker 
indicative of DCs maturation) was not likely to correlate with a phenotype of 
tolerogenic DCs; it is, however, not possible to exclude the presence of this subset 
within the CB-derived cultures presented here (especially since suppression assays were 
not performed). In fact, if the study of CB-derived DCs were to be continued, a 
thorough analysis of all molecules of the CD80-CD86 family should be performed on 
the samples, to elucidate whether their phenotype is more tolerogenic or activatory in 
the conditions used. Moreover, an unbiased evaluation of their functionality (i.e. CD8 T 
cell expansion and suppression assay using the same CB sample as DCs source) would 
be useful to have a definitive assessment of the in vitro activity of CB-derived DCs.  
 
In terms of allogeneic proliferation, while the difference in DC-mediated proliferation 
between the adult and CB samples used in the MLR was statistically significant, it was 
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reasoned that the degree of proliferation obtained was still high enough to suggest an 
effective APC activity. Therefore, DC-CD8 T cell antigen-specific cultures were then 
developed.  
 
4.4.2  ANTIGEN-SPECIFIC SYSTEM: 
 
When selecting a model peptide and a readout technique for the DC-CD8 T cell system 
described in this chapter, MelanA (also known as Mart-1) and tetramer expansion were 
chosen, respectively. The preference for this particular antigen, rather than the CMV-
derived peptide used in the previous chapter, was driven by two different motivations. 
While being aware of the relevance that CMV, a classical cause of death following 
HSCT, has in hematopoietic transplant-related immunotherapy, it was considered that a 
tumour antigen would have provided a stronger stimulus than CMV in the naïve system 
employed in this work, and thereby be easier to detect and to interpret. Moreover, there 
was pre-existent literature describing the expansion of MelanA tetramer+ve cells from 
CB (described in Salio et al., 2003). Even if a potentially important difference in the 
experimental set up was the source of CB (fresh for Salio et al., 2003, frozen in this 
work), it was speculated that for a complex procedure such as antigen-specific CD8 T 
cells generation from CB, the most practical option was to start from already published 
protocols. Before starting this project, there were not any published data on the 
generation of CMV-specific, CB-derived CD8+ve cells. However, in the first months of 
2009 Bollard’s group published the generation of virus (CMV, EBV and adenovirus)-
specific T cells starting from CB in an autologous system and using frozen CB as 
starting material (Hanley et al., 2009). This publication would have provided an ideal 
initial protocol for moving onto a CMV system once the preliminary MelanA 
experiments had been successful. Finally, while tetramers as a preferred choice to judge 
successful CD8 T cell line generation was probably the most difficult route (due to the 
low numbers of precursors and consequently the low levels of expansion) they were still 
considered the most appropriate readout for peptide-specific cells with a prospective use 
in immunotherapy. However, IFN-γ intracellular staining both in adults (data not 
shown) and in CB was also set up as a control.  
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MelanA expression and expansion was assessed in the largest cohort possible of adult 
donors, i.e. all healthy donors having an HLA-A*0201 allele. Even if a tetramer-
specific population was detected in most of them, thus confirming the finding published 
by Romero’s group (Pittet et al., 1999), a MelanA expansion was registered in only one 
of the donors tested. It is difficult to compare the expansion results obtained in this 
project with the published reference on this topic, as Romero’s team first sorted the 
HLA-A*0201-tetramer+ve cells using FACS and then expanded the positive fraction 
with a strong protocol including cytokine, PHA and autologous irradiated fraction 
(Pittet et al., 1999), reaching around 10% of tetramer+ve cells after 15 days of 
expansion. Such a relatively moderate amount of tetramer+ve cells after 2 weeks of 
strong stimulation in healthy adults donors suggested that the level of expansion in the 
adult samples examined in this work could have also been lower. As such, the 
expansion detected in the adult donor was considered successful. Moreover, if not all 
healthy HLA-A*0201+ve donors are able to expand a MelanA-specific population, a 
small number of samples can influence the total number of expansions obtained due to 
stochastic effects. Finally, if such low expansion levels were detected in adults, it was 
speculated that in CB they would have probably reach even lower levels. Salio et al., 
2003, published a percentage of tetramer+ve cells of around 2% after expansion 
(starting from <0.1% on average in resting CB) so this value was taken as reference. 
When the MelanA DC-responder system was set up according to Salio et al., 2003, the 
MelanA-specific CD8 T cells levels did not match the published results (data not 
shown). This might have been due to the stimulation conditions, that needed to be 
stronger -i.e., repeated administration of peptide, increased amount of cytokines in the 
culture, or repeated rounds of DC-peptide presentation- or to unpredictable effects such 
as the starting number of tetramer+ve cells being too low to support a successful 
expansion in the CB samples examined. Before repeating the experiment to optimize 
the expansion conditions, however, viability issues when using frozen CB samples to 
set up the culture were detected.  
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4.4.3  VIABILITY AND OTHER LIMITATIONS: 
 
The decision to choose a peptide-specific system meant that only HLA-A*0201+ve CB 
samples could be used and that each CB available should be typed to detect if it was 
suitable for use. To effectively mimic the CB samples used in clinical settings, frozen 
samples were used in this project. Out of the 10 samples tested, 6 were HLA-A2 
positive, 3 negative and one showed signs of maternal blood contamination and was, 
therefore, discarded (data not shown).  
When the selection of monocytes from the CD14+ve fraction was performed, low 
viability, both at selection and during the DCs differentiation, was experienced. In fact, 
of all the 4/5 frozen CB examined, only one had overall good monocyte/DCs viability. 
More precisely, while DCs generation was achieved more than once when using frozen 
CMBCs as starting material, only from one sample was possible to freeze an aliquot of 
monocytes and, after thawing, use them to successfully prepare DCs (as would have 
been required for a second DC-mediated stimulation of the expanding CD8 T cells). It 
has to be stressed that monocyte viability was generally low upon thawing, while this 
was not necessarily the case with fresh samples; as such, it was impossible using the 
viability data from the fresh sample to predict the outcome after thawing.  
On the other hand, there were issues also when using the CD14-ve or responders 
fraction, as the overall number of cells available was sometimes very low after thawing 
and selection. Moreover, all the results shown in this chapter refer to cells that were 
then re-frozen to be re-thawed when the cultured DCs became available. Even if CD45 
staining was not performed on this second occasion, it is conceivable that the 
percentages would have been even lower- indeed, it was possible to set up a DC-CD8 T 
cell culture only from one of the frozen samples used. The two issues described above -
the poor monocyte viability and the low number of CD45+ve cells in the responder 
fraction- suggested a reassessment for the whole approach to antigen-specific CD8 T 
cells generation. The analysis and evaluation of viability for various cell types within 
the frozen CB cohort is object of active investigation by various members of the group.  
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As for the MelanA-specific response elicited in the CB system, it was not possible to 
detect a convincing tetramer-specific expansion in the samples tested, thus indicating 
that future experiments would need to address stimulation conditions. However, a 
moderate IFN-γ secretion was detected in the CD8 subset, suggesting that a certain 
degree of CD8 activation is promoted by the actual culture conditions.  
 
4.5  FUTURE EXPERIMENTS: 
 
The easiest way to solve the viability issues described in this chapter would be the use 
of fresh, rather than frozen, CB. An alternative option would be to divert some blood at 
collection for CD14+ve selection and DC generation, freeze the rest and use the frozen 
aliquot as responders. However, against both these solutions is the consideration that 
fresh CB samples are not the best match for clinical transplantation-frozen CB is. 
Therefore, every effort should be devoted to optimize the culture conditions in frozen 
samples.  
 
A straightforward way to reduce the need for freeze-thawing procedures would be to 
freeze the CB sample as currently done, saving, however, at this stage an aliquot for 
HLA typing (15-20 X 106 cells would be enough). This would prevent the need to use 
the 5-ml segment of the frozen CB for this operation, as it had to be done in this project; 
one would prepare DCs from this aliquot, discard the CD14-ve fraction at this stage, 
and use the 20-ml section as and when required as responders. This would not likely 
solve the monocyte viability issue, but should help avoid low responder numbers 
affecting the outcome of the expansion. To solve the monocyte issues, one could 
envisage two possible routes: either give priority to monocytes/DCs as APC, and as 
such try every possible strategy to optimize viability, or go for another type of APC. In 
the first case, all the viability data available (as generated by Dr RC Duggleby and the 
Anthony Nolan Cell Therapy Centre) should be analysed to select only CB with 
exceptionally high monocyte viability at fresh. Even better, if it emerged that a 
correlation between viability upon thawing and any other of the parameters analysed 
these informations should be used too. In the second case, the best candidate would 
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probably be a B-LCL cell line. Lymphoblastoid cell lines offer some advantages; they 
are more robust than DCs, while still exerting a reasonable antigen presenting activity 
and crucially, they can be expanded to high numbers. B-LCL generation from frozen 
CB was attempted but difficulties were experienced in establishing a self-replicating 
cell line (data not shown); however, once a CB-specific protocol is established, this 
should be a viable and reasonably easy option. In fact, as Bollard’s group used B-LCL 
in conjunction with DCs for subsequent stimulation following DCs priming (Hanley et 
al., 2009) it would be worth generating B-LCL even when DCs are used as the primary 
APC, as B-LCL could provide a good restimulation tool. 
 
The readout system employed could also be modified. While tetramers are a relatively 
difficult option, due to their high specificity, they should still be included in the protocol 
as they are possibly the most sensitive readout of antigen-specific CD8 T cells 
generation. In addition to tetramer+ve assessment and IFN-γ intracellular staining, an 
attractive choice would then be ELIspot in response to MelanA peptide, as done by 
Hanley et al., 2009. While this approach would arguably require some optimization 
prior its use in CB samples, it would then present the great advantage of requiring a low 
number of cells for its setting up, thus enabling the testing of more stimulation 
conditions (such as different amount of peptide) even with small samples.  
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CHAPTER 5:  
CHARACTERISATION OF CB-DERIVED γδ T CELLS AND COMPARISON TO 
THEIR ADULT HOMOLOGUES 
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5.1  INTRODUCTION: 
 
The aim of this project was to generate and characterise antigen-presenting systems that 
could be used in immunotherapy. After the assessment of the liposome-based artificial 
antigen presenting cell (aAPC) system, it was decided to expand the analysis of the 
antigen presenting cell potential of cord blood (CB)-derived cell populations. CB-
derived dendritic cells (DCs) were evaluated first but other CB-derived cells with APC 
potential were also considered for examination and the focus was on γδ T cells. The 
main γδ T cell subpopulation in adults, called Vγ9Vδ2 cells from the TCR sub-chains 
they express, has been recently shown to possess robust APC activity in vitro both in 
human (Brandes et al., 2005, Moser et al., 2006 and Brandes et al., 2009) and animal 
(bovine, Collins et al., 1998 and murine, Cheng et al., 2008) models. These could then, 
potentially, replace CB-derived DCs in the absence of a viable monocyte population.  
 
Moser’s group (Brandes et al., 2005) reported that freshly isolated γδ T cells (from 
tonsil) expressed HLA-DR, CD80, CD86, as did IPP-expanded, but not resting, 
peripheral blood-derived Vδ2+ve γδ T cells. More functional-based evidence was 
published by Sun’s group (Cheng et al., 2008), who showed antigen-specific 
proliferation of T cells following incubation with purified γδ T cells from the spleen and 
lymph nodes in mice. Recently, Brandes et al., 2009, described that peripheral adult 
blood-derived γδ were able to cross-present soluble antigen to CD8 αβ T cells. 
Moreover, robust proliferation was obtained from naïve CD8 αβ T cells when using 
γδ T cells as stimulators. The evidence that γδ T cells can act as APCs was reinforced 
by Pistoia’s group (Prigione et al., 2009) when they published that Vδ2+ve cells pulsed 
with a C. albicans antigen promoted autologous CD4 T cell proliferation. Since these 
results suggest that γδ T cells can support a naïve T cell response in mice and adult 
humans it was, therefore, decided to investigate the APC potential of CB-derived γδ T 
cells. 
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The published literature for CB-derived γδ T cells is relatively scarce and focuses 
mostly on phenotypical characterisation and analysis of their cytotoxic/effector 
potential. One of the first papers describing γδ T cells in CB was Morita et al., 
analysing the differences in Vγ and Vδ chain combinations between CB and adult 
samples and noting their reduced cytotoxicity when compared to adult (Morita et al., 
1994). Musha et al. described CB-derived γδ T cell expansion in vitro and reported a 
low percentage of Vγ+ve cells in CB even after expansion, in stark contrast with the 
results obtained in adults (Musha et al., 1998). In 2005 Engelmann et al. studied the 
modulation of the immune response to P. falciparum during pregnancy and reported a 
higher percentage of CB-derived γδ T cells expressing CD25 and CD69 in samples 
treated for malarial infection during pregnancy compared to the control groups 
(placental infection at delivery and non-infected cohorts; Engelmann et al., 2005). One 
year later the same group compared the phenotype of CB-derived γδ T cells with γδ T 
cells of maternal origin and found a decreased expression of HLA-DR, perforin and 
granzyme B, both ex vivo and following PMA/ionomycin stimulation, in the 
lymphocytes of CB origin (Engelmann et al., 2006). Cairo et al. examined the 
responsiveness of CB-derived Vδ2+ve γδ T cells to either a phosphoantigen 
(pamidronate) or live BCG, reporting that as their naïve phenotype was rapidly changed 
to an effector one this suggested that γδ T cells are important responders to microbial 
infections in early life (Cairo et al., 2008). Finally, Campos Alberto et al. characterised 
the IFN-γ secretion by CB-derived Vγ9+ve γδ T cells when stimulated with their 
specific ligand IPP and exogenous costimulatory cytokines (TNF-α and IL-12) 
(Campos Alberto et al., 2009). CB-derived γδ T cells therefore, exist, although perhaps 
with some functional differences to adult cells, but prior to this study had not been 
assessed for APC function. 
 
5.2  EXPERIMENTAL AIMS: 
 
The work described in this chapter aims to assess the APC potential of the γδ T cell 
population in CB. In parallel, it was investigated whether there were any major 
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differences in terms of viability, numbers, and phenotype (HLA-DR, costimulatory 
markers, Vγ9 and Vδ2 chain repertoire) between γδ T cells derived from fresh and 
frozen CBMCs. While the main attention was on the CB phenotype, experiments 
assessing APC potential of γδ in adults were also carried out. The work described below 
was performed on healthy adult donor peripheral blood samples and compared with 
both fresh and frozen CB samples.  
 
5.3  RESULTS: 
5.3.1  CB γδ T CELL SELECTION AND KINETICS OF EXPANSION: 
 
The first experiments were aimed at evaluating the overall percentage of γδ T cells 
present in the various types of samples (fresh adult PBMCs and fresh/frozen CBMCs) 
and, after this preliminary assessment, to determine what were the best options to be 
able to work with as pure a γδ T cell population as possible.  
 
Figure 5.1, below, describes the percentages of γδ T cells at day 0 in CB (fresh and 
frozen) and adult peripheral blood samples, together with a representative example of 
the flow cytometry analysis at day 0 in both adult and CB.  
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Figure 5.1A and 5.1B show the percentage of γδ T cells in representative unselected and 
untreated PBMCs (for adults) and CBMCs (for CB). 2.8±2.2% of the lymphocytes, in 
adult PBMCs, were γδ T cells whilst there was a significantly lower proportion in CB 
(1.3±0.6 and 0.8±0.1 for frozen and fresh CB respectively; Figure 5.1C). These findings 
are in line with the literature, which reports 1-5% of γδ T cells on the total lymphocytes 
in adults and significantly less in cord blood.  
 
Of note, while the percentages of γδ T cells in fresh CB samples, and to a lesser degree 
in frozen ones, were quite similar, this was not the case for adults. In fact, it seemed that 
the γδ+ve T cell distribution in the adult samples under examination formed two 
populations; either <2% or 4% and above. The differences in γδ T cell percentages were 
significant between adult vs fresh CB samples but not between fresh vs frozen CB 
samples, suggesting that the freeze-thawing process did not have a significant impact on 
the percentage of γδ T cells in CB.  
 
Figure 5.1: flow cytometry analysis of γδ  T cells at day 0, in adult and cord blood samples. The 
lymphocyte population was selected according to FSC and SSC and within this gate the CD3+ve γδ+ve 
population was highlighted (A, frozen CB, B, fresh adult peripheral blood). C, γδ+ve percentage in all 
three set of samples. The student t-test was used (*P<0.05) and the relevant percentages are reported in 
the text as average ± standard deviation. Frozen CB N=5, fresh CB N=8, adult peripheral blood N= 7. 
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The principal aim of this chapter was to assess the antigen presenting potential of CB-
derived γδ T cells. To achieve this, the ideal starting point would have been a pure γδ T 
cell population, to prevent any contamination from other cell types with professional 
antigen presentation functionality, such as B cells and monocytes, that might affect the 
results. Therefore, the possibility to select γδ T cells using a positive selection 
microbead kit (MILTENYI), from unexpanded PBMCs or CBMCs (i.e. immediately 
after ficoll or thawing) was explored. Figure 5.2, below, shows the purity obtained after 
TCRγδ positive selection with (5.2B) and without (5.2A) prior expansion.  
 
 
 
 
 
 
 
Figure 5.2A shows a typical selection from non-expanded CB samples and, as 
highlighted in the histogram, a purity of approx. 50% γδ T cells was observed for the 
positive fraction (a mean of 58.8±9.7% γδ T cells of lymphocytes was achieved from 3 
unexpanded CB samples). Moreover, the yield of γδ T cells was extremely low for CB 
samples, in all cases ranging from 1-6 X 105 cells from whole cord blood samples 
(average size, 60-100 X 106 CBMCs) and in all cases less than expected judging from 
the percentage of γδ T cells present in any given CB sample (the maximum recovery of 
 Figure 5.2: flow cytometry analysis of γδ  selection. After microbeads selection, the lymphocyte population was gated according to FSC and SSC and the γδ+ve fraction was analysed within the 
lymphocyte gate (histograms). A, unexpanded and B, expanded CB sample. C, graph of γδ T cell purity 
after selection for CB and adult peripheral blood. Expanded and unexpanded CB and expanded adult 
peripheral blood N=3. 
 
% 
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γδ T cells was 50%). Overall, positive γδ T cell selection from non-expanded samples 
resulted in low yield and low purity.  
 
Consequently, a γδ T cell expansion system was developed. Expansion of CBMCs and 
PBMCs was carried out in presence of 1000IU/ml of IL-2 immediately after 
ficoll/thawing. The initial percentage of γδ T cells was assessed at day 0, thereafter all 
the samples were assessed by flow cytometry at day 7 and day 14, while day 21 was 
maintained for frozen samples only (see Figure 5.3A-C). Cell expansion was carried out 
with the two objectives of expanding γδ T cells to ideally a minimum of 10-20% 
percentage of the total cell culture and to identify the optimal time point for microbead 
selection. Following this approach, Figure 5.2B shows a typical selection from 
expanded samples, where a much better purity was achieved in all cases (a mean of 
82.2±8.3% and 80±6.3% γδ T cells of lymphocytes from expanded CB and adult 
samples, respectively; Figure 5.2C). Figure 5.2C summarises the γδ T cell selections in 
expanded and non-expanded samples, with a trend towards better purity when using 
expanded samples being observed, although statistical significance was not achieved 
with 3 samples.  
 
Figure 5.3A-C, below, shows the kinetics of expansion for all the types of samples 
tested, while Figure 5.3D presents the graph for γδ T cells numbers in the frozen CB 
samples’ group and Figure 5.3E shows the overall frozen CMBCs numbers across the 
expansion. 
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Figure 5.3A-D: kinetics of TCRγδ  expansion from adult peripheral blood and CB samples and 
example of total number of cells during expansion. A, frozen CB, B, fresh CB and C, adult peripheral 
blood TCRγδ expansion over 2-3 weeks (the TCRγδ+ve population within the lymphocyte gate is plotted 
in the graphs above; frozen CB N=5, fresh CB N=4, adult peripheral blood N=7). D, Total number of 
TCRγδ+ve cells in the frozen samples across the 3-weeks expansion (N=5). All the data reported in the 
text are expressed as average ± standard deviation.  
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Figure 5.3A-C, above, shows the kinetics of γδ T cell expansion in IL-2- expanded CB 
and adult samples cultures. At day 7, the percentage of γδ T cells was 7.6±4.5% and 
5.9±0.02% of gated lymphocytes in fresh and frozen CB samples and 5.7±5% in adults 
(while at day 0 these values were 1.11±0.34%, 1.35±0.01% and 2.8±2.2% respectively). 
At day 14, γδ T cells constituted 20.1±13.7% and 5.9±0.03% of the culture of fresh and 
frozen CBMCs respectively and 5.2±4.3% of the culture in adult PBMCs. For frozen 
samples only, the total number of γδ T cells in culture was followed as well, as shown 
in Figure 5.3D; three CB samples (CB 100646, 100660 and 100742) reached their 
highest number of γδ T cells at day 7 (range 1.63-9.6 X 105 cells), whilst in the other 
two CB samples (100575 and CB 100797) the maximum amount of γδ T cells was 
reached at day 14 (range 2.29-2.57 X 106 cells). 
 
The results shown in Figure 5.3A-D suggested some preliminary conclusions. Firstly, 
the best moment for microbead selection (when the percentage of γδ T cells is highest) 
varied drastically according to the sample considered. In all frozen CB samples the 
highest γδ T cell proportion was clearly reached between day 7 and 14, as is in 6/7 
adults donors. However, all the fresh CB cultures reached the highest percentage of γδ T 
cells at day 14. Adult PBMCs showed different kinetics of γδ T cell expansion 
compared to both fresh and frozen CB samples. Some of the adult samples (donors 3, 4, 
6) maintained their initial low percentage (<2%) of γδ T cells throughout the expansion.  
Figure 5.3E: total CBMCs over 3 weeks of TCRγδ  expansion. N=5 frozen CB samples. 
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Whilst donors 2 and 5 showed expansion, donor 1 showed a slight decrease at week 
one, and then remained constant. 1 sample (donor 7) showed a clear expansion even 
after week two, when all cultures were stopped, much resembling the kinetics of fresh 
CB samples. Of the cultures, only one went above 10% γδ T cells for frozen CB whilst 
15% was the best achieved for adult and fresh CB. The fresh CB sample 318 was a clear 
exception, but it was also the only sample among all the tested ones that showed such a 
remarkable expansion (>40% TCRγδ+ve cell after two weeks’ expansion). In terms of 
total cell numbers in culture, Figure 5.3E shows a trend of constant and progressive 
decrease down to a very low total cell number for frozen CB samples. The same pattern 
was observed also in all but one of the fresh CB samples; CB 318 was again the 
exception to this decrease as its cell number and γδ T cells’ percentage kept increasing 
until the culture was stopped.  
 
To summarise these results, the data showed that the expansion of frozen CB and adult 
samples was quite variable and that the highest percentage of γδ T cells (around 10-
12%) was usually reached between day 7 and 14. Fresh CB samples, instead, had a 
more homogeneous trend resulting in a continuous expansion and potentially reached 
higher percentages of γδ T cells (up to 40% in a single case). 
 
5.3.2  CB γδ T CELL VIABILITY: 
 
In addition to the overall γδ T cell expansion, the viability of the γδ T cells was also 
analysed during the expansion by co-staining γδ T cells with 7-AAD. Figure 5.4A and 
B, below, report the amount of γδ, 7-AAD double positive cells for frozen CB samples 
during the expansion (5.4A) and their percentage of the whole γδ T cell population 
(5.4B), while figure 5.4C shows a representative example of flow cytometry analysis 
for the incidence of cell death among the γδ+ve cell population during the expansion.  
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At no point during the expansion were a large proportion of γδ+ve 7-AAD+ve cells 
detected (figure 5.4B). Even after 3 weeks the majority of the γδ T cell population 
expanded from frozen CB samples remained 7-AAD-ve; the highest percentage of 7-
AAD+ve cells of the γδ T cell population was approximately 15%, in CB 100575. 
However, the proportion of γδ+ve 7-AAD+ve cells increased in all the samples 
examined over the 3-week expansion (see Figure 5.4B). This finding, coupled with the 
decrease in cell number in the CB samples shown in Figure 5.3E and the decrease in γδ 
T cell percentage/numbers at day 21 (Figure 5.3A-5.3D), suggested that between day 7 
and 21 there has been an overall reduction in the viability and absolute numbers of 
γδ+ve T cells in culture. These findings should be considered before setting up any new 
γδ+ve T cells expansion; the duration of the culture should be shortened in most cases, 
at least in frozen CB samples, and both viability and cell numbers should be used to 
determine when to stop an expansion to select the γδ+ve population. 
Figure 5.4: γδ  T cells viability during expansion. A, table showing the values of γδ 7-AAD double +ve 
cells over the expansion and B, table showing the same parameter as percentage of 7-AAD+ve cells on 
the whole of the γδ+ve population. C. Flow cytometric analysis of the viability of the γδ T cell 
population. Shown is the labelling for TCRγδ and 7-AAD of events gated for lymphocytes and CD3 
events. The flow cytometry results shown above are representative of N=4 independent experiments. 
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5.3.3  CB γδ T CELL PHENOTYPE: 
5.3.3.1  COSTIMULATORY PHENOTYPE: 
 
During the γδ T cell expansion, a full characterisation for molecules relevant for antigen 
presentation (HLA-DR, CD80, CD86) was performed from week 1 onwards. The same 
characterisation at day 0 was not carried out, as the low γδ T cell number in the CB 
samples made a reliable staining impractical.  
 
Figure 5.5, below, shows a representative flow cytometry analysis for each of the time 
points examined (adult and frozen CB samples only). TCRγδ+ve HLA-DR+ve cells are 
shown in Figure 5.5A, TCRγδ+ve CD80+ve cells in Figure 5.5B and TCRγδ+ve 
CD86+ve cells in Figure 5.5C. Flow cytometry analysis is shown at week one (left) and 
at week two (right). 
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As seen above, where a flow cytometry analysis from both a representative frozen CB 
and an adult sample is depicted, a TCRγδ+ve population is clearly present at all time 
points, however the co-expression with HLA-DR and co-stimulatory markers changes 
according to the type of sample and to the time point examined. While both HLA-DR 
and CD86 appear to be more co-expressed in adult TCRγδ+ve than in the same CB 
subset, the opposite is true for CD80 in the examples above. Figures 5.6 and 5.7 
describe a fuller analysis of the TCRγδ+ve surface marker expression for the whole 
Figure 5.5: flow cytometry analysis during expansion. During expansion, the expression of APC-
related markers was analysed in all set of samples. Cells were gated on lymphocytes, then the relevant 
markers (HLA-DR (A), CD80 (B) and CD86 (C)) were plotted against TCRγδ. The samples shown 
above are representative of 7 adult PBMCs samples and 4 (at week one)/5 (at week two) frozen CB 
samples.  
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group of samples (Figure 5.7), including the analysis of the MFI for each marker within 
the TCRγδ+ve population (Figure 5.6). 
 
 
 
All the results shown above in Figure 5.6 were analysed using a student t-test; the 
paired t-test was used to compare the same subsets across the expansion, while the 
unpaired t-test was employed when comparing different subsets (for example, frozen 
CB samples and adult samples). Only the statistically significant results were shown in 
the figure. As a general conclusion, Figure 5.6 showed there was no significant 
Figure 5.6: MFI analysis of HLA-DR, CD80 and CD86 within the TCRγδ+ve population. During 
expansion, the expression of APC-related markers was analysed in all the samples available at week 1 
and 2. The plots above show the MFI for HLA-DR (A), CD80 (B) and CD86 (C) within the TCRγδ+ve 
population; the mean for each set of samples is shown as a black bar. The student t-test was used to 
analyse all the results presented above; values of *P<0.05 were considered significant and the MFI 
values are presented in the text as average of all the results for a specific marker/timepoint ± standard 
deviation. Adult samples N=7; fresh CB N=5 at day 7 and N=4 at day 14; frozen CB N=4 at day 7 
(except for HLA-DR where N=3 due to a staining problem with one sample) and N=5 at day 14.  
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difference between the MFI values of CB and adults samples for any the markers used 
at any time point. There was, however, a significant difference (P=0.04) between the 
MFI of HLA-DR in fresh and frozen CB samples at week one.  
 
The MFI values for each marker were examined separately, starting with HLA-DR. 
This is the most important marker among the ones examined as CD4 cells are HLA 
class II-restricted i.e, they only recognise peptides presented on HLA class II. The 
expression of HLA class II on a potential APC is fundamental, as without it CD4 T cells 
will never receive signal 1 activation. A double +ve (HLA-DR+ve TCRγδ+ve) 
population was observed in all samples at all time points, as seen in Figure 5.5A; 
differences in MFI between the various subsets were observed but they did not reach 
statistical relevance except in the case mentioned above (fresh vs frozen CB samples at 
week one). However, this is likely due to the small number of samples examined 
(especially for frozen CB); ideally, a larger number of CB samples would need to be 
examined for MFI of HLA-DR labelling while in expansion, to assess whether the 
difference seen in this work is genuinely dependent on the freeze-thaw status. At week 
one, TCRγδ+ve cells of adult origin had, on average, higher MFI values for labelling of 
HLA-DR than the equivalent cells in CB (96±69 in adults and 11±3 and 35±10 in fresh 
and frozen CB samples, respectively). The same trend was maintained at week two 
(MFI values were 90±70, 6±1.5 and 18±5 for adult, fresh and frozen CB sample 
respectively). 
 
For CD80, a double +ve (CD80+ve TCRγδ+ve) population was present in all samples at 
all time points examined and the trend for this marker was slightly different from the 
one observed for HLA-DR. At week one, the MFI value for CD80 labelling within the 
TCRγδ+ve population of adult origin was minor than the same value in fresh and frozen 
CB samples, albeit not significantly (P*0.06, MFI values 16±8 vs 39±8 and 37±7, 
respectively). This trend was not maintained at week two, where the MFI for adult 
samples was higher than the same value for either fresh or frozen CB samples, (44±18 
in adults versus 30±4 and 16±7 in fresh and frozen CB samples respectively). 
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In the case of CD86 a double +ve (CD86+ve TCRγδ+ve) population is present in all 
samples at all time points examined. The level of expression for this marker, as 
measured from MFI, was quite modest compared to HLA-DR and CD80, especially in 
CB samples. Both at week one and two the MFI for adult samples is slightly higher than 
the same value in CB samples, regardless fresh or frozen; moreover, the MFI of CD86 
labelling in adult samples is very similar between week one and two (14±8 and 14±10 
respectively). At week one the MFI of fresh CB samples is slightly higher than the same 
value in frozen CB samples, while the opposite is seen at week two. Overall, these 
results might suggest that adult cells express more markers of signal 1 (HLA-DR) and 
signal 2 (CD80 and CD86) of antigen presentation than the equivalent population in 
cord blood. 
 
In addition to the MFI, the extent of co-expression of TCRγδ and HLA-DR, CD80 and 
CD86 was also examined. Figure 5.7, below, presents a plot of all the results 
summarised in Figure 5.5 and shows the percentages of TCRγδ+ve expressing HLA-
DR+ve (5.7A), CD80+ve (5.7B) and CD86+ve cells (5.7C) at week one (on the left) 
and at week two (on the right). 
 
 
 
 
                                                                                                                                          Chapter 5 
  
  
 
 
 
208 
 
 
 
 
 
 
As seen for Figure 5.6, all the results shown above in Figure 5.7 were analysed using a 
student t-test; the paired t-test was used to compare the same subsets across the 
expansion, while the unpaired t-test was employed when comparing different subsets 
(for example, frozen CB samples and adult samples). Only the statistically significant 
results were shown in the figure. As general conclusion, Figure 5.7 showed that there is 
no significant difference between fresh and frozen CB samples for any of the markers 
examined at any of the time points considered. There were, however, differences in the 
expression of APC-related markers between adult and CB γδ T cells. 
  
The phenotype of each of the three markers was examined separately, starting with 
HLA-DR. Within the TCRγδ+ve population, a reasonable HLA-DR+ve expression was 
Figure 5.7: TCRγδ+ve cells phenotype during expansion. During expansion, the expression of APC-
related markers was analysed for all the different conditions tested, at week one and two. The plots show 
the percentage of TCRγδ+ve cells expressing HLA-DR (A), CD80 (B) and CD86 (C), the mean for each 
set of samples is shown as a black bar. The student t-test was used to analyse the results and values of 
*P<0.05 were considered significant; percentages are presented in the text as average ± standard 
deviation. Adult samples N=7; frozen CB N=4 at day 7 (except for HLA-DR where N=3, as seen in 
Figure 5.6) and N=5 at day 14; fresh CB N=5 at day 7 and N=4 at day 14.   
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observed in the adult samples-50.2±7.4% at week one, 50.3±10.5% at week two, where 
the double +ve seemed to have split between a high and low HLA-DR population 
(either >60% or 40% and less as seen in Figure 5.7A, fourth column on the right). 
Within the TCRγδ+ve population, HLA-DR expression was significantly less in fresh 
CB samples than in adults at week two (11.9±3% in fresh CB samples vs 50.3±10.5% in 
adults, P*0.0261).  
 
Within the TCRγδ+ve population, significantly more cells were expressing CD80 in CB 
(75.3±6.7% and 76±3% in fresh and frozen CB; P*0.0176 and 0.0122 respectively) than 
in adult samples at week one (49.5±6%). The same trend was also observed when 
examining the MFI for the same samples (see Figure 5.6B), even if in that case the 
difference was not significant. At week two, CD80 expression was generally maintained 
within the TCRγδ+ve population but the expression was more widespread and there 
were samples (both in adult and frozen CB samples) that had a large decrease in the 
percentage of CD80+ve cells (from around 80% to less than 20% in frozen CB 
samples). Moreover, at week two there was no significant difference in CD80 
expression within the TCRγδ+ve population in any of the set of samples examined.  
 
In the case of CD86 there was no significant difference in CD86 expression within the 
TCRγδ+ve population in any of the samples examined at any time point. At both weeks 
one and two CD86 expression was more noticeable in adult samples than in either CB 
subset. In particular, at week two the expression of CD86 within the TCRγδ+ve 
population in fresh and frozen CB was low (in both cases inferior to 20% on average); 
in this case as well the trend of coexpression of CD86 and TCRγδ mirrored the results 
obtained from MFI analysis (see Figure 5.6C), both in terms of low overall values and 
CB-adults ratio.  
 
To summarise the phenotypic analysis performed so far, PBMCs-derived, IL-2 
expanded γδ T cells express HLA-DR, CD80 and CD86 as reported in literature. 
CBMCs-derived, IL-2 expanded γδ T cells show as well the presence of APC-related 
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markers, even if their level of expression differs from their adult counterparts; in 
particular, the MFI for all three markers tends to be lower in CB than in adults samples 
(with the relevant exception of CD80 at week one) and had low values for CD86. The 
expression of the markers of interest was maintained throughout the culture, albeit 
being different when examined at different time points. While for HLA-DR and CD86 
the level of expression was quite uniform within the same type of samples, for CD80 a 
higher degree of variability within the same group was noticed, especially at week two 
in adult samples. Taken together, these results would suggest that whilst the CB 
samples seem to be expressing the markers of APC function their expression levels 
trend towards lower levels than adult (again with the exception of CD80 at week one). 
This might comprise their function as APC. 
 
5.3.3.2  INCREASING HLA-DR EXPRESSION: 
 
While being cultured in IL-2, CB-derived γδ T cells showed only moderate expression 
of HLA-DR. As this is the most relevant marker for APC functionality, various 
stimulating conditions were attempted on CB-derived, TCRγδ+ve enriched culture to 
see if HLA-DR expression on γδ T cells could be increased. The conditions chosen 
were aimed to stimulate γδ T cells, as activation might lead to an increase in HLA-DR 
expression. IPP was used, as it is one of the best-known activating antigens for γδ T 
cells, and Dynabeads (anti-CD3CD28 beads) were also chosen as a non-specific T cell 
activator. Finally, K562 cells–a MHC-class I negative tumour cell line- were added to 
provide stress signals such as MICA and co-stimulation via NKG2D. Recognition of 
MICA by γδ TCR cells has been reported to be activating (Groh et al., 1999) while also 
exerting a second-signal effect via engagement of NKG2D on the Vγ9Vδ2 subset 
(Casetti and Martino, 2008). Moreover, it was hypothesised that the lack of MHC class 
I on K562 cells may trigger activation via the CD94-NKG2A receptor, which the 
Vγ9Vδ2 subset of γδ T cells, at least, has been reported to express (Hayday, 2009). 
Results for this experiment are shown in Figure 5.8. 
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Following co-incubation of the γδ T cell-enriched cultures with the different stimuli, it 
appeared that only Dynabeads (anti-CD3CD28 beads) promoted an increase in HLA-
DR expression in a small subset of the TCRγδ+ve gated population, as shown by the 
separate peaks in the two samples incubated with anti-CD3CD28 beads (green and 
turquoise line in Figure 5.8). Anti-CD3CD28 beads and K562 cells together had a 
slightly stronger effect on HLA-DR expression up-regulation than anti-CD3CD28 beads 
alone but no effect was seen when incubating the γδ T cell-enriched culture with K562 
cells only. This prompts the conclusion that anti-CD3CD28 beads are the major 
stimulus and the presence of K562 alone cannot elicit any significant effect on its own. 
IPP, despite being one of the commonest physiological ligands for the γδTCR, did not 
up-regulate HLA-DR in CB derived cultures. It remains to be ascertained what 
particular stimulus, if any, could promote HLA-DR up-regulation in this system and this 
issue is currently under investigation by other members of the group. It cannot be 
excluded, for example, that other bisphosphonates such as HMBPP (that is around 
100,000 times a stronger agonist than IPP) would be effective in promoting HLA-DR 
up-regulation. 
Figure 5.8: conditions tested to promote HLA-DR upregulation in CB samples. Different conditions 
were tested on a TCRγδ-enriched CB culture and HLA-DR expression was analysed. (—): -ve control 
(no stimulus). (—): cells incubated with K562 cells and Dynabeads. (—): cells incubated with K562 
cells. (—): cells incubated with IPP and K562 cells. (—): cells incubated with Dynabeads only. (—): 
cells incubated with IPP only. Results are from one representative experiment out of two, the histograms 
refer to a TCRγδ+ve-gated population.  
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5.3.3.3  Vγ9Vδ2 CELLS IN CB: 
 
In addition to co-stimulatory molecules, another phenotype of interest across the 
cultures was the TCR chain combination and pairing, more specifically whether the Vγ9 
and Vδ2 chains were co-expressed in the group of samples under examination and 
whether their co-expression level was similar to the published literature for CB and 
adult samples. The Vγ9Vδ2 double +ve population constitutes up to 80% of circulating 
TCR γδ in adult peripheral blood and has been reported to be present, albeit in small 
amounts, in cord blood too (Morita et al., 1994 and Campos Alberto et al., 2009).  
Another goal was to observe whether a Vγ9Vδ2 double +ve population could be 
expanded from CB samples. Finally, if any APC phenotype was detected in CB, an 
important objective was to investigate if it correlated with the Vγ9Vδ2+ve population 
shown to have APC functionality in adults (Brandes et al., 2005, and Brandes et al., 
2009). Figure 5.9A-C, below, shows the flow cytometry results obtained for CB (A) and 
adult samples (B) and the different percentages in Vγ9Vδ2 double +ve cells obtained in 
the samples under examination (C). 
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The number of Vγ9Vδ2 double +ve cells in CB samples was examined and, as reported 
in literature, it was extremely low in all the fresh samples tested. Indeed, in the frozen 
CB samples, the Vγ9Vδ2 were undetectable (see 5.9A, above). In culture, at all time 
points past day 0, the Vγ9Vδ2 double +ve population became undetectable in both fresh 
and frozen samples (Figure 5.9A, for fresh and frozen CB sample). By contrast, using 
the same staining cocktail resulted in a well defined double +ve population in the adult 
samples (Figure 5.9B), precluding a technical issue as the explanation for the extremely 
low number of Vγ9Vδ2 double +ve cells in CB samples. 
 
 As shown in Figure 5.9C, in the fresh CB samples the percentage of Vγ9Vδ2 double 
+ve events (calculated on the total number of cells expressing either chain) was quite 
uniform and significantly lower than in adult samples (P*0.0024). In the adult samples a 
more widespread distribution was observed, with the majority of donors containing 
Figure 5.9: flow cytometry analysis of Vγ9Vδ2 double +ve population in CB and adult peripheral 
blood samples.  A, Vγ9Vδ2 double +ve cells in fresh and frozen CB at day 0, week 1 and week 2 and 
B, Vγ9Vδ2 double +ve cells in adult at day 0. In all cases, cells were firstly gated for lymphocytes, then 
selected for CD3, then the Vγ9Vδ2 double +ve cells were plotted within the CD3+ve population. C, plot 
of the percentage of Vγ9Vδ2 population detected in fresh CB and adult peripheral blood samples 
calculated over the total population expressing either chain. An unpaired student t-test was performed; 
P*<0.01. Frozen CB N=5, fresh CB N=7, adult N=7.  
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between 40 and 60% of Vγ9Vδ2 double +ve cells, more in line with literature findings. 
The results in Figure 5.9C show the proportion of Vγ9Vδ2 double +ve cells of the 
whole CD3+ve population. Unfortunately it was not possible to assess the Vγ9Vδ2 
labelling in the γδ +ve population, as currently there are not Abs available for these 
markers that are conjugated to different fluorochromes. 
 
Some important conclusions were drawn from the results described in Figure 5.9. First 
of all it should be noted that even detection of Vγ9Vδ2 double +ve cells was quite 
difficult in all CB samples examined, regardless if they were fresh or frozen. Their low 
numbers made any characterisation for APC markers impossible, as event number 
would have been far too low to be meaningful. As such, the APC potential of Vγ9Vδ2 
double +ve γδ cells was not assessed due to the very low numbers or absence of this 
subpopulation. It is possible that Vγ9Vδ2 double +ve cells became lost during cryo-
preservation, as a small but detectable population was observed in all fresh CB samples 
examined but seemed to disappear during expansion in culture.  
 
5.3.4  γδ T CELL SELECTION AFTER EXPANSION: 
 
All the phenotype analyses explained above were performed during the γδ T cell 
expansion, which had the final aim of providing a large enough enrichment prior 
TCRγδ+ve selection.  After expansion, total PBMCs-CBMCs numbers and γδ T cell 
enrichment were assessed within the cultures. The decision to select using the TCRγδ 
microbead kit was taken based on both criteria: in general, samples containing either 
less than 15 millions total PBMCs-CBMCs, or less than 10-15% of γδ T cells, were not 
selected, as the final yield in the +ve fraction would have been too low. These criteria 
unfortunately ruled out selection from all but one of the fresh CB samples, 4/7 adult 
samples and 3/5 of the frozen CB samples. In every TCRγδ positive selection 
performed, regardless of the source, the total number of cells in the positive fraction 
was below 7 X 105 cells. Following selection, a flow cytometry analysis was performed 
to check that the relevant APC phenotype was maintained, as shown in Figure 5.10. 
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As shown above, the γδ T cell purity in the positive fraction was very good, at around 
90% (Figure 5.10A). A clear CD80+ve population was observed in the selected 
population with a less well-defined HLA-DR+ve and CD86+ve populations also being 
present (5.10B, shaded histograms). Therefore, it was concluded that γδ T cells 
maintained their APC-related phenotype after positive selection. 
 
Given the low numbers of γδ+ve T cells retrieved after selection from CB samples 
priority was given to the expansion of selected TCRγδ+ve cells. As a preliminary 
experiment using one cord blood sample (data not shown), the selected positive fraction 
was plated over an autologous feeder layer, with or without IPP. The rationale behind 
this was to provide a γδ−specific stimulus (IPP) to the γδ+ve T cells; moreover, it was 
thought that the feeder layer (frozen and irradiated cells derived from the negative 
fraction of the TCRγδ+ve selection) would provide the “stress” factor that is reported in 
literature to be an important element in activating TCRγδ+ve cells (Hayday, 2009). 
However, this approach was proved unsuccessful and no γδ T cell expansion was 
Figure 5.10: flow cytometry analysis of the APC phenotype of TCRγδ  population after selection. A, 
TCRγδ purity after selection from a TCRγδ-enriched adult PBMC culture and B, level of expression of 
HLA-DR, CD80 and CD86 within the TCRγδ+ve fraction of the selected population. In both A, and B, 
cells were gated on lymphocytes; for B, (—) is double stained and (—) is TCRγδ+ve stained only 
(representative of 3 adult samples).  
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detected in this experiment (data not shown).  
 
5.4  DISCUSSION: 
 
Various groups reported an APC activity for the specific subpopulation Vγ9Vδ2+ve of 
γδ T cells in adults (Brandes et al., 2005, Moser and Brandes, 2006, and Brandes et al., 
2009). Recently, Prigione et al., 2009 added additional evidence by reporting APC 
activity mediated by the Vδ2+ve fraction of γδ T cells in an autologous system. The 
original aim of the work performed in this chapter was to examine the APC potential in 
CB-derived γδ T cells, ideally in the same Vγ9Vδ2 subpopulation but also in the entire 
γδ pool, starting from the hypothesis that CB-derived γδ T cells possess the same APC 
properties as those seen in adult.  
 
5.4.1  CELL YIELD: 
 
At first, the rationale was to select γδ T cells from unexpanded cord and adult blood 
samples using a TCRγδ positive selection kit. This approach had to be re-evaluated as it 
was found that both yield (less than 0.5 X 106 cells on average) and purity (consistently 
less than 60%) of positively selected cells were too low, and a pre-selection expansion 
protocol was introduced.  
 
Low yield and purity were not, however, the only factors that were taken into account in 
the decision not to perform a positive selection at the beginning of the culture and to 
shift this step further down in the protocol. It was also considered that the positive 
selection kit in use, whose microbeads recognize the whole of the γδTCR repertoire 
according to the manufacturer, could have an activating effect on the selected cells. It 
was speculated that the microbeads promote TCR engagement, in absence of secondary 
co-stimulation. This could lead either to undesired activation or even overstimulation 
and death or alternatively to anergy and unresponsiveness. Given that the low numbers 
of γδ Τ cells obtained from CB samples would mean an expansion step, it was 
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considered that such a risk should be avoided. Moreover, the ideal situation for analysis 
was to assess co-stimulatory molecule expression in conditions of activation that could 
be controlled exogenously (for example by adding phosphoantigens, or other stimuli, in 
the culture). By expanding the cells first to enrich for γδ T cells, it was hoped to prevent 
a possible selection-induced unregulated cell activation or anergy. 
 
For selection purposes, absolute numbers of γδ T cells were low either starting from 
either adults or from CB. To overcome the yield issue, at least in adults, it should be 
noted that other adult tissues (for example tonsils, as used in Brandes et al., 2005, or 
intestine) are much richer in γδ T cells than peripheral blood and as such might have 
been a more suitable cell source. However, the focus of this project was to characterise 
the APC potential of γδ T cells in cord blood. Therefore, adult peripheral blood-derived 
γδ T cells were judged the most comparable source of γδ T cells, especially since tonsil 
and blood derived γδ T cells have a different phenotype with regards to APC-related 
markers (Brandes et al., 2005); while tonsillar γδ T cells show intrinsic expression of 
HLA-DR, CD80, CD86 and CD40, γδ T cells of blood origin express the same markers 
only following incubation with IPP.  
 
The low number of cells obtained severely hampered the experiments that could be 
performed, however. Whilst a low yield was not so much of a problem during 
characterisation, small numbers of cells after expansion and selection limited the 
number and type of functional assays that could be performed. It was not possible, for 
example, to test a wide range of conditions for post-selection expansion, nor was it 
possible to perform MLR assays with CB-derived γδ T cells. 
 
5.4.2  EXPANSION PROTOCOL RATIONALE: 
 
Following the discovery of the low starting number of γδ T cells it was decided to try an 
enrichment protocol from unselected CBMCs/PBMCs. This rationale has a wide 
support in the literature (Musha et al., 1998, Cipriani et al., 2002, Brandes et al., 2003, 
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Campos Alberto et al., 2009 and Prigione et al., 2009) and purity after selection became 
considerably better after IL-2 expansion in both adult and CB samples. γδ T cell 
expansion in the literature is usually performed using IPP, IL-2, or a mix of the two in 
various combinations (Cipriani et al., 2002, Prigione et al., 2009, Campos Alberto et 
al., 2009, Vantourout et al., 2009 and Salot et al., 2009). Other protocols described in 
literature for γδ T cell proliferation involve the co-culture of PBMCs with IL-2 and 
PHA-P (Morita et al., 1994), the use of other bisphosphonate-based compounds such as 
BrHPP (Braza et al., and Ismaili et al., 2002) and triphosphoric acid 1-adenosin-5-yl 
ester 3-(3-methylbut-3-enyl) ester (ApppI) (Vantourout et al., 2009), and the use of 
zoledronate, a drug used in myeloma and osteoporosis treatment, both in combination 
with zoledronate-presenting cells (Roelofs et al., 2009) or on its own (Kondo et al., 
2008, and Gruenbacher et al., 2009). However, the lack of commercial availability of 
most bisphosphonates and the consequential requirement for custom-made preparation 
rendered them an unfeasible option in the present study.  
 
For this project the simplest option of IL-2 only was chosen. In addition to its ease of 
use, it was also considered that the most readily available IPP formulation (Sigma) 
might affect the long-term viability of the culture as it is re-suspended in methanol and 
as such would be toxic to all eukaryotic cells. Besides the possible toxicity issue, it is 
one of the known ligands of the γδ TCR and therefore it might promote widespread 
activation prior to, or in contrast with, the expansion. At this stage, such an outcome 
would have been unfavourable. The ideal scenario instead would have been enrichment 
of γδ T cells from the expansion culture, followed by microbead-mediated positive 
selection, followed by activation of the positively selected fraction. This could then be 
attempted with a range of stimuli, both γδ-specific (including, at this point only, IPP) 
and general T cell activation (such as anti-CD3CD28 beads). 
  
Co-cultures of γδ T cells with other cell types have also been effectively used to 
promote γδ T cell expansion (Brandes et al., 2003 and Brandes et al., 2005). More 
specifically, Brandes et al. used either IPP, HMBPP or bacterial lysate presented by 
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EBV-B cell lines (B-LCL) to achieve good γδ T cell expansion (Brandes et al., 2005). 
There is, however, a major caveat against such an approach, despite its effectiveness; it 
results in a mixed culture. Given the very small number of cells involved, it would have 
been extremely difficult to separate the γδ+ve T cells from the feeder cell line after 
expansion. This would have lead to a mixture of cells in all downstream functional 
experiments, complicating the interpretation of the results. It was therefore a priority to  
maintain the post-selection γδ T cells as a pure population to avoid ambiguous  results. 
 
5.4.3  PHENOTYPE-COSTIMULATORY MOLECULES: 
 
The initial aim of the work described in this chapter was to elucidate whether γδ T cells 
from CB samples could have an APC phenotype and exert APC functionality. While 
this project focused on the setting up of γδ T cells culture conditions and the phenotype 
analysis, other members of the group are currently investigating the APC functionality 
of these cells at the Anthony Nolan Research Institute.  
 
As for APC phenotype, no statistically significant difference was detected between 
fresh and frozen CB samples for any of the phenotypic parameters examined (HLA-DR, 
CD80, CD86), with the exception of higher MFI of HLA-DR labelling at week one on 
frozen CB compared with fresh CB. However, a trend of lower MFI between CB 
samples (regardless of freezing status) and adults could be detected for all markers at all 
time points with the exception of CD80 at week one. The same trend was detected when 
assessing the co-expression of TCRγδ with another marker (HLA class II or co-
stimulatory molecule), again with the exception of CD80 that was significantly more 
expressed in CB than in adults at week one. The overall lower expression level of HLA-
DR and co-stimulatory molecules on CB cells compared to adults might suggest CB-
derived cells would be a worse APC. The higher level of CD80 compared to CD86 
might be indicative of a potential tolerogenic phenotype, as it is reported that CD80 is 
likely to be a better ligand for CTLA-4 than for CD28 (Collins et al., 2002). However, 
only functional tests would determine the effects, and eventual differences, of the 
phenotypes observed.   
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The data presented in this chapter for adult samples are in line with what was described 
by Moser’s group (Brandes et al., 2005), and any difference in HLA-DR and co-
stimulatory molecules expression might be explained by the more specific stimulation 
(IPP in the published reference vs IL-2 only in this work).  
 
As for the CB samples, the only two references in the literature to any APC-related 
marker expressed on CB-derived γδ T cells are by Engelmann et al., 2006 and Prigione 
et al., 2009. Prigione et al. reported around 27% expression of CD80 and around 42% 
expression of CD86 on CB-derived, C. albicans-stimulated γδ T cells (Prigione et al., 
2009). Their results are thus quite different from what obtained in this study, both in 
overall percentages for each marker and in CD86 being more highly expressed than 
CD80. However, such a difference could be explained with the different treatment the 
CB-derived γδ T cells underwent compared to our study; Prigione et al. established 
Vδ2+ve cell lines using IPP and used those in all subsequent experiments (Prigione et 
al., 2009). The other paper (Engelmann et al., 2006) described a very low (<1% in all 
cases) HLA-DR expression in γδ T cells in an African cohort, both ex vivo and 
following PMA/ionomycin stimulation. These results are also quite different from the 
ones presented in this work, however a direct comparison is difficult due to the fact that 
in this project staining for HLA class II and co-stimulatory molecules at day 0, for CB 
samples, was not performed, due to the scarcity of γδ T cells in CB. Also, the IL-2-
mediated, prolonged expansion protocol used here for γδ T cells is quite different from 
the brief (4h) PMA/ionomycin stimulation performed by Engelmann et al., 2006. As 
surface expression analysis for CB γδ T cells at day 0 was not taken due to the scarce 
amount of γδ T cells without expansion, it was decided to treat adult samples in the 
same way and follow up their expression during expansion comparing each time point.  
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5.4.4  PHENOTYPE- Vγ9Vδ2 CELLS: 
 
Differences between fresh and frozen CB samples were detected with regards the 
presence or absence of Vγ9Vδ2+ve double +ve cells and in the kinetics of expansion. 
Whilst the difference in the kinetics of expansion was important in term of numbers, the 
Vγ9Vδ2 double +ve population was one of the main targets of this work so it will be 
examined first.  
 
CB-derived Vγ9Vδ2+ve cells were first described in the mid 1990’s (Morita et al., 
1994), when an average of 9.4% γδ T cells were reported to be Vγ9Vδ2+ve in CB. A 
more recent paper (Campos Alberto et al., 2009) referred to a generically low 
percentage of Vγ9Vδ2+ve cells. In this project an average of 11.1% Vγ9Vδ2+ve cells 
was detected in fresh CB samples, which is consistent with the data presented in the 
literature. 
 
In the group of samples used in this work, no detectable Vγ9Vδ2 double +ve population 
was observed in the frozen CB samples after thawing, in contrast to fresh samples 
examined at day 0. During this project, even in the case of fresh samples, the Vγ9Vδ2 
double +ve populations detected by flow cytometry were so small that technical 
difficulties with flow cytometry staining and procedures were suspected. Vγ9Vδ2 
double +ve cells were detected in adult samples, however, suggesting that a technical 
issue was not the explanation for the CB observations. The apparent lack of Vγ9Vδ2 
double +ve cells in CB samples examined after day 0 has not been reported before and 
its significance is unclear. One possible hypothesis is that the antigens that drive the 
Vγ9Vδ2+ve expansion in adults were absent in the CB cultures performed in this 
project. Another possibility is that in CB Vγ9Vδ2 double +ve cells are dependent for 
their survival on DC help; it was recently published that CD56+ve DCs are important 
for γδ T cell expansion (Gruenbacher et al., 2009). The lack of DCs in frozen CB 
samples, or in fresh CB samples after culture, could have had a negative effect on γδ T 
cell survival and expansion.  
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The very low number of Vγ9Vδ2 γδ T cells in CB samples suggested that they are 
likely not the source of the stimulatory and co-stimulatory molecular expression 
observed. Which γδ T cell subpopulation is responsible for the HLA-DR, CD80 and 
CD86 expression detected is still an open question. This issue could not be explored 
fully due to time constraints; moreover, the shortage of commercially available TCR 
single chain-specific antibodies would also have hampered clarification of this point, 
but this is definitely worthy of future assessment. 
 
5.4.5  FRESH VS FROZEN SAMPLES’ EXPANSION: 
 
Differences in the kinetics of expansion were observed between fresh and frozen CB 
samples; cultures from fresh CB samples tended to contain a higher proportion of γδ+ve 
T cells. In both cases however the total cell number after expansion was very small, 
despite these differences. The definitive test to assess whether there is an intrinsic 
difference between chain combinations and proliferation potential for the TCRγδ T cell 
population in fresh and frozen CB would be to check the same CB sample for expansion 
before and after thawing. Unfortunately, this was not possible in the present study as 
frozen CB samples were received as whole cord blood and there were no accessible 
fresh aliquots for testing. However, it should also be considered that in a transplant 
setting the source of CB cells would be frozen CB units. Therefore, the phenotype and 
behaviour of γδ T cells derived from frozen CB units is likely to be the most applicable, 
even if the outcome is less satisfactory than that obtained in fresh CB. 
 
5.4.6  CONCLUSIONS: 
 
Taking into consideration all the data presented so far, γδ T cells from both CB and 
adults presented a phenotype that could be compatible with APC functionality. It was 
found that to obtain a sufficient number of γδ T cells for successful characterisation and 
selection experiments, an expansion step was required. Whilst functional assays, such as 
an MLR, were not performed, the increase of HLA-DR expression was considered an 
absolute priority before performing any APC-functional experiments using CB-derived 
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γδ T cells (other members of the group are actively exploring this issue). Finally, in 
addition to the topics explored in this chapter, some other questions emerged that need 
to be answered, namely: can γδ T cells from CB be expanded further after selection? If 
so, what would be the ideal protocol to do so? It still remains to be assessed whether 
CB-derived γδ T cells are true functional APC, in addition to displaying an APC-like 
phenotype, and if there are other functions, other than antigen presentation, that are 
compatible with the phenotype observed during this project. 
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CHAPTER 6:  
FINAL DISCUSSION 
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6.0  INTRODUCTION: 
 
This PhD project has focused on the development and characterisation of aAPCs as new 
immunotherapeutic tools, with a special interest in CMV infection, as it constitutes one 
of the major complications following HSCT. The design of the whole project focused 
around two key points. Firstly, the main target was to develop a flexible system that 
could be used in a variety of clinical settings for cellular immunotherapy. Within this 
objective, the major interest was the aspect of immunotherapy that was considered the 
main bottleneck in the successful generation of CMV-specific CD8+ve T cells ie., the 
availability of suitable APCs to generate an antigen specific response. At the moment 
the main immunotherapeutic options are patient-specific for both the APC and effector 
cell compartments; therefore, it was considered a priority to develop an alternative 
technique that could be used in many patients with minor adaptation. This would have 
been achievable with the liposome-based aAPC system.  
 
In the following sections a summary will be presented of the main merits and 
disadvantages of each of the approaches that were employed, together with the main 
difficulties encountered and suggestions on how best to proceed with each approach if 
the project were to be taken further. 
 
6.1   LIPOSOMES AND THEIR DEVELOPMENT AS aAPCs: 
 
The development of a liposome-based aAPC was the first subproject carried out during 
the PhD; preliminary data on this topic were generated previously in the laboratory and 
published in De La Pena et al., 2009, during the course of this PhD. The establishment 
of liposome-based aAPCs in both human and murine models was the initial objective of 
this PhD project. It was considered that they would have suited the profile for the ideal 
aAPCs as presented in section 1.4.0 of the Introduction (flexible and biodegradable, 
non-toxic, non-tumorigenic, able to travel in vivo, traceable, capable of forming T cell 
synapses and of delivering adequate T cell activation signals).  
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Therefore, while it was not impossible to foresee some challenges ahead (in terms of 
biochemical standardisation and development of the liposomal aAPCs to suit different 
systems), it was considered that the final goal -the development of a truly flexible 
aAPCs- would have balanced out all the difficulties in setting up the model.  
 
6.1.1  MAIN CHALLENGES: 
 
At the very start of the project -at the stage of liposome loading and assessment-
persisting difficulties were encountered. MHC loading on the liposome surface was 
stochastic and hard to reproduce; its clear detection, using all the means and techniques 
available, proved to be more challenging than expected. The optimisation of loading 
and particularly its detection had also been one of the most difficult elements in the 
previously published work (Prof Dodi, personal communication); therefore, more than 
one procedure (compared to just a dot blot in the published work, De la Peña et al., 
2009) was employed. Consequently, this preliminary part took longer than envisaged in 
the general plan of the PhD.  
Difficulties in reproducing the previously published results were also encountered in the 
tet-specific expansion experiment. Moreover, the framework of published references 
specific to the interaction of cells with liposomes is limited. When searching the 
literature for cell-liposome co-culture protocols, it was discovered that it was extremely 
hard to assess the precise amount/concentration of liposome used when co-cultured on 
cells, regardless of their final use (antigen delivery rather than stimulation, for 
example). In addition to De La Peña et al., 2009, the only other reference stating a 
defined cell:liposome ratio was Marty and Schwendener, 2005. Since only in De La 
Peña et al., 2009, were liposomes used for the antigen-specific targeting of T cells, De 
La Peña et al., 2009 remained the chief reference for this part of the project.  
One hypothesis for the difference in expansion seen between this project and the 
published data could be that the amounts of liposomes used in De la Pena et al., 2009, 
are only compatible with expansion in some donors and not in others. In other words, 
CD8+ve cells that are sensitive even to minimal antigenic stimulation could behave as 
seen in the published reference, while with cells from other donors, the presence of 
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liposomes could tilt the balance between expansion-inhibition of expansion towards 
toxicity promoted by the liposomes. As there are individual differences in the overall 
response to CMV (and, in general, antigenic stimulation) this could partly explain the 
disparity observed between the work presented in this thesis and the published 
reference. At this point in the project, the only way to completely clarify the 
discrepancy between the data presented in this thesis and the ones published in De La 
Pena et al., 2009, would have then been a new step-to-step optimisation starting from 
the very beginning (liposome formulation and loading, as detailed in Sections 2.1.1, 
2.1.2.10 and 2.1.2.11). It was considered, however, that this move would have oriented 
the PhD towards a fully biochemical-based work. It was therefore decided to move 
away from this topic and to explore the potential for cellular-based aAPCs (see next 
sections). 
 
The disadvantages of using liposomes (low reproducibility between different batches, 
stochastic MHC loading, difficulty to assess MHC loading efficiency and decrease in 
viability observed when co-incubating them with Buffy coats and presumably PBMCs) 
cannot, however, offset the one great advantage of liposome use in immunotherapy; 
their full biocompatibility in vivo. They are already used in vivo, albeit only in 
chemotherapy, to deliver therapeutic agents; therefore, once their standardization as 
aAPC was achieved, it is foreseeable their use in a clinical setting could be expedited.  
 
6.1.2 NEXT EXPERIMENTAL STEPS: 
 
In retrospect, and approaching the issue from a biochemical point of view, the 
challenges encountered in this subproject appear a small step towards the optimisation 
of a truly flexible, biocompatible, off-the-shelf aAPC to be used also in vivo. Were this 
project to be re-started, the right person to tackle the optimisation issues described 
above would be a biochemist with previous experience in liposomes. The first task 
would be assessing whether there is an “ideal” liposome formulation for aAPCs, testing 
as many protocols as possible; among the characteristics there should be the possibility 
of prolonging its survival in vitro and delaying uptake by cells in vitro and in vivo. Both 
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the lipid composition and the re-suspension buffer should be assessed independently. 
This objective should be achieved by evaluating various liposome compositions on 
PBMCs, Buffy coat and, ideally, immortalized cell lines (as these would enable 
comparison of the results obtained with the literature, where liposomes are mostly used 
on cell lines). Moreover, the work on primary cells should be performed in as wide a 
cohort as possible, to assess whether the viability issues seen in this project are a 
common trait or a feature regarding only a small subset of possible patients. 
 
The second priority would be solving the loading issue; while the loading mediated via 
Cys-attachment still seems the only physiological method, a new way should be sought 
to optimize its detection. One possibility would be to prepare fluorescent or biotinylated 
(i.e trackable) MHC molecules (something akin to what has been showed in Prakken et 
al., 2005); they would be loaded on the liposomes, as done in this project, but could 
allow a better detection (via specific fluorescence or streptavidin tagging) than an 
unlabelled protein. If fluorescence was used, fluorescent (or confocal) microscopy could 
be used to evaluate the degree of loading. While a possible objection could be that the 
presence of any foreign domain on the MHC protein could impair its tertiary 
conformation and Cys-loading, this appears to be an acceptable compromise between 
the need for a better loading detection and conformational stability. Once the detection 
was established in principle, unlabelled MHC molecules could then be used for 
experiments. Finally, to solve the lack of reproducibility in the expansion, one 
possibility would be to test more HLA-specific donors to assess in each case whether 
liposome presence impairs or not the tet-specific expansion. A further optimization of 
amount of liposome/protein concentration would be beneficial as well.  
 
In the case of the murine model, it would be advisable to perform a separate 
optimization for the amount of liposomes/protein concentration to be added to the 
hybridoma cells. It is possible, in fact, that hybridoma cells are able to withstand higher 
amounts of liposomes/protein than PBMCs. The amount of peptide shown to be 
effective when pulsing the OT-1 spleen cells required for the +ve control of the system 
could provide a general indication of the amount of protein required. The optimisation 
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part of the murine system should be relatively easier and quicker than the one on the 
human system, as no change of the liposome formula is, in principle, required: 
therefore, it could be performed as a preliminary step. However, for clinical use, the 
data obtained in the human system would be more relevant as they would also reflect 
the heterogeneity of donors and patients compared to the uniform genetic background 
and strength of response obtained with the murine hybridoma. 
 
6.2  CB-DERIVED DCs: ADVANTAGES AND DISADVANTAGES:  
 
Following the decision to move to cellular-based aAPCs, the use of CB as source of 
cells for immunotherapy appeared a natural choice, given the growing importance it has 
in all roles of transplantation. Compared to liposomes, CB-derived DCs would have not 
been as flexible and would have not provided the “off-the-shelf” quality required; 
however, it was considered that they could have delivered a stronger and better 
activation signal to responder cells than any acellular aAPC currently available. 
Moreover, the use of CB as a cell source offered the possibility to develop a complete 
DC-CD8 responder system; while both components needed to be evaluated, this system 
would have provided the opportunity to develop all aspects of cellular immunotherapy 
in a well-defined model.  
 
On the APC side, there was not a definite consensus in the literature on what the 
phenotype and functionality of a CB-derived DCs was; the references ranged from 
impaired phenotype and reduced functionality (compared to adults, see for example Liu 
et al., 2001, Langrish et al., 2002 and Naderi et al., 2009) to full APC potential and 
capability to generate antigen-specific CD8 cells (Salio et al., 2003, Park et al., 2006 
and Hanley et al., 2009). Given this mixed evidence, it was fundamental to assess CB-
derived aAPCs, in our hands, before setting up any functional experiment. This could 
have been a disadvantage in terms of a longer time required for setting up the system, 
but overall the full characterisation and comparison to adult DCs was beneficial in 
terms of valuable experience in DCs handling. Moreover, the wide literature 
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background provided a reference frame for CB DCs phenotype/functionality outcome 
(contrarily to what was available for the liposomes). 
 
On the effector side there were two factors to be considered: the general naivety of CB 
T cells could have been both a general clinical advantage (as the use of CB material is 
correlated to less GvHD than adults) and a specific disadvantage for CMV-specific 
immunotherapy (as cells had to be primed to mount a response against CMV, and 
priming would have presumably been more difficult in CB than in adults). In the system 
presented in this thesis, it appears that stronger stimulation conditions should have been 
used to those that were employed, as it was not possible to detect peptide-specific 
expansion. However, before being able to address this challenge, viability issues 
concerning the frozen CB samples used emerged.  
 
6.2.1 MAIN CHALLENGES AND FURTHER EXPERIMENTS: 
 
While it was considered that CB-derived DCs could have provided a stronger 
stimulation than acellular aAPCs, thereby making them an attractive option, it was 
discovered that the use of frozen CB samples as DCs source presented considerable 
hurdles in terms of viability of starting material. These issues could have been solved, 
or at least bettered, using fresh rather than frozen CB. However, there is still the 
consideration that, to enable a perfect comparison with the samples used in clinic, 
frozen CB should be used exclusively.  
Therefore, the first step to address the poor monocyte/DCs performance seen in this 
thesis would be comparing the viability data obtained here with the ones obtained by 
other CB banks, to see if they are similar. While it is generally acknowledged that the 
generation of DCs from frozen samples (regardless of the origin) is more difficult, this 
has been done at least once in the literature (Hanley et al., 2009) so it is not an 
impossible task. However, from the data presented here it appears that the problem with 
generating DCs from frozen samples might be the samples themselves, so this issue 
should be addressed before attempting any further DCs generation from CB. Another 
way to assess whether it is a sample-related problem would be getting frozen CB 
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samples from other CB banks, treat them as the samples described in this chapter and 
see whether different results are obtained. In addition to the analysis of viability data, 
the thawing of frozen CB samples from other CB banks should be useful to highlight 
the presence of a technical/handling issue. If a difference emerged in the general 
performance of frozen CB samples from other banks compared to the ones described 
here, then a protocol-related issue should be considered amongst the possible 
explanations. This hypothesis could be verified only by a thorough assessment of each 
step of the procedure used to thaw, select and differentiate monocytes into DCs. If, 
however, the poor viability persisted, then the most rational way ahead would either be 
the use of another APC or the use only of CB with the highest monocytes’ percentage 
(as described in section 4.5). As all this part would not be aimed to peptide-specific 
CD8 T cell generation no typing would be required.  
 
Once the monocyte/DCs viability issue was resolved, the next step would be to improve 
the efficiency of the antigen-specific CD8 expansion. The conditions used in this thesis 
(and taken from the published reference Salio et al., 2003) did not lead to a detectable 
tet+ve population. Therefore, stimulation conditions should be strengthened either via 
repeated administration of antigens, repeated rounds of stimulation with antigen-pulsed 
autologous cells as APCs (the ideal choice would be B-LCL, as mentioned in section 
4.5), increased amount of IL-2 to boost any response, or a combination of all these 
factor together. A longer DC-responder co-incubation could be tested as well, however, 
this option should not be the first choice given the overall drop in cell number 
encountered in CB cultures longer than two weeks  (see section 5.3.1).   
 
6.3  THE MAIN CHALLENGES OF γδ T CELLS: 
 
After the conclusion of the subproject on CB derived-DCs, it was decided to further 
explore CB as a source of APC and the choice was to focus on γδ T cells. The 
assessment of the APC potential of CB-derived γδ T cells seemed a very promising 
approach considered the strong published evidence for APC potential in the main γδ T 
cell subset in adult blood, which is termed Vγ9Vδ2 (Brandes et al., 2005 and 2009). 
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Moreover, while γδ T cells have been the focus of a large number of studies (see 
Hayday, 2009, for a recent review), their full characterization is still ongoing, especially 
in CB. It was also speculated that they would not be as affected by freeze-thawing as 
monocytes, therefore presenting the possibility of a more robust and viable APC subset. 
The full characterization of γδ T cells and the Vγ9Vδ2 subset in CB cells was however 
hampered by the extremely low number of these cells in CB, especially in frozen 
samples. In particular, the paucity of γδ T cells was the main hurdle against their 
immediate selection from the general PBMCs population without an expansion step and 
their full characterisation including functional experiments. Therefore, if the project 
were to be taken further all the efforts should be devoted initially to increase their 
number in CB-derived cultures.  
 
6.3.1  γδ FUTURE EXPERIMENTS: 
 
Two aspects should be the focus of further research on CB γδ T cells: the development 
of an effective, CB-specific protocol for γδ T cells expansion and the accurate 
determination of the chain repertoire dominant in CB, to see whether it matches any of 
the main populations in adults. The expansion would be the priority, in order to have 
enough γδ T cells to perform a full characterisation. 
 
The objective of a γδ T cell-specific expansion from CBMCs should be to achieve 
ideally 1-2 X 106 of pure γδ T cells. This could be done in two ways; either by positive 
selection following expansion or after initial depletion and subsequent expansion. The 
first method would be recommended for small CB samples (50-100 X 106 CBMCs); in 
this case an IL-2-mediated expansion could be performed, as described in this thesis, 
however the use of phosphoantigens in the final stages of expansion could be 
considered. Their use in the beginning of the culture could promote widespread γδ T 
cell activation; such an outcome would not be favourable at that stage. A depletion 
(provided anti-CD56 antibodies are not present in the selection mix, as a subset of γδ T 
cells express CD56) would be an attractive option for large CB samples (above 200-300 
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X 106 CBMCs). Regardless of the protocol used, it is important to obtain as pure a (or 
as pure as possible, and in particular without any DCs or B cells) γδ T cell population as 
possible prior to its use in functional assays. If the aim is the assessment of APC 
activity, in fact, a moderate contamination with, for example, conventional T cells could 
be allowable, as they should not affect the final result. A DCs or B cells contamination 
would have more relevant, APC-related, effects. 
 
After the increase of γδ T cell number, the next priority would be assessing their chain 
repertoire and to see if they match any of the known main subsets. Some of the papers 
that described their effector activity (Engelmann et al. 2005 and 2006) did not assess 
their repertoire; this information could be important for a general comparison between 
adult and CB-derived γδ T cells. As detailed at the end of chapter 5, the precise chain 
assessment is hampered by a general low cell number and by the lack of commercially 
available, non cross-reactive, chain specific, antibodies. While the repertoire assessment 
challenge could be overcome via RT-PCR, HLA-DR sorting and chain assessment with 
the antibodies currently available or limiting clonal dilution (see section 5.5.1 and 
5.5.2), all these approaches would greatly benefit from a high cell number. Therefore, 
an optimised expansion protocol is still a priority. 
 
Once a large, pure γδ T cell population has been achieved, the proper functional 
assessment could start. The preliminary data presented in this thesis shows that if there 
is an APC functionality by γδ T cells from CB this does not seem to belong to the 
Vγ9Vδ2 subset, as the number of these cells in CB samples is extremely low. It would 
then be relevant to know which repertoire correlated with the HLA-DR, CD80 and 
CD86-expressing γδ T cells. Functional assessment of antigen presentation by γδ T cells 
could include pulsing them with an antigen, followed by co-incubation with autologous, 
carboxyfluorescein diacetate succinimidyl ester (CFSE)-labelled responder cells and the 
evaluation of any antigen-processing capability (as done in Brandes et al., 2009). 
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Another important point to be elucidated would be the interaction between DCs and γδ 
T cells in CB. Gruenbacher et al., 2009, showed that DCs are important for γδ T cell 
activation in adults; therefore, it would be interesting to see whether this interaction is 
occurring in CB as well. Relevant data could be provided by a pure γδ T cell culture 
where autologous DC could be exogenously reintroduced. Any differences between 
DC-enriched and control cultures could then be assessed in terms of antigen-presenting 
capability and general functionality.  
 
 6.3  FINAL CONCLUSIONS: 
 
The results presented in this thesis provide data on three different approaches to the 
development of APCs for immunotherapy in an HSCT setting. The merits and 
disadvantages of each of them have been discussed in this chapter. What is, however, 
the general direction of research for immunotherapy in HSCT? What approaches or 
strategies are predominant, and what will be the foreseeable advances in this field? 
 
The greatest advantage of cellular immunotherapy over more conventional treatments 
such as chemotherapy is that it is disease-specific, targeting only the malignancy or the 
infection in a precise way. This is an invaluable advantage in the treatment of patients 
that are already debilitated by standard chemotherapy treatments. As the world of 
biomedicine is moving away from standard, “one-type-fits-all” treatments such as 
chemotherapy, it can be expected that the relevance of all applications of cellular 
immunotherapy will become greater and greater. In parallel, increasing progress in 
aAPC research is foreseeable, as the aAPC is a necessary requirement to generate the 
specific effector population needed. Within this field a steady, albeit slow, progression 
to clinical trials of more and more acellular aAPCs systems could be expected. In the 
meanwhile, cell-based aAPCs would fill the gap, so to speak, and become more and 
more standardised and widespread. The full potential of aAPCs generation and cellular 
immunotherapy is not been reached yet, therefore, it can be expected that substantial 
progress will be accomplished in the next few years. In this view, the work presented in 
this thesis can highlight some of the main difficulties on this path and help define where 
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to focus efforts (standardisation and interactions between liposomes and primary cells, 
for example) in future research. 
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Appendix 1: pDRIVE vector map 
 
 
 
(courtesy of 
www.qiagen.com/products/cloning/pcrcloningsystem/qiagenpcrcloningkit.aspx#Tabs=t
1) 
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Appendix 2: pET3d vector map 
 
 
(courtesy of http://www.biovisualtech.com/bvplasmid/pET-3d.htm). 
